RBVRR WOMEN'S COLLEGE OF PHARMACY
3-4-343, Barkathpura, Hyderabad - 500027, Ph: 040-27563065
| No. | Title | Publisher |
| 1 | 1979 EVALUATION OF THE UMKC SCHOOL OF PHARMACY EXTERNSHIP PROGRAM | ERIC |
| 2 | 2009 FIP GLOBAL PHARMACY WORKFORCE REPORT | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 3 | 2012 FIP GLOBAL PHARMACY WORKFORCE REPORT | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 4 | 2013 FIPED GLOBAL EDUCATION REPORT | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 5 | 25 YEARS OF THE WHO ESSENTIAL MEDICINES LISTS: PROGRESS AND CHALLENGES | WORLD HEALTH ORGANIZATION |
| 6 | 2ND BIENNIAL SCIENTIFIC CONFERENCE ON MEDICINES REGULATION IN AFRICA. ADDIS ABABA, ETHIOPIA, 30TH NOVEMBER TO 1ST DECEMBER 2015 – BOOK OF ABSTRACTS. CONFERENCE THEME: REGULATORY SYSTEMS STRENGTHENING FOR ADVANCING RESEARCH, INNOVATION AND LOCAL PHARMACEUTICAL PRODUCTION IN AFRICA | WORLD HEALTH ORGANIZATION |
| 7 | 3RD INTERNATIONAL PPRI CONFERENCE 2015: PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES: CHALLENGES BEYOND THE FINANCIAL CRISIS. VIENNA, AUSTRIA, 12-13 OCTOBER 2015 – ABSTRACT POSTER BOOK | WHO COLLABORATING CENTRE FOR PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES |
| 8 | 3RD INTERNATIONAL PPRI CONFERENCE 2015: PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES: CHALLENGES BEYOND THE FINANCIAL CRISIS. VIENNA, AUSTRIA, 12-13 OCTOBER 2015 – COUNTRY POSTER BOOK | WORLD HEALTH ORGANIZATION |
| 9 | A 90-DAY ORAL TOXICITY STUDY AND A 5-DAY METABOLISM STUDY OF DIISOPROPYL METHYLPHOSPHONATE (DIMP) IN MINK | DEFENSE TECHNICAL INFORMATION CENTER |
| 10 | A BEHAVIOUR CHANGE STRATEGY TO PROMOTE THE SAFE AND APPROPRIATE USE OF INJECTIONS | WHO HEADQUARTERS IN GENEVA |
| 11 | A BIBLIOMETRIC REVIEW OF PHARMACY EDUCATION LITERATURE IN THE CONTEXT OF LOW- TO MIDDLE-INCOME COUNTRIES | ELSEVIER |
| 12 | A BIBLIOMETRIC STUDY OF PUBLICATION PATTERNS IN ACCESS TO MEDICINES RESEARCH IN DEVELOPING COUNTRIES – SOUTHERN MED REVIEW VOL 3 ISSUE 1 FEB 2010 | PUBMED CENTRAL |
| 13 | A BIBLIOMETRIC STUDY OF PUBLICATION PATTERNS IN RATIONAL USE OF MEDICINES IN IRAN | A BIBLIOMETRIC STUDY OF PUBLICATION PATTERNS IN RATIONAL USE OF MEDICINES IN IRAN |
| 14 | A CALL TO MAKE VALUABLE INNOVATIVE MEDICINES ACCESSIBLE IN THE EUROPEAN UNION. RECOMMENDATIONS FOR A COORDINATED ACTION TO STIMULATE, MEASURE AND VALORISE PHARMACEUTICAL INNOVATION. BACKGROUND REPORT FOR THE MINISTERIAL CONFERENCE, 23-24 SEPTEMBER 2010 | WORLD HEALTH ORGANIZATION |
| 15 | A COMBINATION THERAPY OF JO-1 AND CHEMOTHERAPY IN OVARIAN CANCER MODELS | DEFENSE TECHNICAL INFORMATION CENTER |
| 16 | A COMBINATION THERAPY OF JO-I AND CHEMOTHERAPY IN OVARIAN CANCER MODELS | DEFENSE TECHNICAL INFORMATION CENTER |
| 17 | A COMPARATIVE ANALYSIS OF THE LIBYAN NATIONAL ESSENTIAL MEDICINES LIST AND THE WHO MODEL LIST OF ESSENTIAL MEDICINES | WORLD HEALTH ORGANIZATION |
| 18 | A COMPARATIVE ANALYSIS OF TOXICITY MODELS | DEFENSE TECHNICAL INFORMATION CENTER |
| 19 | A COMPARATIVE EVALUATION OF PRICE AND QUALITY OF SOME BRANDED VERSUS BRANDED–GENERIC MEDICINES OF THE SAME MANUFACTURER IN INDIA | MEDKNOW PUBLICATIONS |
| 20 | A COMPARATIVE PHARMACOKINETIC STUDY OF THE ROLE OF GENDER AND DEVELOPMENTAL DIFFERENCES IN OCCUPATIONAL AND ENVIRONMENTAL EXPOSURE TO BENZENE | DEFENSE TECHNICAL INFORMATION CENTER |
| 21 | A COMPARISON OF THE MANDATORY CONTINUING EDUCATION (MCE) REQUIREMENTS OF THE REGULATED HEALTH OCCUPATIONS IN MINNESOTA | ERIC |
| 22 | A COMPEND OF ORGANIC AND MEDICAL CHEMISTRY; INCLUDING URINARY ANALYSIS AND THE EXAMINATION OF WATER AND FOOD | P. BLAKISTON’S SON & CO. |
| 23 | A COMPENDIUM OF MODERN PHARMACY AND DRUGGISTS’ FORMULARY | U.S. NATIONAL LIBRARY OF MEDICINE |
| 24 | A COMPREHENSIVE APPROACH IN DISSEMINATION OF EVIDENCE-BASED CARE FOR PTSD | DEFENSE TECHNICAL INFORMATION CENTER |
| 25 | A COMPREHENSIVE SITUATION ASSESSMENT OF INJECTION PRACTICES IN PRIMARY HEALTH CARE HOSPITALS IN BANGLADESH | BMC PUBLIC HEALTH |
| 26 | A COURSE OF PRACTICAL CHEMISTRY ARRANGED FOR THE USE OF MEDICAL STUDENTS | YALE UNIVERSITY |
| 27 | A CROSS SECTIONAL STUDY OF PUBLIC KNOWLEDGE AND ATTITUDE TOWARDS ANTIBIOTICS IN PUTRAJAYA, MALAYSIA – SOUTHERN MED REVIEW VOL 5 ISSUE 2 DECEMBER 2012 | SOUTHERN MED REVIEW |
| 28 | A DELPHI STUDY TO DEVELOP A STANDARD LIST OF ACTIVITIES THAT COMPRISE ROUTINE CLINICAL PHARMACY SERVICES | DEFENSE TECHNICAL INFORMATION CENTER |
| 29 | A DESK REVIEW OF EXISTING LITERATURE ON MEDICINES FOR CHILDREN | GHANA – MINISTRY OF HEALTH, GHANA NATIONAL DRUGS PROGRAMME |
| 30 | A DIFFUSION APPROXIMATION ANALYSIS OF A GENERAL N-COMPARTMENT SYSTEM | NAVAL POSTGRADUATE SCHOOL |
| 31 | A DISPENSATORY, OR COMMENTARY ON THE PHARMACOPOEIAS OF GREAT BRITAIN AND THE UNITED STATES : COMPRISING THE NATURAL HISTORY, DESCRIPTION, CHEMISTRY, PHARMACY, ACTIONS, USES, AND DOSES OF THE ARTICLES OF THE MATERIA MEDICA | LEA & FEBIGER |
| 32 | A FRAMEWORK FOR GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR. GGM MODEL FRAMEWORK. | WHO HEADQUARTERS IN GENEVA |
| 33 | A FRAMEWORK FOR GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR. THE HASHEMITE KINGDOM OF JORDAN | JORDAN – MINISTRY OF HEALTH |
| 34 | A GENERIC DRUG POLICY AS CORNERSTONE TO ESSENTIAL MEDICINES IN CHINA. CHINA HEALTH POLICY NOTES, NO. 04, JUNE 2010 | THE WORLD BANK GROUP |
| 35 | A GUIDE FOR SUPERVISING INJECTIONS | WHO HEADQUARTERS IN GENEVA |
| 36 | A GUIDE FOR THE QUALITY ASSURANCE OF SINGLE USE INJECTION EQUIPMENT | WHO HEADQUARTERS IN GENEVA |
| 37 | A HUMAN RIGHTS APPROACH TO INTELLECTUAL PROPERTY AND ACCESS TO MEDICINES. GLOBAL HEALTH JUSTICE PARTNERSHIP, POLICY PAPER 1, SEPTEMBER 2013 | GLOBAL HEALTH JUSTICE PARTNERSHIP |
| 38 | A HUMAN RIGHTS APPROACH TO THE WHO MODEL LIST OF ESSENTIAL MEDICINES | WHO HEADQUARTERS IN GENEVA |
| 39 | A JOINT VENTURE ANALYSIS FOR A COMBINED ACUTE/CHRONIC HEMODIALYSIS CLINIC AT TRIPLER ARMY MEDICAL CENTER | DEFENSE TECHNICAL INFORMATION CENTER |
| 40 | A KNOWLEDGE, ATTITUDE, BELIEFS AND PRACTICES STUDY ON LOW GENERICS PRESCRIBING IN GHANA | MINISTRY OF HEALTH OF INDONESIA, NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT, UNIT OF VECTOR BORNE DISEASES CONTROL, CIAMIS |
| 41 | A LABORATORY MANUAL OF PHYSIOLOGICAL AND CLINICAL CHEMISTRY AND TOXICOLOGY | CORNELL UNIVERSITY |
| 42 | A LABORATORY MANUAL OF PHYSIOLOGICAL AND PATHOLOGICAL CHEMISTRY FOR STUDENTS IN MEDICINE | CORNELL UNIVERSITY |
| 43 | A LABORATORY MANUAL OF PHYSIOLOGICAL AND PATHOLOGICAL CHEMISTRY. FOR STUDENTS IN MEDICINE | WILEY |
| 44 | A LABORATORY MANUAL OF PHYSIOLOGICAL CHEMISTRY | U.S. NATIONAL LIBRARY OF MEDICINE |
| 45 | A LIFELINE TO TREATMENT: THE ROLE OF INDIAN GENERIC MANUFACTURERS IN SUPPLYING ANTIRETROVIRAL MEDICINES TO DEVELOPING COUNTRIES | BIOMED CENTRAL |
| 46 | A LITERATURE REVIEW – PROBLEM DEFINITION STUDIES ON SELECTED TOXIC CHEMICALS | DEFENSE TECHNICAL INFORMATION CENTER |
| 47 | A LITERATURE REVIEW – PROBLEM DEFINITION STUDIES ON SELECTED TOXIC CHEMICALS. VOLUME 2. OCCUPATIONAL HEALTH AND SAFETY ASPECTS OF PHOSPHORUS SMOKE COMPOUNDS | DEFENSE TECHNICAL INFORMATION CENTER |
| 48 | A LITERATURE REVIEW – PROBLEM DEFINITION STUDIES ON SELECTED TOXIC CHEMICALS. VOLUME 4. OCCUPATIONAL HEALTH AND SAFETY ASPECTS OF THE FOG OILS SGF NO. 1 AND SGF NO. 2 AND SMOKE SCREENS GENERATED FROM THEM | DEFENSE TECHNICAL INFORMATION CENTER |
| 49 | A LITERATURE REVIEW – PROBLEM DEFINITION STUDIES ON SELECTED TOXIC CHEMICALS. VOLUME 6. OCCUPATIONAL HEALTH AND SAFETY AND ENVIRONMENTAL ASPECTS OF UREA-FORMALDEHYDE RESINS | DEFENSE TECHNICAL INFORMATION CENTER |
| 50 | A LITERATURE REVIEW-PROBLEM DEFINITION STUDIES ON SELECTED TOXIC CHEMICALS. VOLUME 1. OCCUPATIONAL HEALTH AND SAFETY ASPECTS OF DIESEL FUEL AND WHITE SMOKE GENERATED FROM IT | DEFENSE TECHNICAL INFORMATION CENTER |
| 51 | A MANUAL OF CHEMICAL ANALYSIS AS APPLIED TO THE EXAMINATION OF MEDICINAL CHEMICALS | CORNELL UNIVERSITY |
| 52 | A MANUAL OF CHEMICAL PHYSIOLOGY : INCLUDING ITS POINTS OF CONTACT WITH PATHOLOGY | LONGMANS, GREEN AND CO. |
| 53 | A MANUAL OF MATERIA MEDICA, THERAPEUTICS AND PHARMACOLOGY, WITH CLINICAL INDEX | LIBRARY OF CONGRESS |
| 54 | A MANUAL OF PHARMACY | KING’S COLLEGE |
| 55 | A MANUAL OF QUALITATIVE ANALYSIS AND OF CLINICAL MEDICAL CHEMISTRY, FOR PHYSICIANS AND STUDENTS | J. J. MCVEY |
| 56 | A MANUAL OF SELECTED BIOCHEMICAL METHODS AS APPLIED TO URINE, BLOOD AND GASTRIC ANALYSIS | WILEY |
| 57 | A MANUAL OF VOLUMETRIC ANALYSIS FOR THE USE OF PHARMACISTS, SANITARY AND FOOD CHEMISTS, AS WELL AS FOR STUDENTS IN THESE BRANCHES | WILEY |
| 58 | A MEDICAL RESEARCH AND EVALUATION (MREF) FACILITY AND STUDIES SUPPORTING THE MEDICAL CHEMICAL DEFENSE PROGRAM | DEFENSE TECHNICAL INFORMATION CENTER |
| 59 | A MODEL QUALITY ASSURANCE SYSTEM FOR PROCUREMENT AGENCIES – RECOMMENDATIONS FOR QUALITY ASSURANCE SYSTEMS FOCUSING ON PREQUALIFICATION OF PRODUCTS AND MANUFACTURERS, PURCHASING, STORAGE AND DISTRIBUTION OF PHARMACEUTICAL PRODUCTS | WORLD HEALTH ORGANIZATION |
| 60 | A NEW ENTITY FOR THE NEGOTIATION OF PUBLIC PROCUREMENT PRICES FOR PATENTED MEDICINES IN MEXICO | WORLD HEALTH ORGANIZATION |
| 61 | A NEW THERAPEUTIC PARADIGM FOR BREAST CANCER EXPLOITING LOW DOSE ESTROGEN-INDUCED APOPTOSIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 62 | A NOVEL HIGH RESOLUTION POSITRON EMISSION TOMOGRAPHY SYSTEM FOR MEASUREMENT OF BONE METABOLISM | DEFENSE TECHNICAL INFORMATION CENTER |
| 63 | A PHARMACOKINETIC STUDY OF THE EFFECTS OF STRESS ON CHEMICAL EXPOSURE | DEFENSE TECHNICAL INFORMATION CENTER |
| 64 | A PRACTICAL GUIDE FOR PROCUREMENT PLANNING AND MANAGEMENT OF STRATEGIC PUBLIC HEALTH SUPPLIES | WORLD HEALTH ORGANIZATION |
| 65 | A PRACTICAL HANDBOOK OF MEDICAL CHEMISTRY, ILLUSTRATED | UNIVERSITY OF TORONTO |
| 66 | A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF ANTIMALARIAL MEDICINES | WORLD HEALTH ORGANIZATION |
| 67 | A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF ANTIRETROVIRAL MEDICINES | WORLD HEALTH ORGANIZATION |
| 68 | A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF MEDICINES USED IN THE TREATMENT OF TUBERCULOSIS: ENHANCING THE SAFETY OF THE TB PATIENT | WORLD HEALTH ORGANIZATION |
| 69 | A PRACTICAL TREATISE ON MATERIA MEDICA AND THERAPEUTICS : WITH ESPECIAL REFERENCE TO THE CLINICAL APPLICATION OF DRUGS | F. A. DAVIS COMPANY |
| 70 | A PRACTICAL TREATISE ON MATERIA MEDICA AND THERAPEUTICS, WITH ESPECIAL REFERENCE TO THE CLINICAL APPLICATION OF DRUGS | PHILADELPHIA COLLEGE OF PHARMACY |
| 71 | A PROCESS FOR MAKING ON-GOING IMPROVEMENTS FOR DISPENSING MEDICATION: USING A TQM APPROACH | NAVAL POSTGRADUATE SCHOOL |
| 72 | A RAPID QUALITY RISK ASSESSMENT MECHANISM FOR ASSESSING NEEDED PHARMACEUTICAL PRODUCTS THAT HAVE NOT COMPLETED A STRINGENT ASSESSMENT. WHO PREQUALIFICATION OF MEDICINES PROGRAMME – BRIEFING PAPER: 27 APRIL 2012. EXPERT REVIEW PANEL, ERP | WORLD HEALTH ORGANIZATION |
| 73 | A REFINEMENT OF RISK ANALYSIS PROCEDURES FOR TRICHLOROETHYLENE THROUGH THE USE OF MONTE CARLO METHOD IN CONJUNCTION WITH PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING | DEFENSE TECHNICAL INFORMATION CENTER |
| 74 | A REVIEW OF 3D IMAGE-BASED DOSIMETRY, TECHNICAL CONSIDERATIONS AND EMERGING PERSPECTIVES IN 90Y MICROSPHERE THERAPY | OPEN MEDSCIENCE LIMITED |
| 75 | A REVIEW ON PHARMACOKINETIC MODELING AND THE EFFECTS OF ENVIRONMENTAL STRESSORS ON PHARMACOKINETICS FOR OPERATIONAL MEDICINE: OPERATIONAL PHARMACOKINETICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 76 | A SAMPLE-SIZE OPTIMAL BAYESIAN PROCEDURE FOR SEQUENTIAL PHARMACEUTICAL TRIALS | DEFENSE TECHNICAL INFORMATION CENTER |
| 77 | A SHORT PHARMACEUTIC CHEMISTRY, INORGANIC AND ORGANIC | P. BLAKISTON’S SON & CO. |
| 78 | A SIMULATION-BASED COMPARISON BETWEEN PARAMETRIC AND NONPARAMETRIC ESTIMATION METHODS IN PBPK MODELS | DEFENSE TECHNICAL INFORMATION CENTER |
| 79 | A SITUATIONAL ANALYSIS AND FEASIBILITY STUDY ON REGIONAL POOLED BULK PROCUREMENT OF ESSENTIAL MEDICINES AND OTHER HEALTH SUPPLIES IN THE EAST AFRICAN COMMUNITY PARTNER STATES. FINAL REPORT, SEPTEMBER 2007 | WORLD HEALTH ORGANIZATION |
| 80 | A STUDY OF OUTPATIENT PHARMACY UTILIZATION AT NAVAL HOSPITAL, CAMP LEJEUNE | GOVERNMENT PRINTING OFFICE |
| 81 | A STUDY OF THE ENDOGENOUS CONTROL OF NEUROINFLAMMATION, A LEADING CAUSE OF MORBIDITY FROM TRAUMATIC BRAIN INJURY | DEFENSE TECHNICAL INFORMATION CENTER |
| 82 | A STUDY TO DETERMINE IF PHARMACEUTICAL COST IS RELATED TO DIAGNOSTIC COMPLEXITY FOR THE TREATMENT OF ESSENTIAL HYPERTENSION PATIENTS AT WOMACK ARMY COMMUNITY HOSPITAL | DEFENSE TECHNICAL INFORMATION CENTER |
| 83 | A SURVEY OF COMPOUNDS FOR RADIATION PROTECTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 84 | A SURVEY OF MEDICINE PRICES IN KENYA – 2004 | WORLD HEALTH ORGANIZATION |
| 85 | A SYSTEM DYNAMICS APPROACH TO THE EFFICACY OF OXIME THERAPY IN SUB LETHAL EXPOSURE TO SARIN GAS | DEFENSE TECHNICAL INFORMATION CENTER |
| 86 | A SYSTEM OF CHEMISTRY FOR THE USE OF STUDENTS OF MEDICINE | U.S. NATIONAL LIBRARY OF MEDICINE |
| 87 | A TEXT-BOOK OF CHEMISTRY | J.B. LIPPINCOTT COMPANY |
| 88 | A TEXT-BOOK OF CHEMISTRY : INTENDED FOR THE USE OF PHARMACEUTICAL AND MEDICAL STUDENTS | J.B. LIPPINCOTT COMPANY |
| 89 | A TEXT-BOOK OF CHEMISTRY, FOR THE USE OF STUDENTS AND PRACTITIONERS OF MEDICINE, DENTISTRY AND PHARMACY | LIBRARY OF CONGRESS |
| 90 | A TEXT-BOOK OF CHEMISTRY, INTENDED FOR THE USE OF PHARMACEUTICAL AND MEDICAL STUDENTS | LIPPINCOTT COMPANY |
| 91 | A TEXT-BOOK OF CHEMISTRY: INTENDED FOR THE USE OF PHARMACEUTICAL AND MEDICAL STUDENTS | LIPPINCOTT COMPANY |
| 92 | A TEXT-BOOK OF INORGANIC CHEMISTRY | LONGMANS, GREEN AND CO. |
| 93 | A TEXT-BOOK OF INORGANIC PHARMACEUTICAL CHEMISTRY | LEA & FEBIGER |
| 94 | A TEXT-BOOK OF MATERIA MEDICA, THERAPEUTICS, AND PHARMACOLOGY | W. B. SAUNDERS CO. |
| 95 | A TEXT-BOOK OF MEDICAL CHEMISTRY AND TOXICOLOGY | W. B. SAUNDERS CO. |
| 96 | A TEXT-BOOK OF VOLUMETRIC ANALYSIS : WITH SPECIAL REFERENCE TO THE VOLUMETRIC PROCESSES OF THE PHARMACOPOEIA OF THE UNITED STATES : DESIGNED FOR THE USE OF PHARMACISTS AND PHARMACEUTICAL STUDENTS | U.S. NATIONAL LIBRARY OF MEDICINE |
| 97 | A TEXT-BOOK OF VOLUMETRIC ANALYSIS, WITH SPECIAL REFERENCE TO THE VOLUMETRIC PROCESSES OF THE PHARMACOPŒIA OF THE UNITED STATES | WILEY |
| 98 | A TEXT-BOOK OF VOLUMETRIC ANALYSIS, WITH SPECIAL REFERENCE TO THE VOLUMETRIC PROCESSES OF THE PHARMACOPŒIA OF THE UNITED STATES | WILEY |
| 99 | A TEXT-BOOK OF VOLUMETRIC ANALYSIS, WITH SPECIAL REFERENCE TO THE VOLUMETRIC PROCESSES OF THE PHARMACOPOEIA OF THE UNITED STATES. DESIGNED FOR THE USE OF PHARMACISTS AND PHARMACEUTICAL STUDENTS | WILEY |
| 100 | A TEXTBOOK OF PHARMACEUTICAL CHEMISTRY | OXFORD UNIVERSITY PRESS |
| 101 | A TEXTBOOK OF PHARMACOLOGY AND THERAPEUTICS | ACADEMIC PRESS |
| 102 | A TEXTBOOK OF PHARMACOLOGY AND THERAPEUTICS : OR THE ACTION OF DRUGS IN HEALTH AND DISEASE | LEA BROTHERS AND CO. |
| 103 | A TEXTBOOK OF PHARMACOLOGY, THERAPEUTICS AND MATERIA MEDICA | WELLCOME LIBRARY |
| 104 | A TEXTBOOK OF PRECONCEPTIONAL MEDICINE AND MANAGEMENT | SAPIENS PUBLISHING |
| 105 | A TRAINING MANUAL FOR NUCLEAR MEDICINE TECHNOLOGISTS | ERIC |
| 106 | A TRANSLATION OF THE PHARMACOPOEIA OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON | KING’S COLLEGE |
| 107 | A TREATISE ON MATERIA MEDICA, PHARMACOLOGY, AND THERAPEUTICS | CORNELL UNIVERSITY |
| 108 | A TREATISE ON PHARMACY : DESIGNED AS A TEXT-BOOK FOR THE STUDENT, AND AS A GUIDE FOR THE PHYSICIAN AND PHARMACEUTIST, CONTAINING THE OFFICINAL AND MANY UNOFFICINAL FORMULAS, AND NUMEROUS EXAMPLES OF EXTEMPORANEOUS PRESCRIPTIONS | EMORY UNIVERSITY |
| 109 | ABC OF AIDS | BMJ PUBLISHING GROUP LTD. |
| 110 | ABSTRACTS FROM THE 3RD INTERNATIONAL PPRI CONFERENCE 2015: PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES: CHALLENGES BEYOND THE FINANCIAL CRISIS. VIENNA, AUSTRIA, 12-13 OCTOBER 2015 | WHO COLLABORATING CENTRE FOR PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES |
| 111 | ACAMPROSATE IN RELAPSE PREVENTION OF ALCOHOLISM | SPRINGER |
| 112 | ACCELERATED STABILITY STUDIES OF WIDELY USED PHARMACEUTICAL SUBSTANCES UNDER SIMULATED TROPICAL CONDITIONS | WHO HEADQUARTERS IN GENEVA |
| 113 | ACCESS TO AND RATIONAL USE OF MEDICINES AT THE FACILITY LEVEL | NIGERIA MINISTRY OF HEALTH |
| 114 | ACCESS TO AND RATIONAL USE OF MEDICINES AT THE HOUSEHOLD LEVEL | NIGERIA MINISTRY OF HEALTH |
| 115 | ACCESS TO AND USE OF MEDICINES BY HOUSEHOLDS IN UGANDA. REPORT OF A SURVEY CONDUCTED 2008 | UGANDA – MINISTRY OF HEALTH |
| 116 | ACCESS TO ANTIBIOTICS IN NEW DELHI, INDIA: IMPLICATIONS FOR ANTIBIOTIC POLICY | UGANDA – MINISTRY OF HEALTH |
| 117 | ACCESS TO ANTIRETROVIRAL DRUGS IN LOW- AND MIDDLE-INCOME COUNTRIES: TECHNICAL REPORT, JULY 2014 | WHO HEADQUARTERS IN GENEVA |
| 118 | ACCESS TO ART AND OTHER ESSENTIAL MEDICINES IN SUB-SAHARAN AFRICA: INTELLECTUAL PROPERTY AND RELEVANT LEGISLATIONS, SEPTEMBER 2007 | UNITED NATIONS DEVELOPMENT PROGRAMME |
| 119 | ACCESS TO CANCER TREATMENT: A STUDY OF MEDICINE PRICING ISSUES WITH RECOMMENDATIONS FOR IMPROVING ACCESS TO CANCER MEDICATION | UNITED NATIONS DEVELOPMENT PROGRAMME |
| 120 | ACCESS TO CARE AND MEDICINES, BURDEN OF HEALTH CARE EXPENDITURES, AND RISK PROTECTION: RESULTS FROM THE WORLD HEALTH SURVEY | UNITED NATIONS DEVELOPMENT PROGRAMME |
| 121 | ACCESS TO CARE FOR PATIENTS WITH INSULIN-REQUIRING DIABETES IN DEVELOPING COUNTRIES. CASE STUDIES OF MOZAMBIQUE AND ZAMBIA | UNITED NATIONS DEVELOPMENT PROGRAMME |
| 122 | ACCESS TO CONTROLLED MEDICATIONS PROGRAMME – FRAMEWORK | WHO HEADQUARTERS IN GENEVA |
| 123 | ACCESS TO DRUGS FOR HIV/AIDS AND RELATED OPPORTUNISTIC INFECTIONS IN NIGERIA. A STATUS REPORT ON THE SOCIOPOLITICAL, ECONOMIC, AND POLICY CLIMATE ON DRUG AVAILABILITY FOR PEOPLE LIVING WITH HIV/AIDS (PLWHA) AND RECOMMENDATIONS FOR FUTURE ACCESS | POLICY PROJECT |
| 124 | ACCESS TO DRUGS FOR TREATMENT OF NONCOMMUNICABLE DISEASES | ACCESS TO DRUGS FOR TREATMENT OF NONCOMMUNICABLE DISEASES |
| 125 | ACCESS TO ESSENTIAL MEDICINES AND STANDARD TREATMENT FOR CHRONIC DISEASES | ACCESS TO DRUGS FOR TREATMENT OF NONCOMMUNICABLE DISEASES |
| 126 | ACCESS TO ESSENTIAL MEDICINES IN KENYA. A HEALTH FACILITY SURVEY | KENYA – MINISTRY FOR MEDICAL SERVICES |
| 127 | ACCESS TO ESSENTIAL MEDICINES IN KENYA. A HOUSEHOLD SURVEY | KENYA – MINISTRY FOR MEDICAL SERVICES |
| 128 | ACCESS TO ESSENTIAL MEDICINES IN NATIONAL CONSTITUTIONS | WHO HEADQUARTERS IN GENEVA |
| 129 | ACCESS TO ESSENTIAL MEDICINES IN PAKISTAN: POLICY AND HEALTH SYSTEMS RESEARCH CONCERNS | PLOS |
| 130 | ACCESS TO ESSENTIAL MEDICINES: GHANA, JULY 2003 | MANAGEMENT SCIENCES FOR HEALTH |
| 131 | ACCESS TO HEPATITIS C MEDICINES | WHO HEADQUARTERS IN GENEVA |
| 132 | ACCESS TO HEPATITIS C MEDICINES: IMPROVING ACCESS TO ESSENTIAL INNOVATIVE TREATMENTS. ACCESS-TO-MEDICINE STRATEGY ANALYSIS, 24 NOVEMBER, 2015 | ACCESS TO MEDICINE FOUNDATION |
| 133 | ACCESS TO HIGH COST MEDICINES IN THE AMERICAS | WORLD HEALTH ORGANIZATION |
| 134 | ACCESS TO HIGH-COST MEDICINES IN THE AMERICAS: SITUATION, CHALLENGES AND PERSPECTIVES | ACCESS TO HIGH-COST MEDICINES IN THE AMERICAS: SITUATION, CHALLENGES AND PERSPECTIVES |
| 135 | ACCESS TO HIGH-COST MEDICINES IN THE AMERICAS: SITUATION, CHALLENGES AND PERSPECTIVES. | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE AMERICAS |
| 136 | ACCESS TO HIGH-COST MEDICINES IN THE AMERICAS: SITUATION, CHALLENGES AND PERSPECTIVES;TECHNICAL SERIES NO. 1 – ESSENTIAL MEDICINE, ACCESS, AND INNOVATION | WORLD HEALTH ORGANIZATION |
| 137 | ACCESS TO INHALED CORTICOSTEROIDS IS KEY TO IMPROVING QUALITY OF CARE FOR ASTHMA IN DEVELOPING COUNTRIES | ACCESS TO INHALED CORTICOSTEROIDS IS KEY TO IMPROVING QUALITY OF CARE FOR ASTHMA IN DEVELOPING COUNTRIES |
| 138 | ACCESS TO INSULIN: CURRENT CHALLENGES AND CONSTRAINTS. OCTOBER 2015 | HEALTH ACTION INTERNATIONAL – AFRICA |
| 139 | ACCESS TO MEDICINE FOUNDATION – LONGITUDINAL ANALYSIS 2010-2012. CHANGES IN PERFORMANCE OF THE RESEARCH-BASED PHARMACEUTICAL INDUSTRY WITH REGARD TO ACCESS TO ESSENTIAL MEDICINES IN 103 LOW- AND MIDDLEINCOME COUNTRIES | HEALTH ACTION INTERNATIONAL |
| 140 | ACCESS TO MEDICINE INDEX – METHODOLOGY REPORT 2013 FOR THE 2014 ACCESS TO MEDICINE INDEX | ACCESS TO MEDICINE FOUNDATION |
| 141 | ACCESS TO MEDICINE INDEX METHODOLOGY REPORT 2012 – STAKEHOLDER REVIEW – MAY 2012 | ACCESS TO MEDICINE FOUNDATION |
| 142 | ACCESS TO MEDICINE INDEX, 2010 | ACCESS TO MEDICINE FOUNDATION |
| 143 | ACCESS TO MEDICINE INDEX, 2012 | ACCESS TO MEDICINE FOUNDATION |
| 144 | ACCESS TO MEDICINES – OVERCOMING THE BARRIERS | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 145 | ACCESS TO MEDICINES AN ISSUE OF SOCIAL JUSTICE. CONTACT N°196 – DECEMBER 2013 | WORLD COUNCIL OF CHURCHES |
| 146 | ACCESS TO MEDICINES AND DRUG REGULATION IN DEVELOPING COUNTRIES: A RESOURCE GUIDE FOR DFID | DFID HEALTH RESOURCE CENTRE |
| 147 | ACCESS TO MEDICINES AND INTELLECTUAL PROPERTY: THE CONTRIBUTION OF THE WORLD HEALTH ORGANIZATION. SOUTH CENTRE, RESEARCH PAPER 47, MAY 2013 | THE SOUTH CENTRE |
| 148 | ACCESS TO MEDICINES FROM A HEALTH SYSTEM PERSPECTIVE | ACCESS TO MEDICINES FROM A HEALTH SYSTEM PERSPECTIVE |
| 149 | ACCESS TO MEDICINES IN CHURCH HEALTH SERVICES IN AFRICA. A CROSS-COUNTRY ANALYSIS OF COMPLIANCE WITH THE ECUMENICAL PHARMACEUTICAL NETWORK GUIDELINES ON EFFECTIVE AND EFFICIENT PHARMACEUTICAL SERVICES | ECUMENICAL PHARMACEUTICAL NETWORK |
| 150 | ACCESS TO MEDICINES IN LATIN AMERICA AND THE CARIBBEAN (LAC): A SCOPING STUDY – BMJ OPEN 2013 | BMJ PUBLISHING GROUP LTD. |
| 151 | ACCESS TO MEDICINES PUBLICATIONS IN DEVELOPING COUNTRIES: A BIBLIOMETRIC STUDY AND ITS IMPLICATIONS FOR THE ACCESS TO MEDICINES RESEARCH NETWORK | BMJ PUBLISHING GROUP LTD. |
| 152 | ACCESS TO MEDICINES VERSUS ACCESS TO TREATMENT: THE CASE OF TYPE 1 DIABETES | WORLD HEALTH ORGANIZATION |
| 153 | ACCESS TO MEDICINES. MEDICINE SUPPLY: LESSONS LEARNT IN TANZANIA AND MOZAMBIQUE | SWISS AGENCY FOR DEVELOPMENT AND COOPERATION |
| 154 | ACCESS TO MEDICINES: KEY TO MDGS ON CHILD HEALTH. CONTACT N°191 – APRIL 2011 | WORLD COUNCIL OF CHURCHES |
| 155 | ACCESS TO OPIOID ANALGESICS: ESSENTIAL FOR QUALITY CANCER CARE | WORLD COUNCIL OF CHURCHES |
| 156 | ACCESS TO ORPHAN DRUGS: A COMPREHENSIVE REVIEW OF LEGISLATIONS, REGULATIONS AND POLICIES IN 35 COUNTRIES | WORLD COUNCIL OF CHURCHES |
| 157 | ACCESS TO PAIN TREATMENT AS A HUMAN RIGHT | WORLD COUNCIL OF CHURCHES |
| 158 | ACCESS TO PHARMACEUTICAL SERVICES. ANNUAL REPORT 2009–2010, OUTCOME 2 – AUSTRALIA | AUSTRALIAN GOVERNMENT – DEPARTMENT OF HEALTH AND AGEING |
| 159 | ACCESS TO TREATMENT FOR DIABETES AND HYPERTENSION IN RURAL CAMBODIA: PERFORMANCE OF EXISTING SOCIAL HEALTH PROTECTION SCHEMES | PLOS |
| 160 | ACCREDITED DRUG DISPENSING OUTLETS IN TANZANIA STRATEGIES FOR ENHANCING ACCESS TO MEDICINES PROGRAM | MANAGEMENT SCIENCES FOR HEALTH |
| 161 | ACCREDITING RETAIL DRUG SHOPS TO STRENGTHEN TANZANIA’S PUBLIC HEALTH SYSTEM: AN ADDO CASE STUDY | BIOMED CENTRAL |
| 162 | ACT 234 – DANGEROUS DRUGS ACT 1952 (REVISED 1980). INCORPORATING LATEST AMENDMENT | MALAYSIA – MINISTRY OF HEALTH |
| 163 | ACT 368 – SALE OF DRUGS ACT 1952 (REVISED 1989). INCORPORATING LATEST AMENDMENT – ACT A1084/2000 | MALAYSIA – MINISTRY OF HEALTH |
| 164 | ACTION NEEDED: SPIRALING DRUG PRICES EMPTY RUSSIAN POCKETS | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 165 | ACTIVE PHARMACEUTICAL INGREDIENTS FOR ANTIRETROVIRAL TREATMENT IN LOW- AND MIDDLE-INCOME COUNTRIES: A SURVEY | ACTIVE PHARMACEUTICAL INGREDIENTS FOR ANTIRETROVIRAL TREATMENT IN LOW- AND MIDDLE-INCOME COUNTRIES: A SURVEY |
| 166 | ACUTE ORAL TOXICITY OF DIETHYLENEGLYCOL DINITRATE (DEGDN) IN RATS | DEFENSE TECHNICAL INFORMATION CENTER |
| 167 | ACUTE ORAL TOXICITY OF TRIMETHYLOLETHANE TRINITRATE (TMETN) IN SPRAGUE- DAWLEY RATS | DEFENSE TECHNICAL INFORMATION CENTER |
| 168 | ADDING DATA ACCESSIBILITY AND RULE-BASED TARGETED DATA COLLECTION TO THE CALIFORNIA CANCER REPORTING SYSTEM FOR BREAST CASES | DEFENSE TECHNICAL INFORMATION CENTER |
| 169 | ADJUVANT IMMUNOTHERAPY FOR PATIENTS AT HIGH RISK OF RECURRENCE FOLLOWING RADIATION THERAPY FOR PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 170 | ADVANCED PHARMACEUTICS | MARCEL DEKKER INC. |
| 171 | ADVANCES IN MARINE CHITIN AND CHITOSAN | MDPI AG |
| 172 | ADVANCES IN PHARMA BUSINESS MANAGEMENT AND RESEARCH: VOLUME 1 | SPRINGER |
| 173 | AEROSPACE TOXICOLOGY: AN OVERVIEW | DEFENSE TECHNICAL INFORMATION CENTER |
| 174 | AFGHANISTAN PHARMACEUTICAL SECTOR DEVELOPMENT: PROBLEMS AND PROSPECTS – SOUTHERN MED REVIEW VOL 4 ISSUE 1 APRIL 2011 | AFGHANISTAN – MINISTRY OF PUBLIC HEALTH |
| 175 | AFRICA PHARMACOVIGILANCE MEETING, 2012: MEETING PROCEEDINGS | MANAGEMENT SCIENCES FOR HEALTH |
| 176 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 2, NUMBER 1, SEPTEMBER 2005. IMPLEMENTATION OF NATIONAL MEDICINE POLICIES. HAS IT IMPROVED ACCESS TO ESSENTIAL MEDICINES IN THE AFRICAN REGION? | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 177 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 3, NUMBER 2, SEPTEMBER 2006. PHARMACEUTICAL PRODUCTS: THE CASE OF SIERRA LEONE | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 178 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 4, NUMBER 1, JULY 2007. SNAKES AND SNAKE BITES – PART 1: PREVENTION OF SNAKE BITES | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 179 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 5, NUMBER 1, MARCH 2008. SNAKES AND SNAKE BITES – PART 2: VENOMS AND ANTIVENOMS | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 180 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 5, NUMBER 2, OCTOBER 2008. COUNTERFEIT MEDICINES | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 181 | AFRO PHARMACEUTICALS NEWSLETTER, VOLUME 6, NUMBER 1, OCTOBER 2009. GOOD GOVERNANCE FOR MEDICINES PROGRAMME. IMPLEMENTATION IN THE WHO AFRICAN REGION AND BEYOND | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 182 | AIDS TO THE ANALYSIS OF FOOD AND DRUGS | WELLCOME LIBRARY |
| 183 | AIR FORCE HEALTH STUDY. AN EPIDEMIOLOGIC INVESTIGATION OF HEALTH EFFECTS IN AIR FORCE PERSONNEL FOLLOWING EXPOSURE TO HERBICIDES | DEFENSE TECHNICAL INFORMATION CENTER |
| 184 | AIR FORCE HEALTH STUDY. AN EPIDEMIOLOGIC INVESTIGATION OF HEALTH EFFECTS IN AIR FORCE PERSONNEL FOLLOWING EXPOSURE TO HERBICIDES. VOLUME 1 | DEFENSE TECHNICAL INFORMATION CENTER |
| 185 | AKAMAI NETWORK FOR DIAGNOSIS, TREATMENT AND MANAGEMENT TO SUPPORT TELEPRESENCE | DEFENSE TECHNICAL INFORMATION CENTER |
| 186 | ALANINE DOSIMETRY ACCURATELY DETERMINES RADIATION DOSE IN NONHUMAN PRIMATES | DEFENSE TECHNICAL INFORMATION CENTER |
| 187 | ALTERNATIVE DRUG PRICING POLICIES IN THE AMERICAS – HEALTH ECONOMICS AND DRUGS SERIES NO. 001 | WHO HEADQUARTERS IN GENEVA |
| 188 | ALTERNATIVE REGULATORY MODELS FOR PHARMACEUTICAL PROMOTIONS INVOLVING CIVIL SOCIETY AND OTHER NON-GOVERNMENT STAKEHOLDERS | MEDICINES TRANSPARENCY ALLIANCE |
| 189 | AN ADDRESS DELIVERED BEFORE THE MASSACHUSETTS COLLEGE OF PHARMACY, AT THE NINTH ANNUAL COMMENCEMENT, ON THE RELATIONS OF CHEMISTRY TO PHARMACY AND THERAPEUTICS | U.S. NATIONAL LIBRARY OF MEDICINE |
| 190 | AN ANALYSIS OF PHARMACEUTICAL LENDING BY THE WORLD BANK | THE WORLD BANK GROUP |
| 191 | AN ANALYSIS OF THE COST-EFFECTIVENESS AND EFFICACY OF TOBACCO CESSATION AIDS | DEFENSE TECHNICAL INFORMATION CENTER |
| 192 | AN ANALYSIS OF THE EFFECTIVENESS OF THE RETAIL PHARMACY UTILIZATION INTERVENTION AT GENERAL LEONARD WOOD ARMY COMMUNITY HOSPITAL | DEFENSE TECHNICAL INFORMATION CENTER |
| 193 | AN ANALYSIS OF WHO GUIDELINES FOR DRUG DONATIONS FOR BETTER DONATION PRACTICE IN EMERGENCY SITUATIONS | LEEDS INSTITUTE OF HEALTH SCIENCES, UNIVERSITY OF LEEDS |
| 194 | AN ASSESSMENT OF THE PHARMACEUTICAL SECTOR IN GHANA, NOVEMBER 2002 | WORLD HEALTH ORGANIZATION |
| 195 | AN ASSESSMENT OF US PHARMACEUTICAL DONATIONS: PLAYERS, PROCESSES, AND PRODUCTS | HARVARD SCHOOL OF PUBLIC HEALTH |
| 196 | AN EFFICACY AND PHARMACOKINETIC EVALUATION OF A DOSE OF DIAZEPAM THAT WILL REDUCE THE INCIDENCE OF CONVULSIONS IN INDIAN RHESUS MONKEYS PRETREATED WITH PYRIDOSTIGMINE BROMIDE, CHALLENGED WITH SOMAN, AND TREATED WITH ATROPINE AND PRALIDOXIME CHLORIDE WITH THE DIAZEPAM | DEFENSE TECHNICAL INFORMATION CENTER |
| 197 | AN ELEMENTARY COURSE IN INORGANIC PHARMACEUTICAL AND MEDICAL CHEMISTRY; DESIGNED ESPECIALLY FOR STUDENTS OF PHARMACY AND MEDICINE | WILEY |
| 198 | AN EMPIRICAL ANALYSIS OF THREE STOCHASTIC INVENTORY MODELS IN A NAVAL HOSPITAL | DEFENSE TECHNICAL INFORMATION CENTER |
| 199 | AN EVALUATION OF THE FIJI NATIONAL DRUGS POLICY | AN EVALUATION OF THE FIJI NATIONAL DRUGS POLICY |
| 200 | AN EVALUATION OF WHO’S ACTION PROGRAMME ON ESSENTIAL DRUGS | KIT |
| 201 | AN EVALUATION OF WHO’S ACTION PROGRAMME ON ESSENTIAL DRUGS, VOL. 2: COUNTRY STUDIES | KIT |
| 202 | AN EVALUATION OF WHO’S ACTION PROGRAMME ON ESSENTIAL DRUGS, VOL. 3: COUNTRY STUDIES | KIT |
| 203 | AN INAUGURAL ESSAY ON THE EFFECTS, & MODUS OPERANDI OF THE CARBONATES OF LIME, MAGNESIA, AND POTASH, IN THE CURE OF GENERAL & LOCAL DISEASES | U.S. NATIONAL LIBRARY OF MEDICINE |
| 204 | AN INTRODUCTION TO PRACTICAL PHARMACY [MICROFORM] : DESIGNED AS A TEXTBOOK FOR THE STUDENT AND AS A GUIDE TO THE PHYSICIAN AND PHARMACEUTIST : WITH MANY FORMULAS AND PRESCRIPTIONS | BLANCHARD AND LEA |
| 205 | AN INVENTORY AND SAFETY STOCK ANALYSIS OF AIR FORCE MEDICAL SERVICE PHARMACEUTICALS | DEFENSE TECHNICAL INFORMATION CENTER |
| 206 | AN UPDATED VIEW ON AN EMERGING TARGET: SELECTED PAPERS FROM THE 8TH INTERNATIONAL CONFERENCE ON PROTEIN KINASE CK2 | MDPI AG |
| 207 | ANALYSIS OF DRUG PRESCRIPTIONS IN PRIMARY HEALTH CARE CENTRES IN BAHRAIN | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 208 | ANALYSIS OF INVESTIGATIONAL DRUGS IN BIOLOGICAL FLUIDS-METHOD DEVELOPMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 209 | ANALYSIS OF INVESTIGATIONAL DRUGS IN BIOLOGICAL FLUIDS. METHOD DEVELOPMENT AND ROUTINE ASSAY | DEFENSE TECHNICAL INFORMATION CENTER |
| 210 | ANALYSIS OF INVESTIGATIONAL DRUGS IN BIOLOGICAL FLUIDS. METHOD DEVELOPMENT AND ROUTINE ASSAY. APPENDIX B. | DEFENSE TECHNICAL INFORMATION CENTER |
| 211 | ANALYSIS OF LEGAL ASPECTS OF LOCAL PHARMACEUTICAL PRODUCTION IN RWANDA | GERMAN TECHNICAL COOPERATION AGENCY |
| 212 | ANALYSIS OF THE POTENTIAL FOR PLANT UPTAKE OF TRICHLOROETHYLENE AND AN ASSESSMENT OF THE RELATIVE RISK FROM DIFFERENT CROP TYPES | DEFENSE TECHNICAL INFORMATION CENTER |
| 213 | ANALYSIS OF THE PUBLIC, PRIVATE AND MISSION SECTOR SUPPLY CHAINS FOR ESSENTIAL DRUGS IN ZAMBIA | MIT-ZARAGOZA INTERNATIONAL LOGISTICS PROGRAM |
| 214 | ANALYZING AND CONTROLLING PHARMACEUTICAL EXPENDITURES | MANAGEMENT SCIENCES FOR HEALTH |
| 215 | ANGOLA – COUNTRY DATA PROFILE ON THE PHARMACEUTICAL SITUATION IN THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY | ANGOLA MINISTRY OF HEALTH |
| 216 | ANNUAL PHARMACEUTICAL SECTOR PERFORMANCE REPORT 2013-2014 – UGANDA | UGANDA – MINISTRY OF HEALTH |
| 217 | ANNUAL REPORT 2003 – ESSENTIAL DRUGS AND MEDICINES POLICY | WHO HEADQUARTERS IN GENEVA |
| 218 | ANNUAL REPORT OF PHARMACY COUNCIL, MARCH 2010 – MARCH 2011 – ST. VINCENT AND THE GRENADINES | ST. VINCENT AND THE GRENADINES, MINISTRY OF HEALTH & THE ENVIRONMENT |
| 219 | ANNUAL REPORT ON THE PROGRESS OF PHARMACY | U.S. NATIONAL LIBRARY OF MEDICINE |
| 220 | ANTI-MALARIA DRUG POLICY FOR GHANA, 2ND REVISED VERSION 2009 | GHANA, MINISTRY OF HEALTH |
| 221 | ANTIBACTERIAL DRUG RESISTANCE | SWEDISH STRATEGIC PROGRAMME FOR THE RATIONAL USE OF ANTIMICROBIAL AGENTS AND SURVEILLANCE OF RESISTANCE |
| 222 | ANTIBIOTIKA-FORSCHUNG: PROBLEME UND PERSPEKTIVEN | DE GRUYTER |
| 223 | ANTIHYPERTENSIVE DRUGS | INTECH |
| 224 | ANTIMICROBIAL USE IN A COUNTRY WITH INSUFFICIENT ENFORCEMENT OF PHARMACEUTICAL REGULATIONS: A SURVEY OF CONSUMPTION AND RETAIL SALES IN ULAANBAATAR, MONGOLIA – SOUTHERN MED REVIEW VOL 3 ISSUE 1 FEB 2010 | WORLD HEALTH ORGANIZATION |
| 225 | ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE | MEDISCRIPT |
| 226 | ANTITUBERCULAR DRUG THERAPY – PAST, PRESENT AND FUTURE | SCIENCE PUBLISHING GROUP |
| 227 | ANTIVIRAL DRUGS – ASPECTS OF CLINICAL USE AND RECENT ADVANCES | INTECH |
| 228 | APPLICATION OF NANOTECHNOLOGY IN DRUG DELIVERY | INTECH |
| 229 | APPLIED CLINICAL PHARMACOKINETICS | MCGRAW-HILL |
| 230 | APPLIED E-LEARNING AND E-TEACHING IN HIGHER EDUCATION | DUBLIN INSTITUTE OF TECHNOLOGY |
| 231 | APPROACHES TO PROMOTE AVAILABILITY OF ESSENTIAL DRUGS IN PRIMARY HEALTH CARE IN SOUTH-EAST ASIA REGIONAL. REPORT OF AN LNTERCOUNTRY CONSULTATIVE MEETING NEW DELHI, 21-25 APRIL 1997 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR SOUTH-EAST ASIA |
| 232 | APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS | FOOD AND DRUG ADMINISTRATION |
| 233 | APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS CUMULATIVE SUPPLEMENT 6 JUNE 2016 | FOOD AND DRUG ADMINISTRATION |
| 234 | APPROVED DRUG LIST, MARCH 2011 – MALDIVES | REPUBLIC OF MALDIVES, MINISTRY OF HEALTH & FAMILY |
| 235 | ARE PHARMACEUTICALS INEXPENSIVE IN NORWAY? A COMPARISON OF PRICES OF PRESCRIPTION PHARMACEUTICALS BETWEEN NORWAY AND NINE WEST EUROPEAN COUNTRIES. SNF REPORT NO. 05/08 | INSTITUTE FOR RESEARCH IN ECONOMICS AND BUSINESS ADMINISTRATION, BERGEN, NORWAY |
| 236 | ARGENTINA PHARMACEUTICAL COUNTRY PROFILE, 2010 | ARGENTINA – MINISTRY OF HEALTH |
| 237 | ARITHMETIC FOR PHARMACY TECHNICIANS | U.S. NATIONAL LIBRARY OF MEDICINE |
| 238 | ARMENIA PHARMACEUTICAL COUNTRY PROFILE, 2010 | ARMENIA MINISTRY OF HEALTH |
| 239 | ARMENIAN PHARMACEUTICAL INDUSTRY, 2008. INVESTMENT HANDBOOK | ARMENIAN DEVELOPMENT AGENCY |
| 240 | ARMY DRUG DEVELOPMENT PROGRAM. PHASE 1. CLINICAL TESTING | DEFENSE TECHNICAL INFORMATION CENTER |
| 241 | ARMY DRUG DEVELOPMENT PROGRAM. PHASE I. CLINICAL TESTING | DEFENSE TECHNICAL INFORMATION CENTER |
| 242 | ARMY DRUG DEVELOPMENT PROGRAM. PHASE I. CLINICAL TESTING. | DEFENSE TECHNICAL INFORMATION CENTER |
| 243 | ASSESSING DIFFERENT PERSPECTIVES ON THE VALUE OF A PHARMACEUTICAL INNOVATION – SOUTHERN MED REVIEW VOL 3 ISSUE 1 FEB 2010 | WORLD HEALTH ORGANIZATION |
| 244 | ASSESSING EQUITY IN THE GEOGRAPHICAL DISTRIBUTION OF COMMUNITY PHARMACIES IN SOUTH AFRICA IN PREPARATION FOR A NATIONAL HEALTH INSURANCE SCHEME | WORLD HEALTH ORGANIZATION |
| 245 | ASSESSING PHARMACISTS’ IMPACTS IN PRIMARY HEALTH CARE: ARE WE ASKING THE RIGHT QUESTIONS? – SOUTHERN MED REVIEW VOL 4 ISSUE 1 APRIL 2011 | ASSESSING PHARMACISTS’ IMPACTS IN PRIMARY HEALTH CARE: ARE WE ASKING THE RIGHT QUESTIONS? – SOUTHERN MED REVIEW VOL 4 ISSUE 1 APRIL 2011 |
| 246 | ASSESSMENT OF GOVERNANCE AND CORRUPTION IN THE PHARMACEUTICAL SECTOR: LESSONS LEARNED FROM LOW AND MIDDLE INCOME COUNTRIES | THE WORLD BANK GROUP |
| 247 | ASSESSMENT OF MEDICAL PRACTITIONERS’ PERCEPTIONS OF CLINICAL PRACTICE GUIDELINES | PHILADELPHIA COLLEGE OF PHARMACY |
| 248 | ASSESSMENT OF NEEDS IN INFORMATION ON PHARMACEUTICAL AVAILABILITY AND PRICES – KYRGYZSTAN | WORLD HEALTH ORGANIZATION |
| 249 | ASSESSMENT OF PHARMACEUTICAL WHOLESALE MARKET IN GHANA. AN INCENTIVE SURVEY. META GHANA | MEDICINES TRANSPARENCY ALLIANCE |
| 250 | ASSESSMENT OF PHARMACOVIGILANCE AND MEDICINE SAFETY SYSTEM IN RWANDA, JULY 2009 | MANAGEMENT SCIENCES FOR HEALTH |
| 251 | ASSESSMENT OF REGULATORY IMPACTS ON PHARMACEUTICAL PROMOTION. BISHKEK, 2015 – KYRGYZSTAN | MEDICINES TRANSPARENCY ALLIANCE |
| 252 | ASSESSMENT OF THE GOOD MANUFACTURING PRACTICES INSPECTION PROGRAM OF THE BANGLADESH DIRECTORATE GENERAL OF DRUG ADMINISTRATION | MANAGEMENT SCIENCES FOR HEALTH |
| 253 | ASSESSMENT OF THE IMPACT OF PHARMACY BENEFIT MANAGERS | UNIVERSITY OF WISCONSIN |
| 254 | ASSESSMENT OF THE NATIONAL PHARMACEUTICAL SECTOR, LEVEL II HEALTH FACILITIES SURVEY. NORTH SUDAN, 2007 | SUDAN NATIONAL MINISTRY OF HEALTH |
| 255 | ASSESSMENT OF THE PHARMACEUTICAL HUMAN RESOURCES IN TANZANIA AND THE STRATEGIC FRAMEWORK | UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE |
| 256 | ASSESSMENT OF THE PHARMACEUTICAL SECTOR IN ETHIOPIA, OCTOBER 2003 | WORLD HEALTH ORGANIZATION |
| 257 | ASSESSMENT OF THE PHARMACEUTICAL SITUATION IN KENYA. A BASELINE SURVEY | WORLD HEALTH ORGANIZATION |
| 258 | ASSESSMENT OF THE REGULATORY SYSTEMS AND CAPACITY OF THE DIRECTORATE GENERAL FOR DRUG ADMINISTRATION IN BANGLADESH | MANAGEMENT SCIENCES FOR HEALTH |
| 259 | ASSESSMENT OF THE TB PHARMACEUTICAL MANAGEMENT SYSTEM IN NAMIBIA: FEBRUARY 13–MARCH 4, 2011 | MANAGEMENT SCIENCES FOR HEALTH |
| 260 | ATLAS OF VASCULAR DISEASE | CURRENT MEDICINE GROUP |
| 261 | ATROPINE’S EFFECTS UPON THE HEART AND ITS SYSTEMIC OUTPUT | DEFENSE TECHNICAL INFORMATION CENTER |
| 262 | AUDITABLE PHARMACEUTICAL TRANSACTIONS AND SERVICES (APTS): FINDINGS OF THE BASELINE ASSESSMENT AT FEDERAL, ADDIS ABABA, AND TEACHING HOSPITALS. JULY 2014 | MANAGEMENT SCIENCES FOR HEALTH |
| 263 | AUSTRALIAN GUIDELINE FOR PHARMACOVIGILANCE RESPONSIBILITIES OF SPONSORS OF REGISTERED MEDICINES REGULATED BY DRUG SAFETY AND EVALUATION BRANCH | AUSTRALIAN GOVERNMENT – DEPARTMENT OF HEALTH AND AGEING |
| 264 | AUSTRALIAN NATIONAL DRUG POLICIES: FACILITATING OR FRAGMENTING HEALTH? | AUSTRALIAN NATIONAL DRUG POLICIES: FACILITATING OR FRAGMENTING HEALTH? |
| 265 | AUSTRALIAN SCHEDULE OF PHARMACEUTICAL BENEFITS, 1 SEPTEMBER 2012 – 30 SEPTEMBER 2012 | AUSTRALIAN NATIONAL DRUG POLICIES: FACILITATING OR FRAGMENTING HEALTH? |
| 266 | AUSTRIA – PHARMACEUTICAL COUNTRY PROFILE, 2010 | AUSTRIAN FEDERAL MINISTRY OF HEALTH |
| 267 | AVAILABILITY OF FIVE ESSENTIAL MEDICINES FOR CHILDREN IN PUBLIC HEALTH FACILITIES IN INDIA: A SNAPSHOT SURVEY | JOURNAL OF PHARMACOLOGY AND PHARMACOTHERAPEUTICS |
| 268 | AZERBAIJAN PHARMACEUTICAL COUNTRY PROFILE, 12 MAY 2011 | AZERBAIJAN, MINISTRY OF HEALTH |
| 269 | BAHRAIN – PHARMACEUTICAL SECTOR COUNTRY PROFILE | BAHRAIN MINISTRY OF HEALTH |
| 270 | BALTIC STATISTICS ON MEDICINES 2010–2012 | ESTONIAN STATE AGENCY OF MEDICINES |
| 271 | BANGLADESH: A TOUGH BATTLE FOR A NATIONAL DRUG POLICY | BANGLADESH: A TOUGH BATTLE FOR A NATIONAL DRUG POLICY |
| 272 | BARBADOS NATIONAL DRUG FORMULARY (BNDF). A GUIDE TO RATIONAL PRESCRIBING. THIRTIETH EDITION, 2011-2012 | BARBADOS MINISTRY OF HEALTH, BARBADOS DRUG SERVICE |
| 273 | BARBADOS PHARMACEUTICAL COUNTRY PROFILE, SEPTEMBER 2011 | BARBADOS MINISTRY OF HEALTH, BARBADOS DRUG SERVICE |
| 274 | BARRIERS AND OPPORTUNITIES TO EFFECTIVELY ENGAGE PRIVATE SECTOR RETAIL PHARMACIES AS DOTS CENTERS IN PAKISTAN. FEBRUARY – JUNE 2015 | MANAGEMENT SCIENCES FOR HEALTH |
| 275 | BASELINE ASSESSMENT OF THE NIGERIAN PHARMACEUTICAL SECTOR – 2002 | NIGERIA MINISTRY OF HEALTH |
| 276 | BASELINE ASSESSMENT OF THE PHARMACEUTICAL SITUATION IN SOUTHERN AFRICAN DEVELOPMENT COMMUNITY COUNTRIES. FACT BOOK 2009 | WHO HEADQUARTERS IN GENEVA |
| 277 | BASELINE STUDY OF PRIVATE DRUG SHOPS IN BANGLADESH: FINDINGS AND RECOMMENDATIONS. FINAL REPORT, SEPTEMBER 2015 | MANAGEMENT SCIENCES FOR HEALTH |
| 278 | BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA, 2002 | UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE |
| 279 | BASIC AND CLINICAL PHARMACOLOGY | MCGRAW-HILL |
| 280 | BASIC AND CLINICAL PHARMACOLOGY KATZUNG 13 ED | MCGRAW-HILL |
| 281 | BASIC PHARMACOKINETIC CONCEPTS AND SOME CLINICAL APPLICATIONS | INTECH |
| 282 | BASIC TESTS FOR DRUGS – PHARMACEUTICAL SUBSTANCES, MEDICINAL PLANT MATERIALS AND DOSAGE FORMS | WHO HEADQUARTERS IN GENEVA |
| 283 | BASIC TESTS FOR PHARMACEUTICAL DOSAGE FORMS | WHO HEADQUARTERS IN GENEVA |
| 284 | BASIC TESTS FOR PHARMACEUTICAL SUBSTANCES | WHO HEADQUARTERS IN GENEVA |
| 285 | BEATING PAIN: A POCKET GUIDE FOR PAIN MANAGEMENT IN AFRICA | AFRICAN PALLIATIVE CARE ASSOCIATION |
| 286 | BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE | DEFENSE TECHNICAL INFORMATION CENTER |
| 287 | BELAU NATIONAL HOSPITAL DRUG FORMULARY, 2006 – REPUBLIC OF PALAU | PALAU – MINISTRY OF HEALTH |
| 288 | BELGIUM – PHARMACEUTICAL SECTOR COUNTRY PROFILE | WORLD HEALTH ORGANIZATION |
| 289 | BELIZE DRUG FORMULARY AND THERAPEUTICS MANUAL, 9TH EDITION, 2009-2011 | BELIZE – MINISTRY OF HEALTH |
| 290 | BEN TAUB GENERAL HOSPITAL & LIFEGIFT: STRENGTHENING A PARTNERSHIP TO SAVE LIVES AND IMPROVE HEALTHCARE DELIVERY | DEFENSE TECHNICAL INFORMATION CENTER |
| 291 | BENCHMARKS FOR TRAINING IN AYURVEDA | WHO HEADQUARTERS IN GENEVA |
| 292 | BENCHMARKS FOR TRAINING IN NATUROPATHY | WHO HEADQUARTERS IN GENEVA |
| 293 | BENCHMARKS FOR TRAINING IN NUAD THAI | WHO HEADQUARTERS IN GENEVA |
| 294 | BENCHMARKS FOR TRAINING IN OSTEOPATHY | WHO HEADQUARTERS IN GENEVA |
| 295 | BENCHMARKS FOR TRAINING IN TRADITIONAL CHINESE MEDICINE | WHO HEADQUARTERS IN GENEVA |
| 296 | BENCHMARKS FOR TRAINING IN TUINA | WHO HEADQUARTERS IN GENEVA |
| 297 | BENCHMARKS FOR TRAINING IN UNANI MEDICINE | WHO HEADQUARTERS IN GENEVA |
| 298 | BEST KEPT SECRETS: A HISTORY OF WHAT HAS BEEN GOING ON BEHIND THE SCENES | UNIVERSAL LIBRARY |
| 299 | BETA-BLOCKERS: AN ABSTRACTED BIBLIOGRAPHY | DEFENSE TECHNICAL INFORMATION CENTER |
| 300 | BETTER MEDICINES FOR CHILDREN IN INDIA. REPORT ON INFORMAL CONSULTATION WHO-SEARO, NEW DELHI, INDIA, 2–3 FEBRUARY 2010 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR SOUTH-EAST ASIA |
| 301 | BETTER MEDICINES FOR CHILDREN PROJECT. OVERVIEW OF METHODS FOR MEDICINES AVAILABILITY AND PRICING SURVEYS | WHO HEADQUARTERS IN GENEVA |
| 302 | BETTER MEDICINES FOR CHILDREN. COMMUNICATIONS. QUICK PLANNING GUIDE | WHO HEADQUARTERS IN GENEVA |
| 303 | BETTER PROCUREMENT AND SUPPLY MANAGEMENT OF HIV/AIDS DRUGS AND SUPPLIES | THE WORLD BANK GROUP |
| 304 | BEYOND RANDOMIZED TRIALS – TB TREATMENT IN CHILDREN | THE WORLD BANK GROUP |
| 305 | BHUTAN ESSENTIAL DRUGS PROGRAMME: A CASE HISTORY | WHO HEADQUARTERS IN GENEVA |
| 306 | BHUTAN NATIONAL DRUG POLICY 2007 | BHUTAN MINISTRY OF HEALTH |
| 307 | BIG PHARMA AND SOCIAL RESPONSIBILITY — THE ACCESS TO MEDICINE INDEX | BIG PHARMA AND SOCIAL RESPONSIBILITY — THE ACCESS TO MEDICINE INDEX |
| 308 | BIGPHARMA AND UNETHICAL MARKETING OF MEDICINAL PRODUCTS – SOUTHERN MED REVIEW VOL 4 ISSUE 2 DEC 2011 | BIGPHARMA AND UNETHICAL MARKETING OF MEDICINAL PRODUCTS – SOUTHERN MED REVIEW VOL 4 ISSUE 2 DEC 2011 |
| 309 | BIOACTIVE COMPOUNDS FROM MARINE-DERIVED ASPERGILLUS, PENICILLIUM, TALAROMYCES AND TRICHODERMA SPECIES | MDPI AG |
| 310 | BIOACTIVE COMPOUNDS IN PHYTOMEDICINE | INTECH |
| 311 | BIOACTIVE FOOD PEPTIDES IN HEALTH AND DISEASE | INTECH |
| 312 | BIOAVAILABILITY OF ORAL PYRIDOSTIGMINE AND INHIBITION OF RED BLOOD CELL ACETYLCHOLINESTERASE BY ORAL AND INTRAVENOUS PYRIDOSTIGMINE | DEFENSE TECHNICAL INFORMATION CENTER |
| 313 | BIOAVAILABILITY OF VOLATILE ORGANICS AND OTHER HYDROCARBONS FROM ENVIRONMENTAL MEDIA: INGESTION IN DRINKING WATER | DEFENSE TECHNICAL INFORMATION CENTER |
| 314 | BIODEGRADABLE POLYMERS AS DRUG DELIVERY SYSTEMS | MARCEL DEKKER INC. |
| 315 | BIOLOGICAL CONTROL OF GASTRO-INTESTINAL NEMATODES OF RUMINANTS USING PREDACIOUS FUNGI : PROCEEDINGS OF A WORKSHOP | FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS |
| 316 | BIOLOGICAL-MATHEMATICAL MODELING OF CHRONIC TOXICITY | DEFENSE TECHNICAL INFORMATION CENTER |
| 317 | BIOMEDICAL CHEMISTRY | DE GRUYTER |
| 318 | BIOMEDICAL EFFECTS OF CHEMICAL-THREAT-AGENT ANTIDOTE AND PRETREATMENT DRUGS. AN ABSTRACTED BIBLIOGRAPHY. VOLUME 1. | DEFENSE TECHNICAL INFORMATION CENTER |
| 319 | BIOSYNTHESIS, DEGRADATION, AND INTRACELLULAR TARGETING OF EAAC1 GLUTAMATE/ASPARTATE TRANSPORTER IN C6 GLIOMA CELLS | UNIVERSITY OF FLORIDA |
| 320 | BIOTECHNOLOGY AND THE ECONOMICS OF DISCOVERY IN THE PHARMACEUTICAL INDUSTRY | OHE |
| 321 | BIOTERRORISM | INTECH |
| 322 | BLISTER PACKAGING MEDICATION TO INCREASE TREATMENT ADHERENCE AND CLINICAL RESPONSE: IMPACT ON SUICIDE-RELATED MORBIDITY AND MORTALITY | DEFENSE TECHNICAL INFORMATION CENTER |
| 323 | BLOOD SUBSTITUTES: EFFECTS ON DRUG PHARMACOKINETICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 324 | BLOOD-BRAIN BARRIER TRANSPORT OF URANIUM | DEFENSE TECHNICAL INFORMATION CENTER |
| 325 | BOOSTING PHARMACEUTICAL CAPACITY TO INCREASE ACCESS TO TREATMENT. A PARTNERSHIP OF 15 AFRICAN COUNTRIES, THE EU, ACP AND WHO | INTERNATIONAL ATOMIC ENERGY AGENCY |
| 326 | BOTSWANA ESSENTIAL DRUG LIST (BEDL). FIRST EDITION, 2005 | BOTSWANA ESSENTIAL DRUG ACTION PROGRAMME |
| 327 | BOTSWANA ESSENTIAL DRUG LIST (BEDL). SECOND EDITION, 2012 | BOTSWANA ESSENTIAL DRUG ACTION PROGRAMME |
| 328 | BOTSWANA NATIONAL DRUG (MEDICINE) POLICY (BNDP). FIRST EDITION, AUGUST 2002 | BOTSWANA MINISTRY OF HEALTH |
| 329 | BRITISH NATIONAL FORMULARY | BMJ PUBLISHING GROUP LTD. |
| 330 | BRITISH NATIONAL FORMULARY FOR CHILDREN | BMJ PUBLISHING GROUP LTD. |
| 331 | BRITISH VIRGIN ISLANDS PHARMACEUTICAL COUNTRY PROFILE, 2013 | BRITISH VIRGIN ISLANDS – MINISTRY OF HEALTH AND SOCIAL DEVELOPMENT |
| 332 | BROADLY APPLICABLE NANOWAFER DRUG DELIVERY SYSTEM FOR TREATING EYE INJURIES | DEFENSE TECHNICAL INFORMATION CENTER |
| 333 | BRUNEI DARUSSALAM GUIDELINES FOR MANUFACTURING AND HANDLING OF HALAL MEDICINAL PRODUCTS, TRADITIONAL MEDICINES AND HEALTH SUPPLEMENTS. GUIDANCE DOCUMENT GD24, FIRST EDITION, MAY 2010 | THE RELIGIOUS COUNCIL NEGARA BRUNEI DARUSSALAM |
| 334 | BUILDING CLINICAL TRIAL CAPACITY TO DEVELOP A NEW TREATMENT FOR MULTIDRUG-RESISTANT TUBERCULOSIS | WHO HEADQUARTERS IN GENEVA |
| 335 | BUILDING CLINICAL TRIALS CAPACITY FOR TUBERCULOSIS DRUGS IN HIGH-BURDEN COUNTRIES | BUILDING CLINICAL TRIALS CAPACITY FOR TUBERCULOSIS DRUGS IN HIGH-BURDEN COUNTRIES |
| 336 | BUILDING LOCAL CAPACITY FOR CLINICAL PHARMACY SERVICE IN ETHIOPIA THROUGH A HOLISTIC IN-SERVICE TRAINING APPROACH | MANAGEMENT SCIENCES FOR HEALTH |
| 337 | BUILDING LOCAL COALITIONS FOR CONTAINING DRUG RESISTANCE: A GUIDE | MANAGEMENT SCIENCES FOR HEALTH |
| 338 | BUT SOME DRUGS ARE MORE ESSENTIAL THAN OTHERS! | WHO HEADQUARTERS IN GENEVA |
| 339 | CAFFEINE, ADENOSINE RECEPTORS AND ESTROGEN IN TOXIN MODELS OF PARKINSON’S DISEASE | DEFENSE TECHNICAL INFORMATION CENTER |
| 340 | CALCIUM CHANNEL BLOCKERS | SPRINGER |
| 341 | CAN NGOS REGULATE MEDICINES MARKETS? SOCIAL ENTERPRISE IN WHOLESALING, AND ACCESS TO ESSENTIAL MEDICINES | WORLD HEALTH ORGANIZATION |
| 342 | CAN THE PUBLIC CENTRAL MEDICAL SUPPLIES CORPORATION OF SUDAN BALANCE A POLICY FOR DELIVERING LOW-COST MEDICINES WHILST MAINTAINING QUALITY? | WORLD HEALTH ORGANIZATION |
| 343 | CANCER PAIN MANAGEMENT | THE BRITISH PAIN SOCIETY |
| 344 | CANCER PAIN RELIEF | WORLD HEALTH ORGANIZATION |
| 345 | CAPILLARY ELECTROPHORESIS METHODS FOR PHARMACEUTICAL ANALYSIS | ELSEVIER |
| 346 | CENTRAL BIOGENIC AMINE RECEPTOR ADAPTATION DURING ANTIDEPRESSANT TREATMENT : STUDIES DIRECTED AT THERAPEUTIC MECHANISMS | UNIVERSITY OF FLORIDA |
| 347 | CHARACTERIZATION OF THE HUMAN PROTEOMIC RESPONSE TO HYDROCODONE: A PRELIMINARY STUDY | DEFENSE TECHNICAL INFORMATION CENTER |
| 348 | CHARACTERIZATION OF THE MECHANISM OF THE SUB-TYPE SELECTIVE, SLOW-DISSOCIATION OF A CARBOSTYRIL BASED B-ADRENERGIC RECEPTOR AGONIST FROM THE B2-ADRENERGIC RECEPTOR | UNIVERSITY OF FLORIDA |
| 349 | CHEMICAL ANALYSIS OF SULFONES USED FOR THE TREATMENT OF MALARIA | DEFENSE TECHNICAL INFORMATION CENTER |
| 350 | CHEMICAL BIOLOGY | INTECH |
| 351 | CHEMICAL EXAMINATION OF ERIODICTYON | WELLCOME LIBRARY |
| 352 | CHEMICAL EXAMINATION OF GYMNEMA LEAVES | WELLCOME LIBRARY |
| 353 | CHEMICAL KINETICS | INTECH |
| 354 | CHEMOMODULATION OF DOXORUBICIN PHARMACODYNAMICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 355 | CHILDREN’S MEDICINES: A SITUATIONAL ANALYSIS. NOVEMBER 2011 | WORLD HEALTH ORGANIZATION |
| 356 | CHIRAL CAPILLARY ELECTROPHORESIS IN CURRENT PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | INTECH |
| 357 | CLEVELAND HOSPITAL AND HEALTH SURVEY | CLEVELAND HOSPITAL COUNCIL |
| 358 | CLINICAL APPLICATIONS OF PHARMACOGENETICS | INTECH |
| 359 | CLINICAL CONSIDERATIONS IN THE USE OF PYRIDOSTIGMINE BROMIDE AS PRETREATMENT FOR NERVE-AGENT EXPOSURE | DEFENSE TECHNICAL INFORMATION CENTER |
| 360 | CLINICAL GUIDELINES FOR THE USE OF BUPRENORPHINE IN THE TREATMENT OF OPIOID ADDICTION. TREATMENT IMPROVEMENT PROTOCOL (TIP) SERIES 40 | ERIC |
| 361 | CLINICAL INVESTIGATIONS | DEFENSE TECHNICAL INFORMATION CENTER |
| 362 | CLINICAL PHARMACOLOGY AND THERAPEUTICS | HODDER ARNOLD |
| 363 | CLINICAL PHARMACOLOGY IN HEALTH CARE, TEACHING AND RESEARCH | WORLD HEALTH ORGANIZATION |
| 364 | CLINICAL TRIALS NETWORK / BUILDING INFRASTRUCTURE TO ACCELERATE TRANSFER OF BASIC RESEARCH IN SPINAL CORD INJURY (SCI) TO CLINICAL PRACTICE | DEFENSE TECHNICAL INFORMATION CENTER |
| 365 | CLINICAL USE OF LOCAL ANESTHETICS | INTECH |
| 366 | CODE OF CONDUCT FOR PHARMACISTS AND BODIES CORPORATE, 2009 – PHARMACY BOARD MALAYSIA | MALAYSIA – MINISTRY OF HEALTH |
| 367 | CODE OF CONDUCT FOR REGISTERED HEALTH PRACTITIONERS – PHARMACY BOARD OF AUSTRALIA | MALAYSIA – MINISTRY OF HEALTH |
| 368 | COLLABORATION BETWEEN NGOS, MINISTRIES OF HEALTH AND WHO IN DRUG DISTRIBUTION AND SUPPLY – EDM RESEARCH SERIES NO. 027 | WHO HEADQUARTERS IN GENEVA |
| 369 | COLOR ATLAS OF PHARMACOLOGY | THIEME MEDICAL PUBLISHERS |
| 370 | COMBATING COUNTERFEIT, FALSIFIED AND SUBSTANDARD MEDICINES: DEFINING THE WAY FORWARD? CHATHAM HOUSE BRIEFING PAPER, NOVEMBER 2010 | CENTRE ON GLOBAL HEALTH SECURITY |
| 371 | COMBINATION THERAPY OF AIDS | SPRINGER |
| 372 | COMMUNITY HEALTH WORKERS AND DRUGS: A CASE STUDY OF THAILAND – EDM RESEARCH SERIES NO. 015 | WHO HEADQUARTERS IN GENEVA |
| 373 | COMMUNITY INTERVENTION TO IMPROVE KNOWLEDGE AND PRACTICES ON COMMONLY USED DRUGS | COMMUNITY INTERVENTION TO IMPROVE KNOWLEDGE AND PRACTICES ON COMMONLY USED DRUGS |
| 374 | COMMUNITY PHARMACY BASED RESEARCH ACTIVITY IN INDIA: A BIBLIOMETRIC STUDY OF THE PAST TEN YEARS – SOUTHERN MED REVIEW VOL 3 ISSUE 1 FEB 2010 | ANNAMALAI UNIVERSITY |
| 375 | COMPANION HANDBOOK TO THE WHO GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS | WHO HEADQUARTERS IN GENEVA |
| 376 | COMPARATIVE ANALYSES OF CHINA NATIONAL & TWENTY-TWO SELECTED PROVINCIAL ESSENTIAL MEDICINE LISTS TO THE WHO 2011 MODEL LIST | WORLD HEALTH ORGANIZATION |
| 377 | COMPARATIVE ANALYSIS OF NATIONAL DRUG POLICIES – SECOND WORKSHOP GENEVA, 10-13 JUNE 1996 – EDM RESEARCH SERIES NO. 025 | WORLD HEALTH ORGANIZATION |
| 378 | COMPARATIVE ANALYSIS OF PHARMACOVIGILANCE SYSTEMS IN FIVE ASIAN COUNTRIES | MANAGEMENT SCIENCES FOR HEALTH |
| 379 | COMPARATIVE KINETICS AND DISTRIBUTION TO TARGET TISSUES OF ORGANOPHOSPHATES USING PHYSIOLOGICALLY – BASED PHARMACOKINETIC MODELING | DEFENSE TECHNICAL INFORMATION CENTER |
| 380 | COMPARISON OF THE PHARMACOKINETICS AND TOXICITY OF SULFISOXAZOLE IN HUMANS AND TWO MONOGASTRIC ANIMAL SPECIES | UNIVERSITY OF FLORIDA |
| 381 | COMPENDIUM OF GOOD MANUFACTURING PRACTICES (GMP) TECHNICAL DOCUMENTS FOR HARMONIZATION OF MEDICINES REGULATION IN THE EAST AFRICAN COMMUNITY, 2014 | EAST AFRICAN COMMUNITY |
| 382 | COMPENDIUM OF QUALITY MANAGEMENT SYSTEM (QMS) TECHNICAL DOCUMENTS FOR HARMONIZATION OF MEDICINES REGULATION IN THE EAST AFRICAN COMMUNITY, 2104 | EAST AFRICAN COMMUNITY |
| 383 | COMPETENCE TRAINING FOR PHARMACY | MDPI AG |
| 384 | COMPETENCES FOR PHARMACY EDUCATION AND PRACTICE IN EUROPE | MDPI AG |
| 385 | COMPETITION THROUGH INNOVATION, INNOVATION THROUGH COMPETITION | OHE |
| 386 | COMPLEMENTARY AND ALTERNATIVE MEDICINE TREATMENTS IN PSYCHIATRY | FLYING PUBLISHER |
| 387 | COMPREHENSIVE ASSESSMENT OF PHARMACOVIGILANCE SYSTEMS AND THEIR PERFORMANCE IN SUB-SAHARAN AFRICA | MANAGEMENT SCIENCES FOR HEALTH |
| 388 | COMPREHENSIVE SYSTEMS BIOMEDICINE | FRONTIERS MEDIA SA |
| 389 | COMPUTATIONAL APPROACHES FOR PREDICTING NONLINEAR INTERACTIONS OF CHEMICAL MIXTURES IN BIOLOGICAL SYSTEMS | DEFENSE TECHNICAL INFORMATION CENTER |
| 390 | COMPUTATIONAL MODELS IN ONCOLOGY: FROM TUMOR INITIATION TO PROGRESSION TO TREATMENT | FRONTIERS MEDIA SA |
| 391 | COMPUTATIONAL PHARMACOKINETICS | CHAPMAN & HALL |
| 392 | COMPUTER ASSISTED TWO-COMPARTMENT PHARMACOKINETICS FOR THE INDIVIDUALIZATION OF DRUG DOSING | NA |
| 393 | COMPUTERS IN PHARMACEUTICAL MANAGEMENT | MANAGEMENT SCIENCES FOR HEALTH |
| 394 | CONDITION-ACTION DIAGRAM FLOWCHARTS. PHARMACY MANUAL SYSTEMS | DEFENSE TECHNICAL INFORMATION CENTER |
| 395 | CONSIDERATIONS FOR REQUESTING ANALYSIS OF DRUG SAMPLES. WHO TECHNICAL REPORT SERIES, NO. 902, 2002, ANNEX 4 | WORLD HEALTH ORGANIZATION |
| 396 | CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION: WHAT’S NEW. POLICY BRIEF. NOVEMBER 2015 | WHO HEADQUARTERS IN GENEVA |
| 397 | CONSOLIDATION AND COMPETITION IN THE PHARMACEUTICAL INDUSTRY | OHE |
| 398 | CONTAINING ANTIMICROBIAL RESISTANCE – WHO POLICY PERSPECTIVES ON MEDICINES, NO. 010, APRIL 2005 | WHO HEADQUARTERS IN GENEVA |
| 399 | CONTINUITY AND CHANGE — IMPLEMENTING THE THIRD WHO MEDICINES STRATEGY 2008-2013. WHO POLICY PERSPECTIVES ON MEDICINES, NO. 011, APRIL 2010 | WHO HEADQUARTERS IN GENEVA |
| 400 | CONTINUITY AND CHANGE: IMPLEMENTING THE THIRD WHO MEDICINES STRATEGY – 2008-2013 | WHO HEADQUARTERS IN GENEVA |
| 401 | CONTROLLING THE COST OF IMPORTED MEDICINES. A CASE STUDY: TUNISIA – REGULATORY SUPPORT SERIES, NO. 010 | WHO HEADQUARTERS IN GENEVA |
| 402 | CORPORATE RESPONSIBILITIES FOR ACCESS TO MEDICINES | NOVARTIS FOUNDATION FOR SUSTAINABLE DEVELOPMENT |
| 403 | CORRUPTION IN THE PHARMACEUTICAL SECTOR. DIAGNOSING THE CHALLENGES | TRANSPARENCY INTERNATIONAL – PHARMACEUTICALS & HEALTHCARE PROGRAMME |
| 404 | COST ANALYSIS FOR THE RETURN AND DISPOSAL OF EXPIRED NAVY PHARMACEUTICALS | NAVAL POSTGRADUATE SCHOOL |
| 405 | COST SAVINGS OF SWITCHING PRIVATE SECTOR CONSUMPTION FROM ORIGINATOR BRAND MEDICINES TO GENERIC EQUIVALENTS. WORLD HEALTH REPORT (2010) – BACKGROUND PAPER, 35 | WHO HEADQUARTERS IN GENEVA |
| 406 | COST-ANALYSIS OF THE WHO ESSENTIAL MEDICINES LIST IN A RESOURCE-LIMITED SETTING: EXPERIENCE FROM A DISTRICT HOSPITAL IN INDIA | WORLD HEALTH ORGANIZATION |
| 407 | COST-CONTAINMENT MECHANISMS FOR ESSENTIAL MEDICINES, INCLUDING ANTIRETROVIRALS, IN CHINA – HEALTH ECONOMICS AND DRUGS SERIES NO. 013 | WHO HEADQUARTERS IN GENEVA |
| 408 | COSTS AND BENEFITS OF REGULATING NEW PRODUCT DEVELOPMENT IN THE UK PHARMACEUTICAL INDUSTRY | OHE |
| 409 | COUNSELING MANUAL ON HEALTH CAREERS IN STATE OF MISSOURI | ERIC |
| 410 | COUNTERFEIT AND SUBSTANDARD DRUGS IN MYANMAR AND VIET NAM – REPORT OF A STUDY CARRIED OUT IN COOPERATION WITH THE GOVERNMENTS OF MYANMAR AND VIET NAM – EDM RESEARCH SERIES N0. 029 | WHO HEADQUARTERS IN GENEVA |
| 411 | COUNTERFEIT DRUGS KILL! | INTERNATIONAL MEDICAL PRODUCTS ANTI-COUNTERFEITING TASKFORCE |
| 412 | COUNTERFEIT DRUGS. GUIDELINES FOR THE DEVELOPMENT OF MEASURES TO COMBAT COUNTERFEIT DRUGS | WORLD HEALTH ORGANIZATION |
| 413 | COUNTERFEIT DRUGS. REPORT OF THE WHO/IFPMA WORKSHOP, 1-3 APRIL 1992 | WHO HEADQUARTERS IN GENEVA |
| 414 | COUNTRY PHARMACEUTICAL SITUATIONS. FACT BOOK ON WHO LEVEL 1 INDICATORS, 2007 | WHO HEADQUARTERS IN GENEVA |
| 415 | COUNTRY REPORTS. THE STUDY PROGRAMME FOR THE PHARMACEUTICAL AFFAIRS EXPERTS. NOVEMBER 2009, JAPAN | JAPAN – MINISTRY OF HEALTH, LABOUR AND WELFARE |
| 416 | CPD PROGRAMS FOR PHARMACY PROFESSIONALS ASSESSMENT REPORT ON STATUS OF IMPLEMENTATION IN KENYA | KENYA MINISTRY OF HEALTH – PHARMACY AND POISONS BOARD |
| 417 | CREATING SAFER AND MORE EFFICIENT PHARMACIES THROUGH EVIDENCE-BASED DESIGN | CREATING SAFER AND MORE EFFICIENT PHARMACIES THROUGH EVIDENCE-BASED DESIGN |
| 418 | CRITERIA AND PROCEDURE OF DRUG REGISTRATION. DECREE NUMBER: HK.00.05.3.1950 – INDONESIA | INDONESIA – NATIONAL AGENCY OF DRUG AND FOOD CONTROL |
| 419 | CROATIA PHARMACEUTICAL COUNTRY PROFILE, 01 JUNE 2011 | CROATIA, MINISTRY OF HEALTH AND SOCIAL WELFARE |
| 420 | CROSSOVER COMPARISON OF THE PHARMACOKINETICS OF ATROPINE AND PRALIDOXIME CHLORIDE IN THREE MULTICHAMBERED AUTOINJECTOR SYSTEMS AND THE MARK 1. TASK 90-15 | DEFENSE TECHNICAL INFORMATION CENTER |
| 421 | CURRICULUM GUIDELINES & REGULATORY CRITERIA FOR FAMILY NURSE PRACTITIONERS SEEKING PRESCRIPTIVE AUTHORITY TO MANAGE PHARMACOTHERAPEUTICS IN PRIMARY CARE | ERIC |
| 422 | DAKAR DECLARATION. ACAME, 2006 (AFRICAN ASSOCIATION OF ESSENTIAL DRUGS NATIONAL PURCHASING CENTRES) | ACAME – ASSOCIATION AFRICAINE DES CENTRALES D’ACHATS DE MÉDICAMENTS ESSENTIELS / AFRICAN ASSOCIATION OF ESSENTIAL DRUGS NATIONAL PURCHASING CENTRES |
| 423 | DEALING WITH UNCERTAINTY IN CHEMICAL RISK ANALYSIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 424 | DECONTAMINATION OF COMBAT WOUNDS IN THE INJURED SOLDIER | DEFENSE TECHNICAL INFORMATION CENTER |
| 425 | DECREASE IN PRICES OF ANTIRETROVIRAL DRUGS FOR DEVELOPING COUNTRIES: FROM POLITICAL “PHILANTHROPY” TO REGULATED MARKETS? | DECREASE IN PRICES OF ANTIRETROVIRAL DRUGS FOR DEVELOPING COUNTRIES: FROM POLITICAL “PHILANTHROPY” TO REGULATED MARKETS? |
| 426 | DEFINING AND MEASURING PHARMACEUTICAL SYSTEMS STRENGTHENING: REPORT OF THE SIAPS PARTNERS’ CONSULTATIVE MEETING. SEPTEMBER 11-12, 2014 | MANAGEMENT SCIENCES FOR HEALTH |
| 427 | DEMONSTRATION PROJECT ON MAMMOGRAPHIC COMPUTER-AIDED DIAGNOSIS FOR BREAST CANCER DETECTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 428 | DESIGN, SYNTHESIS, PHARMACOKINETIC, AND PHARMACODYNAMIC EVALUATION OF A NEW CLASS OF SOFT ANTICHOLINERGICS | UNIVERSITY OF FLORIDA |
| 429 | DETECTING SPONSORED RECOMMENDATIONS | ARXIV |
| 430 | DETERMINATION OF DRUG PHARMACOKINETICS AND METABOLIC PROFILE. VOLUME 1 | DEFENSE TECHNICAL INFORMATION CENTER |
| 431 | DETERMINATION OF DRUG PHARMACOKINETICS AND METABOLIC PROFILE. VOLUME 2 | DEFENSE TECHNICAL INFORMATION CENTER |
| 432 | DETERMINATION OF PARTITION COEFFICIENTS FOR A MIXTURE OF VOLATILE ORGANIC COMPOUNDS IN RATS AND HUMANS AT DIFFERENT LIFE STAGES | DEFENSE TECHNICAL INFORMATION CENTER |
| 433 | DETERMINATION OF SUBPICOGRAM QUANTITIES OF DRUGS AND NARCOTICS IN URINE OF HUMAN SUBJECTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 434 | DEVELOPING AND IMPLEMENTING CARIBBEAN PHARMACEUTICAL POLICY | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE AMERICAS |
| 435 | DEVELOPING PHARMACY PRACTICE: A FOCUS ON PATIENT CARE. HANDBOOK – 2006 EDITION | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 436 | DEVELOPING STANDARD METHODS TO MONITOR ADHERENCE TO ANTIRETROVIRAL MEDICINES AND TREATMENT DEFAULTING IN RESOURCE-POOR SETTINGS | WHO HEADQUARTERS IN GENEVA |
| 437 | DEVELOPING, IMPLEMENTING, AND MONITORING THE USE OF STANDARD TREATMENT GUIDELINES: A SIAPS HOW-TO MANUAL | MANAGEMENT SCIENCES FOR HEALTH |
| 438 | DEVELOPMENT AND VALIDATION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF CHLORAL HYDRATE AND ITS MAIN METABOLITES | DEFENSE TECHNICAL INFORMATION CENTER |
| 439 | DEVELOPMENT AND VALIDATION OF METHODS FOR APPLYING PHARMACOKINETIC DATA IN RISK ASSESSMENT. VOLUME 1. EXECUTIVE SUMMARY/INTRODUCTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 440 | DEVELOPMENT AND VALIDATION OF METHODS FOR APPLYING PHARMACOKINETIC DATA IN RISK ASSESSMENT. VOLUME 2. TRICHLOROETHYLENE | DEFENSE TECHNICAL INFORMATION CENTER |
| 441 | DEVELOPMENT AND VALIDATION OF METHODS FOR APPLYING PHARMACOKINETIC DATA IN RISK ASSESSMENT. VOLUME 4. METHYLCHLOROFORM | DEFENSE TECHNICAL INFORMATION CENTER |
| 442 | DEVELOPMENT AND VALIDATION OF METHODS FOR APPLYING PHARMACOKINETIC DATA IN RISK ASSESSMENT. VOLUME 5. VINYL CHLORIDE | DEFENSE TECHNICAL INFORMATION CENTER |
| 443 | DEVELOPMENT AND VALIDATION OF METHODS FOR APPLYING PHARMACOKINETIC DATA IN RISK ASSESSMENT. VOLUME 6. SENSITIVITY AND UNCERTAINTY ANALYSIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 444 | DEVELOPMENT OF A FDA-APPROVED PHARMACEUTICAL TO TREAT NOISE-INDUCED HEARING LOSS | DEFENSE TECHNICAL INFORMATION CENTER |
| 445 | DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF TRICHLOROETHYLENE AND ITS METABOLITES FOR USE IN RISK ASSESSMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 446 | DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF TRICHLOROETHYLENE AND ITS METABOLITIES FOR USE IN RISK ASSESSMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 447 | DEVELOPMENT OF A THERAPEUTIC AGENT FOR WOUND-HEALING ENHANCEMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 448 | DEVELOPMENT OF IN VITRO ISOLATED PERFUSED PORCINE SKIN FLAPS FOR STUDY OF PERCUTANEOUS ABSORPTION OF XENOBIOTICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 449 | DEVELOPMENT OF INDICATORS FOR MONITORING NATIONAL DRUG POLICIES – EDM RESEARCH SERIES NO. 004 | WHO HEADQUARTERS IN GENEVA |
| 450 | DEVELOPMENT OF MICROCOMPUTER METHODS FOR ANALYSIS AND SIMULATION OF CLINICAL PHARMACOKINETIC DATA RELEVANT TO NEW DRUG DEVELOPMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 451 | DEVELOPMENT OF NOVEL EPIDERMAL GROWTH RECEPTOR-BASED RADIOPHARMACEUTICALS: IMAGING AGENTS FOR BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 452 | DEVELOPMENT OF NOVEL TECHNETIUM-99M-LABELED STEROIDS AS ESTROGEN-RESPONSIVE BREAST CANCER IMAGING AGENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 453 | DEVELOPMENT OF PAEDIATRIC MEDICINES: POINTS TO CONSIDER IN FORMULATION. WHO TECHNICAL REPORT SERIES, NO. 970, 2012, ANNEX 5 | WORLD HEALTH ORGANIZATION |
| 454 | DEVELOPMENT OF SYSTEMS FOR DELIVERY OF ANTIVIRAL DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 455 | DEVELOPMENT OF TRADITIONAL MEDICINE IN THE SOUTH-EAST ASIA REGION. REPORT OF A REGIONAL CONSULTATIVE MEETING, PYONGYANG, DPR KOREA, 22-24 JUNE 2005 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR SOUTH-EAST ASIA |
| 456 | DEVELOPMENTS IN QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSAR). A REVIEW | DEFENSE TECHNICAL INFORMATION CENTER |
| 457 | DIAGNOSTIC AND THERAPEUTIC RADIOPHARMACEUTICAL AGENTS FOR SELECTIVE DISCRIMINATION OF PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 458 | DIAGNOSTIC IMAGING/MAMMOGRAPHY CERTIFICATION AND QUANTITATIVE EVALUATION OF ULTRASOUND CT BREAST IMAGING SYSTEM | DEFENSE TECHNICAL INFORMATION CENTER |
| 459 | DIAZEPAM PHARMACOKINETICS IN RHESUS MACAQUE (MACACA MULATTA) | DEFENSE TECHNICAL INFORMATION CENTER |
| 460 | DIFFERENCES IN THE AVAILABILITY OF MEDICINES FOR CHRONIC AND ACUTE CONDITIONS IN THE PUBLIC AND PRIVATE SECTORS OF DEVELOPING COUNTRIES | WHO HEADQUARTERS IN GENEVA |
| 461 | DIFFERENTIAL DIAGNOSIS IN INTERNAL MEDICINE | THIEME MEDICAL PUBLISHERS |
| 462 | DIFFERENTIAL PRICING FOR PHARMACEUTICALS. REVIEW OF CURRENT KNOWLEDGE, NEW FINDINGS AND IDEAS FOR ACTION | MIT-ZARAGOZA INTERNATIONAL LOGISTICS PROGRAM |
| 463 | DILLING’S CLINICAL PHARMACOLOGY | CASSELL AND COMPANY.LTD |
| 464 | DIRECT COSTS AND AVAILABILITY OF DIABETES MEDICINES IN LOW-INCOME AND MIDDLE-INCOME COUNTRIES | HEALTH ACTION INTERNATIONAL |
| 465 | DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2001 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE | EUROPEAN UNION |
| 466 | DISCOUNTS AND REBATES GRANTED FOR MEDICINES FOR HOSPITAL USE IN FIVE EUROPEAN COUNTRIES | DISCOUNTS AND REBATES GRANTED FOR MEDICINES FOR HOSPITAL USE IN FIVE EUROPEAN COUNTRIES |
| 467 | DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR MEDICINES IN EUROPEAN COUNTRIES – SOUTHERN MED REVIEW VOL 5 ISSUE 1 JULY 2012 | WORLD HEALTH ORGANIZATION |
| 468 | DISEASE MANAGEMENT, THE NHS AND THE PHARMACEUTICAL INDUSTRY | OHE |
| 469 | DISPOSABLE BIOPROCESSING SYSTEMS | TAYLOR & FRANCIS ONLINE |
| 470 | DISPOSAL OF LIQUID PROPELLANTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 471 | DISSOLUTION KINETICS OF HIGH EXPLOSIVE COMPOUNDS | DEFENSE TECHNICAL INFORMATION CENTER |
| 472 | DISTRICT-LEVEL ASSESSMENT OF PHARMACEUTICAL MANAGEMENT OF LIFE-SAVING RMNCH COMMODITIES: LAKSHMIPUR, BANGLADESH | MANAGEMENT SCIENCES FOR HEALTH |
| 473 | DOSING INSTRUCTIONS FOR THE USE OF CURRENTLY AVAILABLE FIXED-DOSE COMBINATION TB MEDICINES FOR CHILDREN | WORLD HEALTH ORGANIZATION |
| 474 | DR-TB DRUGS UNDER THE MICROSCOPE – SOURCES AND PRICES FOR DRUG-RESISTANT TUBERCULOSIS MEDICINES. 2ND EDITION, NOVEMBER 2012 | INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE |
| 475 | DR-TB DRUGS UNDER THE MICROSCOPE – SOURCES AND PRICES FOR DRUG-RESISTANT TUBERCULOSIS MEDICINES. 3ND EDITION, OCTOBER 2013 | INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE |
| 476 | DR-TB DRUGS UNDER THE MICROSCOPE – SOURCES AND PRICES FOR DRUG-RESISTANT TUBERCULOSIS MEDICINES. 4TH EDITION, MARCH 2016 | MÉDECINS SANS FRONTIÈRES |
| 477 | DRIFTING THROUGH TIME: PHARMACEUTICAL POLICIES IN MEXICO | DRIFTING THROUGH TIME: PHARMACEUTICAL POLICIES IN MEXICO |
| 478 | DRUG ABUSE HANDBOOK | CRC PRESS |
| 479 | DRUG ADDICTION | OHE |
| 480 | DRUG ADDICTION RESEARCH AND THE HEALTH OF WOMEN : EXECUTIVE SUMMARY | NATIONAL INSTITUTES OF HEALTH |
| 481 | DRUG AND THERAPEUTICS COMMITTEES – A PRACTICAL GUIDE | MANAGEMENT SCIENCES FOR HEALTH |
| 482 | DRUG CLASS REVIEWS | OREGON HEALTH & SCIENCE UNIVERSITY |
| 483 | DRUG DELIVERY AND TARGETING | MARCEL DEKKER INC. |
| 484 | DRUG DELIVERY SYSTEMS | AJPRD |
| 485 | DRUG DEVELOPMENT – A CASE STUDY BASED INSIGHT INTO MODERN STRATEGIES | INTECH |
| 486 | DRUG DEVELOPMENT AND CONSERVATION OF BIODIVERSITY IN WEST AND CENTRAL AFRICA | DEFENSE TECHNICAL INFORMATION CENTER |
| 487 | DRUG DISCOVERY | INTECH |
| 488 | DRUG DISCOVERY AND DEVELOPMENT – FROM MOLECULES TO MEDICINE | INTECH |
| 489 | DRUG DISCOVERY AND DEVELOPMENT – PRESENT AND FUTURE | INTECH |
| 490 | DRUG DISCOVERY RESEARCH IN PHARMACOGNOSY | INTECH |
| 491 | DRUG DONATIONS: WHAT LIES BENEATH | WORLD HEALTH ORGANIZATION |
| 492 | DRUG EVALUATION IN THE PLASMODIUM FALCIPARUM – AOTUS MODEL | DEFENSE TECHNICAL INFORMATION CENTER |
| 493 | DRUG EXPORTS TO DEVELOPING COUNTRIES: PROBLEMS REMAIN UNSOLVED. ESSENTIAL DRUGS MONITOR, NO. 020 | DRUG EXPORTS TO DEVELOPING COUNTRIES: PROBLEMS REMAIN UNSOLVED. ESSENTIAL DRUGS MONITOR, NO. 020 |
| 494 | DRUG EXTRACTION : A STUDY OF REPERCOLATION | UNIVERSITY OF FLORIDA |
| 495 | DRUG FORMULARY 2009 – BAHRAIN | BAHRAIN MINISTRY OF HEALTH |
| 496 | DRUG METABOLISM, PHARMACOKINETICS AND BIOANALYSIS | MDPI AG |
| 497 | DRUG MISUSE | OHE |
| 498 | DRUG PATENTS UNDER THE SPOTLIGHT. SHARING PRACTICAL KNOWLEDGE ABOUT PHARMACEUTICAL PATENTS | MÉDECINS SANS FRONTIÈRES |
| 499 | DRUG POLICY FOR THE JAMMU AND KASHMIR STATE – INDIA, 2012 | INDIA – GOVERNMENT OF JAMMU AND KASHMIR |
| 500 | DRUG POLICY OF HIMACHAL PRADESH, JUNE 1999 – INDIA | INDIA – GOVERNMENT OF HIMACHAL PRADESH, DEPARTMENT OF HEALTH AND FAMILY WELFARE |
| 501 | DRUG POLICY OF THE NATIONAL CAPITAL TERRITORY OF DELHI, APRIL 1994 – INDIA | INDIA – GOVERNMENT OF NATIONAL CAPITAL TERRITORY OF DELHI |
| 502 | DRUG PROCUREMENT IN ODISHA STATE AND THE POST SURVEY ACTIVITIES IN ODISHA AND CHHATTISGARH. TECHNICAL REPORT | WORLD HEALTH ORGANIZATION |
| 503 | DRUG PROMOTION – WHAT WE KNOW, WHAT WE HAVE YET TO LEARN – REVIEWS OF MATERIALS IN THE WHO/HAI DATABASE ON DRUG PROMOTION – EDM RESEARCH SERIES NO. 032 | HEALTH ACTION INTERNATIONAL |
| 504 | DRUG QUALITY CONTROL LABORATORIES | WORLD HEALTH ORGANIZATION |
| 505 | DRUG QUALITY SCREENING IN DEVELOPING COUNTRIES: ESTABLISHMENT OF AN APPROPRIATE LABORATORY IN SWAZILAND | WHO HEADQUARTERS IN GENEVA |
| 506 | DRUG RECLASSIFICATION: AN ANALYSIS OF ORGANIZATIONAL AND PROFESSIONAL PERSPECTIVES | DEFENSE TECHNICAL INFORMATION CENTER |
| 507 | DRUG REGISTRATION GUIDANCE DOCUMENT, APRIL 2011 REVISION | MALAYSIA – NATIONAL PHARMACEUTICAL CONTROL BUREAU |
| 508 | DRUG REGULATION: HISTORY, PRESENT AND FUTURE. IN: VAN BOXTEL CJ, SANTOSO B, EDWARDS IR EDS., DRUG BENEFITS AND RISKS: INTERNATIONAL TEXTBOOK OF CLINICAL PHARMACOLOGY, REVISED 2ND ED. (CHAPTER 6). IOS PRESS AND UPPSALA MONITORING CENTRE, 2008 | MALAYSIA – NATIONAL PHARMACEUTICAL CONTROL BUREAU |
| 509 | DRUG REPOSITIONING: CURRENT ADVANCES AND FUTURE PERSPECTIVES | FRONTIERS MEDIA SA |
| 510 | DRUG RESISTANCE IN MALARIA | WHO HEADQUARTERS IN GENEVA |
| 511 | DRUG SELECTION, A WAY TO BETTER THERAPY? | WHO HEADQUARTERS IN GENEVA |
| 512 | DRUG SELLER INITIATIVES. (MDS-3: MANAGING ACCESS TO MEDICINES AND HEALTH TECHNOLOGIES, CHAPTER 32) | MANAGEMENT SCIENCES FOR HEALTH |
| 513 | DRUG SITUATION ANALYSIS FOR THE WEST BANK AND GAZA STRIP | WHO HEADQUARTERS IN GENEVA |
| 514 | DRUG SUPPLY BY RATION KITS. REPORT OF AN EVALUATION | WHO HEADQUARTERS IN GENEVA |
| 515 | DRUG SUPPLY SYSTEMS OF MISSIONARY ORGANIZATIONS. IDENTIFYING FACTORS AFFECTING EXPANSION AND EFFICIENCY: CASE STUDIES FROM UGANDA AND KENYA. | WORLD HEALTH ORGANIZATION |
| 516 | DRUG TESTING LABORATORIES. REPORT OF THE SOUTH-EAST ASIA REGIONAL MEETING. BANGKOK, THAILAND, 27 APRIL 2013 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR SOUTH-EAST ASIA |
| 517 | DRUG USE EPIDEMIOLOGY IN LATIN AMERICA AND THE CARIBBEAN: A PUBLIC HEALTH APPROACH | WORLD HEALTH ORGANIZATION |
| 518 | DRUG USE EVALUATION REPORT. INVESTIGATING MEROPENEM USAGE AT THE COLONIAL WAR MEMORIAL HOSPITAL FROM OCTOBER 2013 TO OCTOBER 2014 – FIJI | FIJI – PHARMACEUTICAL & BIOMEDICAL SERVICES CENTRE |
| 519 | DRUG USE GUIDELINES FOR PRIMARY HEALTH CARE FACILITIES. FIRST EDITION, OCTOBER 1997 | UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH AND SOCIAL WELFARE |
| 520 | DRUG USE INDICATOR SURVEY, 1991 – MALAWI ESSENTIAL DRUGS PROGRAMME | WHO HEADQUARTERS IN GENEVA |
| 521 | DRUG USE PATTERN IN PRIMARY HEALTH CARE FACILITIES OF KASKI DISTRICT, WESTERN NEPAL | INTERNATIONAL NETWORK FOR RATIONAL USE OF DRUGS |
| 522 | DRUG USE REVIEWS—A PRACTICAL STRATEGY TO ENSURE THE RATIONAL USE OF ANTI-TUBERCULOSIS MEDICINES, OCTOBER 2014 | MANAGEMENT SCIENCES FOR HEALTH |
| 523 | DRUG UTILIZATION STUDIES : METHODS AND USES | DRUG UTILIZATION STUDIES : METHODS AND USES |
| 524 | DRUG-ACCEPTOR INTERACTIONS: MODELING THEORETICAL TOOLS TO TEST AND EVALUATE EXPERIMENTAL EQUILIBRIUM EFFECTS | TAYLOR & FRANCIS ONLINE |
| 525 | DRUG-DIAGNOSTICS CO-DEVELOPMENT IN ONCOLOGY | FRONTIERS MEDIA SA |
| 526 | DRUG-RESISTANT TB SURVEILLANCE & RESPONSE. SUPPLEMENT TO GLOBAL TUBERCULOSIS REPORT 2014 | WHO HEADQUARTERS IN GENEVA |
| 527 | DRUGS (IMPORT & EXPORT) RULES, 1976 | PAKISTAN GOVERNMENT |
| 528 | DRUGS ACT – LAW OF MONGOLIA, ULAANBAATAR, 7 MAY 1998 | MONGOLIA – STATE GREAT HURAL |
| 529 | DRUGS ACT, 1976. ADVERTISING OF DRUGS, ETC. | PAKISTAN GOVERNMENT |
| 530 | DRUGS ACT, 2035, (1978). ACT NUMBER 21 OF THE YEAR 2053, 1978 (25 OCTOBER 1978). AN ACT MADE TO MAKE PROVISIONS RELATING TO DRUGS – NEPAL | NEPAL GOVERNMENT |
| 531 | DRUGS AND MONEY – PRICES, AFFORDABILITY AND COST CONTAINMENT | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 532 | DRUGS FOR ELDERLY, SECOND EDITION | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 533 | DRUGS IN GENERAL PRACTICE. REPORT ON A WHO MEETING, OCTOBER 1982. EURO REPORTS AND STUDIES 91 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 534 | DRUGS QUALITY CONTROL (THEORETICAL FOUNDATION AND PRACTICAL APPLICATION): THE COURSEBOOK | NA |
| 535 | DRUGS REGISTRATION RULES, 2038 (1981). (PUBLICATION IN NEPAL GAZETTE, 3 AUG. 1981) | NEPAL GOVERNMENT |
| 536 | DRUGS, BRAINS AND BEHAVIOR | RUTGERS UNIVERSITY |
| 537 | DRUGS, DOCTORS AND DINNERS. HOW DRUG COMPANIES INFLUENCE HEALTH IN THE DEVELOPING WORLD | CONSUMERS INTERNATIONAL |
| 538 | DYING OF DIABETES | DYING OF DIABETES |
| 539 | DYNAMIC ENERGY BUDGETS AND BIOACCUMULATION: A MODEL FOR MARINE MAMMALS AND MARINE MAMMAL POPULATIONS | DEFENSE TECHNICAL INFORMATION CENTER |
| 540 | EARLY DETECTION OF NF1 BRAIN TUMOR GROWTH AND TREATMENT RESPONSE BY MRI, MRS AND PET IN A TRIAL OF NOVEL ANTITUMOR DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 541 | EARLY LIFE STRESS AND SLEEP RESTRICTION AS RISK FACTORS IN PTSD: AN INTEGRATIVE PRE-CLINICAL APPROACH | DEFENSE TECHNICAL INFORMATION CENTER |
| 542 | EASTERN CAPE PROVINCE FORMULARY. ALL LEVELS 2003, 2ND EDITION | SOUTH AFRICA – EASTERN CAPE DEPARTMENT OF HEALTH |
| 543 | ECONOMICS AND INNOVATION THE PHARMACEUTICAL INDUSTRY | OHE |
| 544 | ECONOMICS FOR PHARMACEUTICAL MANAGEMENT. (MDS-3: MANAGING ACCESS TO MEDICINES AND HEALTH TECHNOLOGIES, CHAPTER 10) | MANAGEMENT SCIENCES FOR HEALTH |
| 545 | ECONOMICS OF INNOVATIVE PAYMENT MODELS COMPARED WITH SINGLE PRICING OF PHARMACEUTICALS | OHE |
| 546 | ECOTOXICOLOGY | INTECH |
| 547 | EDLIZ 2011 – 6TH ESSENTIAL MEDICINES LIST AND STANDARD TREATMENT GUIDELINES FOR ZIMBABWE | ZIMBABWE MINISTRY OF HEALTH AND CHILD WELFARE |
| 548 | EDUCATIONAL INITIATIVES FOR MEDICAL AND PHARMACY STUDENTS ABOUT DRUG PROMOTION: AN INTERNATIONAL CROSS-SECTIONAL SURVEY – EDM RESEARCH SERIES NO. 036 | EUROPEAN UNION |
| 549 | EDUCATIONAL STATISTICS FOR SELECTED HEALTH OCCUPATIONS | ERIC |
| 550 | EFFECT OF PRETREATMENT WITH HUMAN BUTYRYCHOLINESTERASE SCAVENGERS ON THE TOXICOKINETICS AND BINDING OF NERVE AGENTS IN GUINEA PIGS AND MARMOSETS | DEFENSE TECHNICAL INFORMATION CENTER |
| 551 | EFFECT OF THE ECONOMIC RECESSION ON PHARMACEUTICAL POLICY AND MEDICINE SALES IN EIGHT EUROPEAN COUNTRIES | WHO HEADQUARTERS IN GENEVA |
| 552 | EFFECT OF TIME OF MENSTRUAL CYCLE ON DRUG PHARMACOKINETICS AND PHARMACODYNAMICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 553 | EFFECTIVE DRUG REGULATION – A MULTICOUNTRY STUDY AND ANNEX 1: GUIDE FOR DATA COLLECTION TO ASSESS DRUG REGULATORY PERFORMANCE | WHO HEADQUARTERS IN GENEVA |
| 554 | EFFECTIVE DRUG REGULATION: A MULTICOUNTRY STUDY | WORLD HEALTH ORGANIZATION |
| 555 | EFFECTIVE MEDICINES REGULATION: ENSURING SAFETY, EFFICACY AND QUALITY – WHO POLICY PERSPECTIVES ON MEDICINES, NO. 007, NOVEMBER 2003 | WHO HEADQUARTERS IN GENEVA |
| 556 | EFFECTS OF CHOLINERGIC PERTURBATIONS ON NEUROMOTOR – COGNITIVE PERFORMANCE | DEFENSE TECHNICAL INFORMATION CENTER |
| 557 | EFFECTS OF SAINT JOHN’S WORT AND VITAMIN E ON BREAST CANCER CHEMOTHERAPEUTIC AGENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 558 | EFFICACY OF THE GLUK1/AMPA RECEPTOR ANTAGONIST LY293558 AGAINST SEIZURES AND NEUROPATHOLOGY IN A SOMAN-EXPOSURE MODEL WITHOUT PRETREATMENT AND ITS PHARMACOKINETICS AFTER INTRAMUSCULAR ADMINISTRATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 559 | EFPIA HCP CODE – EFPIA CODE ON THE PROMOTION OF PRESCRIPTION-ONLY MEDICINES TO, AND INTERACTIONS WITH, HEALTHCARE PROFESSIONALS. | EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS |
| 560 | EGYPT PHARMACEUTICAL COUNTRY PROFILE, JULY 2011 | EGYPT – MINISTRY OF HEALTH & POPULATION |
| 561 | EGYPTIAN ESSENTIAL DRUG LIST 2012-2013 | EGYPT – MINISTRY OF HEALTH & POPULATION |
| 562 | EGYPTIAN NATIONAL FORMULARY, 2007 | EGYPT – MINISTRY OF HEALTH & POPULATION |
| 563 | EIGHTH INTERNATIONAL CONGRESS OF APPLIED CHEMISTRY | CORNELL UNIVERSITY |
| 564 | ELECTROCHEMICAL STUDIES ON MINOXIDIL AND ITS DETERMINATION IN TABLETS BY DIFFERENTIAL-PULSE POLAROGRAPHY | DEFENSE TECHNICAL INFORMATION CENTER |
| 565 | ELEMENTS OF MATERIA MEDICA AND PHARMACY | U.S. NATIONAL LIBRARY OF MEDICINE |
| 566 | ELEMENTS OF THE MATERIA MEDICA AND THERAPEUTICS | EMORY UNIVERSITY |
| 567 | EMERGENCY DRUG GUIDELINES, 2ND EDITION 2008 – FIJI | FIJI – NATIONAL MEDICINES & THERAPEUTIC COMMITTEE |
| 568 | EMERGENCY DRUG GUIDELINES, DECEMBER 2007 – KIRIBATI | KIRIBATI – MINISTRY OF HEALTH |
| 569 | EMERGENCY MEDICAL SERVICES PROGRAM GUIDE | ERIC |
| 570 | EMERGENCY MEDICINE | WIKIPEDIA |
| 571 | EMERGENCY MEDICINES LIST (EML). FIRST EDITION, NOVEMBER 2014 – ETHIOPIA | ETHIOPIA – FOOD, MEDICINES AND HEALTHCARE ADMINISTRATION AND CONTROL AUTHORITY |
| 572 | EMERGING ROLES AND COMPETENCIES OF DISTRICT AND SUB-DISTRICT PHARMACISTS: A CASE STUDY FROM CAPE TOWN | EMERGING ROLES AND COMPETENCIES OF DISTRICT AND SUB-DISTRICT PHARMACISTS: A CASE STUDY FROM CAPE TOWN |
| 573 | ENANTIOMER SEPARATION | SPRINGER |
| 574 | ENANTIOMER SEPARATION [ELECTRONIC RESOURCE] : FUNDAMENTALS AND PRACTICAL METHODS | SPRINGER |
| 575 | ENCOURAGING INCREASED ADHERENCE TO TREATMENT STANDARDS THROUGH DRUG UTILIZATION REVIEWS IN UKRAINE | MANAGEMENT SCIENCES FOR HEALTH |
| 576 | ENCYCLOPEDIA OF HOME REMEDIES FOR BETTER LIFE | GUTENBERG |
| 577 | ENHANCING EFFICIENCY IN PHARMACY AND PATIENT MANAGEMENT: THE RXSOLUTION EXPERIENCE AT THE INTERMEDIATE HOSPITAL OSHAKATI, NAMIBIA | MANAGEMENT SCIENCES FOR HEALTH |
| 578 | ENHANCING THE RATIONAL USE OF NEW MEDICINES ACROSS EUROPEAN HEALTH CARE SYSTEMS | THE PIPERSKA GROUP |
| 579 | ENSURING BALANCE IN NATIONAL POLICIES ON CONTROLLED SUBSTANCES. GUIDANCE FOR AVAILABILITY AND ACCESSIBILITY OF CONTROLLED MEDICINES – REFERENCE LIST | WHO HEADQUARTERS IN GENEVA |
| 580 | ENSURING BALANCE IN NATIONAL POLICIES ON CONTROLLED SUBSTANCES: GUIDANCE FOR AVAILABILITY AND ACCESSIBILITY OF CONTROLLED MEDICINES | WHO HEADQUARTERS IN GENEVA |
| 581 | ENSURING EFFICIENCY IN PHARMACEUTICAL EXPENDITURES, IN OECD, ACHIEVING BETTER VALUE FOR MONEY IN HEALTH CARE, 2009. (PAGES :101–128). OECD PUBLISHING | ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT |
| 582 | ENSURING ETHICAL DRUG PROMOTION – WHOSE RESPONSIBILITY? | ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT |
| 583 | ENSURING GOOD DISPENSING PRACTICES. | MANAGEMENT SCIENCES FOR HEALTH |
| 584 | ENSURING QUALITY MEDICINES: A DECADE OF PREQUALIFICATION | WHO HEADQUARTERS IN GENEVA |
| 585 | ENSURING THAT ESSENTIAL MEDICINES ARE ALSO AFFORDABLE MEDICINES: CHALLENGES AND OPTIONS. DISCUSSION PAPER UNITAID | UNITAID |
| 586 | ENSURING THE QUALITY OF MEDICINES IN RESOURCE-LIMITED COUNTRIES: AN OPERATIONAL GUIDE | UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT |
| 587 | ENTITY-RELATIONSHIP VERSUS OBJECT-ORIENTED MODELING AND THE UNDERLYING DBMS | DEFENSE TECHNICAL INFORMATION CENTER |
| 588 | ENZYME INHIBITION AND BIOAPPLICATIONS | INTECH |
| 589 | EPIDURAL ANALGESIA – CURRENT VIEWS AND APPROACHES | INTECH |
| 590 | EQUITABLE ACCESS TO ESSENTIAL MEDICINES: A FRAMEWORK FOR COLLECTIVE ACTION – WHO POLICY PERSPECTIVES ON MEDICINES, NO. 008, MARCH 2004 | WHO HEADQUARTERS IN GENEVA |
| 591 | EQUITABLE PRICING OF NEWER ESSENTIAL MEDICINES FOR DEVELOPING COUNTRIES: EVIDENCE FOR THE POTENTIAL OF DIFFERENT MECHANISMS | LONDON BUSINESS SCHOOL |
| 592 | ERITREA – PHARMACEUTICAL SECTOR COUNTRY PROFILE | ERITREAN MINISTRY OF HEALTH |
| 593 | ERITREAN NATIONAL LIST OF MEDICINES. ENLM 5TH EDITION, JUNE 2010 | ERITREAN MINISTRY OF HEALTH |
| 594 | ERITREAN NATIONAL MEDICINES POLICY, AUGUST 2007 | ERITREAN MINISTRY OF HEALTH |
| 595 | ERITREAN NATIONAL MEDICINES POLICY, JANUARY 2010 | ERITREAN MINISTRY OF HEALTH |
| 596 | ESSENTIAL AND COMPLEMENTARY MEDICINES AND VACCINES FOR MYANMAR. NATIONAL LIST (NLEM), 2010 | MYANMAR – MINISTRY OF HEALTH |
| 597 | ESSENTIAL CHRONIC DRUG LIST 2010 – LEBANON | LEBANON – MINISTRY OF PUBLIC HEALTH |
| 598 | ESSENTIAL DRUG LIST (EDL-2013). ESSENTIAL DRUGS, SURGICAL PRODUCTS AND SUTURES LIST. 4TH EDITION, JULY 2013 – GOVERNMENT OF CHHATTISGARH, INDIA | INDIA – DEPARTMENT OF HEALTH AND FAMILY WELFARE, GOVERNMENT OF CHHATTISGARH |
| 599 | ESSENTIAL DRUG LIST OF THE REPUBLIC OF ARMENIA, 2010 | ARMENIA MINISTRY OF HEALTH |
| 600 | ESSENTIAL DRUG LIST, JULY 2006, ORISSA, INDIA. FOURTH REVISED EDITION | ORISSA GOVERNMENT |
| 601 | ESSENTIAL DRUGS | MEDECINS SANS FRONTIERES |
| 602 | ESSENTIAL DRUGS AND REGISTRATION OF PHARMACEUTICALS: THE SRI LANKAN EXPERIENCE | WHO HEADQUARTERS IN GENEVA |
| 603 | ESSENTIAL DRUGS IN THE GAMBIA | WHO HEADQUARTERS IN GENEVA |
| 604 | ESSENTIAL DRUGS IN THE NEW INTERNATIONAL ECONOMIC ENVIRONMENT | WHO HEADQUARTERS IN GENEVA |
| 605 | ESSENTIAL DRUGS LIST, 2007 – BHUTAN | BHUTAN MINISTRY OF HEALTH |
| 606 | ESSENTIAL DRUGS LIST, 2009 – BHUTAN | BHUTAN MINISTRY OF HEALTH |
| 607 | ESSENTIAL DRUGS LIST, 2010 – IRAQ | BHUTAN MINISTRY OF HEALTH |
| 608 | ESSENTIAL DRUGS LIST, 2011 – BHUTAN | BHUTAN MINISTRY OF HEALTH |
| 609 | ESSENTIAL DRUGS. ACTION FOR EQUITY | BHUTAN MINISTRY OF HEALTH |
| 610 | ESSENTIAL DRUGS. BASIC INFORMATION FOR HEALTH CENTER STAFF AND DRUG SELLERS, 2003 | CAMBODIA MINISTRY OF HEALTH |
| 611 | ESSENTIAL DRUGS. PRACTICAL GUIDELINES INTENDED FOR PHYSICIANS, PHARMACISTS, NURSES AND MEDICAL AUXILIARIES. 2013 EDITION | MÉDECINS SANS FRONTIÈRES |
| 612 | ESSENTIAL DRUGS: PRACTICAL GUIDELINES | MEDECINS SANS FRONTIERES |
| 613 | ESSENTIAL EMERGENCY SURGICAL, PROCEDURES IN RESOURCE-LIMITED FACILITIES: A WHO WORKSHOP IN MONGOLIA. | ESSENTIAL EMERGENCY SURGICAL, PROCEDURES IN RESOURCE-LIMITED FACILITIES: A WHO WORKSHOP IN MONGOLIA. |
| 614 | ESSENTIAL LAWS FOR MEDICINES ACCESS – A PILOT STUDY ON NATIONAL LEGISLATION (AUSTRALIA, THE NETHERLANDS, SOUTH AFRICA AND TONGA). REPORT TO THE WHO-EMP DEPARTMENT ON WORK UNDERTAKEN IN GENEVA, JUNE-AUGUST 2010 | UTRECHT UNIVERSITY SCHOOL OF LAW, THE NETHERLANDS |
| 615 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE BULGARIA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 616 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE CANADA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 617 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE COLOMBIA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 618 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE COSTA RICA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 619 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE FRANCE, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 620 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE GHANA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 621 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE INDONESIA, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 622 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE NEW ZEALAND, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 623 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE SENEGAL, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 624 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE SINGAPORE, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 625 | ESSENTIAL LAWS FOR MEDICINES ACCESS – COUNTRY PROFILE SPAIN, 2015 | UNIVERSITY OF GRONINGEN, THE NETHERLANDS |
| 626 | ESSENTIAL MEDICINE LIST, 2009 – MALDIVES | REPUBLIC OF MALDIVES, MINISTRY OF HEALTH & FAMILY |
| 627 | ESSENTIAL MEDICINES – ANNUAL REPORT 2004 | WORLD HEALTH ORGANIZATION |
| 628 | ESSENTIAL MEDICINES – ANNUAL REPORT 2005 | WORLD HEALTH ORGANIZATION |
| 629 | ESSENTIAL MEDICINES – ANNUAL REPORT 2006 | WORLD HEALTH ORGANIZATION |
| 630 | ESSENTIAL MEDICINES AND BASIC HEALTH TECHNOLOGIES FOR NONCOMMUNICABLE DISEASES: TOWARDS A SET OF ACTIONS TO IMPROVE EQUITABLE ACCESS IN MEMBER STATES. WHO DISCUSSION PAPER, 2 JULY 2015 | WHO HEADQUARTERS IN GENEVA |
| 631 | ESSENTIAL MEDICINES AND HEALTH PRODUCTS – BIENNIAL REPORT 2012–2013 | WHO HEADQUARTERS IN GENEVA |
| 632 | ESSENTIAL MEDICINES AND HEALTH PRODUCTS INFORMATION PORTAL | WHO HEADQUARTERS IN GENEVA |
| 633 | ESSENTIAL MEDICINES AND HEALTH SUPPLIES LIST FOR UGANDA 2012 | UGANDA – MINISTRY OF HEALTH |
| 634 | ESSENTIAL MEDICINES AND HUMAN RIGHTS: WHAT CAN THEY LEARN FROM EACH OTHER? | WHO HEADQUARTERS IN GENEVA |
| 635 | ESSENTIAL MEDICINES ARE MORE AVAILABLE THAN OTHER MEDICINES AROUND THE GLOBE | ESSENTIAL MEDICINES ARE MORE AVAILABLE THAN OTHER MEDICINES AROUND THE GLOBE |
| 636 | ESSENTIAL MEDICINES BIENNIAL REPORT 2006–2007: THE PHARMACEUTICAL SCENE IN 2006–2007 | WHO HEADQUARTERS IN GENEVA |
| 637 | ESSENTIAL MEDICINES BIENNIAL REPORT: 2008–2009 – THE PHARMACEUTICAL SCENE IN 2008–2009 | WHO HEADQUARTERS IN GENEVA |
| 638 | ESSENTIAL MEDICINES FOR CHILDREN: SHOULD WE FOCUS ON A PRIORITY LIST OF MEDICINES FOR THE PRESENT? | WHO HEADQUARTERS IN GENEVA |
| 639 | ESSENTIAL MEDICINES FOR NON COMMUNICABLE DISEASES. FIRST GLOBAL MINISTERIAL CONFERENCE ON HEALTHY LIFESTYLES AND NONCOMMUNICABLE DISEASE CONTROL (MOSCOW, 28-29 APRIL 2011). DISCUSSION PAPER | WHO HEADQUARTERS IN GENEVA |
| 640 | ESSENTIAL MEDICINES FOR NON-COMMUNICABLE DISEASES (NCDS). BACKGROUND PAPER | WHO HEADQUARTERS IN GENEVA |
| 641 | ESSENTIAL MEDICINES FOR REPRODUCTIVE HEALTH: DEVELOPING EVIDENCE BASED INTERAGENCY LIST – SOUTHERN MED REVIEW VOL 4 ISSUE 2 DEC 2011 | SOUTHERN MED REVIEW |
| 642 | ESSENTIAL MEDICINES FOR REPRODUCTIVE HEALTH: GUIDING PRINCIPLES FOR THEIR INCLUSION ON NATIONAL MEDICINES LISTS | WORLD HEALTH ORGANIZATION |
| 643 | ESSENTIAL MEDICINES LIST (FIFTH REVISION 2010) – NIGERIA | NIGERIA MINISTRY OF HEALTH |
| 644 | ESSENTIAL MEDICINES LIST 2007 FOR THE COOK ISLANDS | COOK ISLANDS – MINISTRY OF HEALTH |
| 645 | ESSENTIAL MEDICINES LIST FOR EMERGENCIES AND DISASTERS IN THE CARIBBEAN | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE AMERICAS |
| 646 | ESSENTIAL MEDICINES LIST FOR TIMOR LESTE (EMLTL). FOR REFERRAL HOSPITALS AND PRIMARY HEALTHCARE LEVEL. 3RD ISSUE, JANUARY 2010 | MINISTÉRIO DA SAÚDE |
| 647 | ESSENTIAL MEDICINES LIST FOR UGANDA | UGANDA – MINISTRY OF HEALTH |
| 648 | ESSENTIALS OF CHEMISTRY : INORGANIC AND ORGANIC, FOR THE USE OF STUDENTS IN MEDICINE | YALE UNIVERSITY |
| 649 | ESSENTIALS OF MEDICAL AND CLINICAL CHEMISTRY. WITH LABORATORY EXERCISES | CORNELL UNIVERSITY |
| 650 | ESSENTIALS OF MEDICAL CHEMISTRY AND URINALYSIS | MORTON PUBLISHING COMPANY |
| 651 | ESSENTIALS OF MEDICAL CHEMISTRY, ORGANIC AND INORGANIC | W. B. SAUNDERS CO. |
| 652 | ESTABLISHING A REASONABLE PRICE FOR AN ORPHAN DRUG | OHE |
| 653 | ESTABLISHMENT OF STATUTORY DRUG REGULATION IN DEVELOPING COUNTRIES | WHO COLLABORATING CENTRE FOR INTERNATIONAL DRUG MONITORING |
| 654 | ESTIMATING DRUG REQUIREMENTS – A PRACTICAL MANUAL | WHO HEADQUARTERS IN GENEVA |
| 655 | ESTIMATION OF DERMAL PERMEABILITY COEFFICIENTS FOR DIBROMOMETHANE AND BROMOCHLOROMETHANE PHARMACOKINETIC APPROACH | DEFENSE TECHNICAL INFORMATION CENTER |
| 656 | ESTONIA PHARMACEUTICAL COUNTRY PROFILE, 15 JUNE 2011 | ESTONIA, MINISTRY OF SOCIAL AFFAIRS |
| 657 | ESTROGENS AND ANTIESTROGENS II [ELECTRONIC RESOURCE] : PHARMACOLOGY AND CLINICAL APPLICATION OF ESTROGENS AND ANTIESTROGEN | SPRINGER |
| 658 | ETHICAL CRITERIA FOR MEDICINAL DRUG PROMOTION | WHO HEADQUARTERS IN GENEVA |
| 659 | ETHICAL CRITERIA FOR THE PROMOTION, ADVERTISEMENT, AND PUBLICITY OF MEDICINES – PANDRH SERIES TECHNICAL DOCUMENT NO 12 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE AMERICAS |
| 660 | ETHICAL INFRASTRUCTURE FOR GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR: WORKING DRAFT FOR FIELD TESTING AND REVISION. NOVEMBER 2006 | WORLD HEALTH ORGANIZATION |
| 661 | ETHIOPIA – LIST OF DRUGS FOR HEALTH CENTERS, 2002 | ETHIOPIA – DRUG ADMINISTRATION AND CONTROL AUTHORITY |
| 662 | ETHIOPIA – LIST OF DRUGS FOR ZONAL HOSPITALS, 2002 | ETHIOPIA – DRUG ADMINISTRATION AND CONTROL AUTHORITY |
| 663 | ETHIOPIA – PHARMACEUTICAL SECTOR COUNTRY PROFILE | ETHIOPIA – MINISTRY OF HEALTH |
| 664 | ETHIOPIA: NATIONAL SURVEY OF THE INTEGRATED PHARMACEUTICAL LOGISTICS SYSTEM | JOHN SNOW INC. |
| 665 | ETHIOPIAN MEDICINES FORMULARY. SECOND EDITION, 2013 | ETHIOPIA – FOOD, MEDICINES AND HEALTHCARE ADMINISTRATION AND CONTROL AUTHORITY |
| 666 | ETHIOPIAN NATIONAL DRUG FORMULARY, FIRST EDITION, 2008 | ETHIOPIA – DRUG ADMINISTRATION AND CONTROL AUTHORITY |
| 667 | ETHNICITY, MIGRATION AND MINORITY GROUPS: MEDICINES ACCESS AND USE IN HIGH-INCOME ECONOMIES – SOUTHERN MED REVIEW VOL 5 ISSUE 2 DECEMBER 2012 | SOUTHERN MED REVIEW |
| 668 | EU/ACP/WHO RENEWED PARTNERSHIP : STRENGTHENING PHARMACEUTICAL SYSTEMS AND IMPROVING ACCESS TO QUALITY MEDICINES – ETHIOPIA, 2012–2016 | WHO HEADQUARTERS IN GENEVA |
| 669 | EU/ACP/WHO RENEWED PARTNERSHIP: STRENGTHENING PHARMACEUTICAL SYSTEMS AND IMPROVING ACCESS TO QUALITY MEDICINES IN 15 AFRICAN ACP COUNTRIES, 2012–2016 | WHO HEADQUARTERS IN GENEVA |
| 670 | EVALUATING AVAILABILITY AND PRICE OF ESSENTIAL MEDICINES IN BOSTON AREA (MASSACHUSETTS, USA) USING WHO/HAI METHODOLOGY. | EUROPEAN MEDICINES AGENCY |
| 671 | EVALUATING MEDICINES DISPENSING PATTERNS AT PRIVATE COMMUNITY PHARMACIES IN TAMILNADU, INDIA | WHO HEADQUARTERS IN GENEVA |
| 672 | EVALUATION OF AVAILABILITY, ACCESSIBILITY AND PRESCRIBING PATTERN OF MEDICINES IN THE ISLAMIC REPUBLIC OF IRAN | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 673 | EVALUATION OF CEFTRIAXONE UTILIZATION IN INTERNAL MEDICINE WARDS OF GENERAL HOSPITALS IN ADDIS ABABA, ETHIOPIA: A COMPARATIVE RETROSPECTIVE STUDY | WHO HEADQUARTERS IN GENEVA |
| 674 | EVALUATION OF DRUG PROMOTIONAL MATERIALS IN A HOSPITAL SETTING IN NEPAL | WHO HEADQUARTERS IN GENEVA |
| 675 | EVALUATION OF DRUG USE IN JORDAN USING WHO PATIENT CARE AND HEALTH FACILITY INDICATORS | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 676 | EVALUATION OF DRUG USE IN JORDAN USING WHO PRESCRIBING INDICATORS | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 677 | EVALUATION OF LEVOFLOXACIN PHARMACODYNAMICS IN A MOUSE MODEL OF INHALATIONAL BACILLUS ANTHRACIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 678 | EVALUATION OF PROGRESS IN DRUG CONTROL IN SURINAME 2005-2006 | ORGANIZATION OF AMERICAN STATES |
| 679 | EVALUATION OF RATIONAL DRUG USE AT TEACHING HOSPITALS IN PUNJAB, PAKISTAN | EVALUATION OF RATIONAL DRUG USE AT TEACHING HOSPITALS IN PUNJAB, PAKISTAN |
| 680 | EVALUATION OF THE GOOD GOVERNANCE FOR MEDICINES PROGRAMME (2004–2012): BRIEF SUMMARY OF FINDINGS | WHO HEADQUARTERS IN GENEVA |
| 681 | EVALUATION OF THE IMPLEMENTATION STATUS, OUTCOMES AND CHALLENGES OF “AUDITABLE PHARMACEUTICALS TRANSACTIONS AND SERVICES” IN SELECTED HOSPITALS OF ETHIOPIA. OCTOBER 2015 | JIMMA UNIVERSITY, ETHIOPIA |
| 682 | EVALUATION OF THE PHARMACOKINETICS AND TOLERANCE OF ALLOPURINOL RIBOSIDE IN HUMAN VOLUNTEERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 683 | EVALUATION OF THE REVOLVING DRUG FUND (RDF) PROJECT IN THE SUDAN: THE LEADERSHIP’S PERSPECTIVES | SUDAN NATIONAL MINISTRY OF HEALTH |
| 684 | EVIDENCE-BASED ADVANCE AND MANAGEMENT OF ADVERSE EVENTS OF IMMUNOTHERAPY FOR CANCER | FRONTIERS MEDIA SA |
| 685 | EVIDENCE-BASED PROCESS FOR DECISION-MAKING IN THE ANALYSIS OF LEGAL DEMANDS FOR MEDICINES IN BRAZIL | WHO HEADQUARTERS IN GENEVA |
| 686 | EVIDENCE-BASED STRATEGIES IN HERBAL MEDICINE, PSYCHIATRIC DISORDERS AND EMERGENCY MEDICINE | INTECH |
| 687 | EXAMINATION OF ACUTE SENSITIVITY TO MORPHINE AND MORPHINE SELF-ADMINISTRATION FOLLOWING PHYSICAL AND ENVIRONMENTAL STRESSORS IN FISCHER-344 AND LEWIS FEMALE RATS | DEFENSE TECHNICAL INFORMATION CENTER |
| 688 | EXAMINING THE GROWING PROBLEMS OF PRESCRIPTION DRUG AND HEROIN ABUSE: STATE AND LOCAL PERSPECTIVES | GOVERNMENT PUBLISHING OFFICE |
| 689 | EXPANDING MARKETS WHILE IMPROVING HEALTH IN INDONESIA: PRIVATE HEALTH SECTOR MARKET IN THE JKN ERA | NA |
| 690 | EXPENSIVE MEDICINES: ENSURING OBJECTIVE APPRAISAL AND EQUITABLE ACCESS | WHO HEADQUARTERS IN GENEVA |
| 691 | EXPERIENCE WITH SUPPORTING PHARMACEUTICAL POLICIES AND SYSTEMS IN KENYA. PROGRESS, LESSONS AND THE ROLE OF WHO | WHO HEADQUARTERS IN GENEVA |
| 692 | EXPERIENCES WITH DIABETES AS A PRACTISING PHARMACIST IN PAKISTAN | EXPERIENCES WITH DIABETES AS A PRACTISING PHARMACIST IN PAKISTAN |
| 693 | EXPERT COMMITTEE ON HABIT-FORMING DRUGS: REPORT ON THE FIRST SESSION, JANUARY 1949 | WHO HEADQUARTERS IN GENEVA |
| 694 | EXPERT DELPHI SURVEY ON RESEARCH AND DEVELOPMENT INTO DRUGS FOR NEGLECTED DISEASES | WHO HEADQUARTERS IN GENEVA |
| 695 | EXPLORATORY STUDY ON ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING FOR ESSENTIAL MEDICINES | THE WORLD BANK GROUP |
| 696 | EXPLORING CAREERS IN HEALTH AND MEDICINE | ERIC |
| 697 | EXPLORING GENDER AND SEX DIFFERENCES IN BEHAVIORAL DYSCONTROL: FROM DRUG ADDICTION TO IMPULSE CONTROL DISORDERS | FRONTIERS MEDIA SA |
| 698 | EXPLORING THE REGULATORY DECISION-MAKING PROCESS FOR MEDICINES | EXPLORING THE REGULATORY DECISION-MAKING PROCESS FOR MEDICINES |
| 699 | EXTERNAL EVALUATION OF THE PHARMACEUTICAL SECTOR IN MOZAMBIQUE. CONSOLIDATED REPORT, JULY 2007 | EXPLORING THE REGULATORY DECISION-MAKING PROCESS FOR MEDICINES |
| 700 | FACTORS INFLUENCING CURRICULUM CHANGE IN PROFESSIONAL PROGRAMS. ASHE ANNUAL MEETING PAPER | ERIC |
| 701 | FATE OF PHENOLIC COMPOUNDS IN THE AMERICAN LOBSTER, HOMARUS AMERICANUS | UNIVERSITY OF FLORIDA |
| 702 | FIELD TESTS FOR RATIONAL DRUG USE IN TWELVE DEVELOPING COUNTRIES | FIELD TESTS FOR RATIONAL DRUG USE IN TWELVE DEVELOPING COUNTRIES |
| 703 | FIJI PHARMACEUTICAL COUNTRY PROFILE, 2013 | FIJI – MINISTRY OF HEALTH |
| 704 | FINANCING DRUGS IN SOUTH-EAST ASIA – REPORT OF THE FIRST MEETING OF THE WHO/SEARO WORKING GROUP ON DRUG FINANCING, KORAT, THAILAND, 26-28 NOVEMBER 1996 – HEALTH ECONOMICS AND DRUGS SERIES NO. 004 | WORLD HEALTH ORGANIZATION |
| 705 | FINANCING DRUGS IN SOUTH-EAST ASIA. REPORT OF THE SECOND MEETING OF THE WHO/SEARO WORKING GROUP ON DRUG FINANCING – HEALTH ECONOMICS AND DRUGS NO. 008 | WORLD HEALTH ORGANIZATION |
| 706 | FINLAND PHARMACEUTICAL COUNTRY PROFILE, JULY 2011 | FINLAND – MINISTRY OF SOCIAL AFFAIRS AND HEALTH |
| 707 | FIP STATEMENT OF PROFESSIONAL STANDARDS – CODE OF ETHICS FOR PHARMACIST | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 708 | FIP STATEMENT OF PROFESSIONAL STANDARDS – THE ROLE OF THE PHARMACIST IN ENCOURAGING ADHERENCE TO LONG-TERM TREATMENTS (2003, SYDNEY) | INTERNATIONAL PHARMACEUTICAL FEDERATION |
| 709 | FIRST INTERCOUNTRY WORKSHOP ON NATIONAL DRUG INFORMATION SERVICES. CHENNAI, INDIA, 8-11 MAY 2007. SEA-DRUGS-156 | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR SOUTH-EAST ASIA |
| 710 | FIRST REGULATORY INSPECTIONS MEASURING ADHERENCE TO GOOD PHARMACY PRACTICES IN THE PUBLIC SECTOR IN UGANDA: A CROSS-SECTIONAL COMPARISON OF PERFORMANCE BETWEEN SUPERVISED AND UNSUPERVISED FACILITIES | WHO HEADQUARTERS IN GENEVA |
| 711 | FLUOROQUINOLONE ANTIBIOTICS | CAMBRIDGE UNIVERSITY PRESS |
| 712 | FOOD ADDITIVES AND HYPERKINESIS: A CONTROLLED DOUBLE-BLIND EXPERIMENT | ERIC |
| 713 | FOOD AND DRUGS ACT – TRINIDAD AND TOBAGO | MINISTRY OF LEGAL AFFAIRS – TRINIDAD AND TOBAGO |
| 714 | FOOD TOXICOLOGY | MARCEL DEKKER, INC |
| 715 | FOREIGN PHARMACEUTICAL MANUFACTURING COMPANY REGISTRATION GUIDELINE FOR AFGHANISTAN | AFGHANISTAN – MINISTRY OF PUBLIC HEALTH |
| 716 | FORMATION AND MANAGEMENT OF AN EXPERT TOXICOLOGICAL REVIEW TEAM FOR LITERATURE SEARCH, EVALUATION AND ORGANIZATION OF CURRENTLY AVAILABLE RAPID TOXICOLOGICAL TESTS. VOLUME I. | DEFENSE TECHNICAL INFORMATION CENTER |
| 717 | FORMS FOR DOCUMENTING RADIATION SAFETY PROGRAMS | DEFENSE TECHNICAL INFORMATION CENTER |
| 718 | FORMULARY OF NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES FOR ETHIOPIA, FEBRUARY 2004 | ETHIOPIA – DRUG ADMINISTRATION AND CONTROL AUTHORITY |
| 719 | FORT MADISON COMMUNITY BETTERMENT SURVEY | ERIC |
| 720 | FOUNDATION OF PHARMACOKINETICS | MARCEL DEKKER INC. |
| 721 | FRAMEWORK FOR GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR. MALAYSIA, NOVEMBER 2009, FIRST EDITION | MALAYSIA – MINISTRY OF HEALTH |
| 722 | FRAMEWORK FOR IMPLEMENTATION OF EQUIVALENCE REQUIREMENTS FOR PHARMACEUTICAL PRODUCTS – PANDRH TECHNICAL REPORT Nº8 | MALAYSIA – MINISTRY OF HEALTH |
| 723 | FRAMEWORK FOR IMPLEMENTATION OF EQUIVALENCE REQUIREMENTS FOR PHARMACEUTICAL PRODUCTS. PANDRH TECHNICAL REPORT Nº 8, PAN AMERICAN NETWORK ON DRUG REGULATORY HARMONIZATION | WORLD HEALTH ORGANIZATION |
| 724 | FUNCTIONAL ANALYSIS OF THE GENERAL DIRECTORATE OF PHARMACEUTICAL AFFAIRS (GDPA) OF THE MINISTRY OF PUBLIC HEALTH (MOPH) OF AFGHANISTAN. JULY 2012 | AFGHANISTAN – MINISTRY OF PUBLIC HEALTH |
| 725 | FUTURE STRATEGY – ACTION PROGRAMME ON ESSENTIAL DRUGS | WHO HEADQUARTERS IN GENEVA |
| 726 | GALENIC PHARMACY : A PRACTICAL HANDBOOK TO THE PROCESSES OF THE BRITISH PHARMACOPOEIA | J. & A. CHURCHILL |
| 727 | GAMBIA – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | GAMBIA – MINISTRY OF HEALTH, WELFARE AND WOMEN’S AFFAIRS |
| 728 | GATEWAY TO THE FUTURE. SKILL STANDARDS FOR THE BIOSCIENCE INDUSTRY FOR TECHNICAL WORKERS IN PHARMACEUTICAL COMPANIES, BIOTECHNOLOGY COMPANIES, AND CLINICAL LABORATORIES | ERIC |
| 729 | GAUTENG PROVINCIAL PHARMACY AND THERAPEUTICS COMMITTEE. BIENNIAL REPORT, 1 APRIL 2012 – 31 MARCH 2014 | MANAGEMENT SCIENCES FOR HEALTH |
| 730 | GENERAL GUIDELINES FOR A MANUAL ON DRUG PROCUREMENT AND DISTRIBUTION APPROPRIATE FOR DEVELOPING COUNTRIES | WHO HEADQUARTERS IN GENEVA |
| 731 | GENERAL GUIDELINES FOR SUBMITTING APPLICATIONS FOR REGISTRATION OF A MEDICINE. FIRST EDITION, 2008 – ZAMBIA | ZAMBIA MINISTRY OF HEALTH |
| 732 | GENERATION OF RECOMBINANT HUMAN ACHE OP-SCAVENGERS WITH EXTENDED CIRCULATORY LONGEVITY | DEFENSE TECHNICAL INFORMATION CENTER |
| 733 | GENERIC DRUG POLICIES IN LATIN AMERICA | THE WORLD BANK GROUP |
| 734 | GENOME-BASED THERAPEUTICS: TARGETED DRUG DISCOVERY AND DEVELOPMENT | NATIONAL ACADEMIES PRESS |
| 735 | GERRY’S REAL WORLD GUIDE TO PHARMACOKINETICS AND OTHER THINGS | BOOKLOCKER.COM, INC. |
| 736 | GET FREE FROM MEDICINE BY JUST CHANGING YOUR HABIT | MEDCRAVE |
| 737 | GHANA ESSENTIAL MEDICINES LIST, 5TH EDITION, 2004 | GHANA, MINISTRY OF HEALTH |
| 738 | GHANA ESSENTIAL MEDICINES LIST. SIXTH EDITION, 2010 | GHANA, MINISTRY OF HEALTH |
| 739 | GHANA NATIONAL DRUG POLICY | GHANA, MINISTRY OF HEALTH |
| 740 | GHANA PHARMACEUTICAL COUNTRY PROFILE, FEBRUARY 2012 | GHANA, MINISTRY OF HEALTH |
| 741 | GLOBAL COMPARATIVE PHARMACEUTICAL EXPENDITURES WITH RELATED REFERENCE INFORMATION – HEALTH ECONOMICS AND DRUGS SERIES NO. 003 | WHO HEADQUARTERS IN GENEVA |
| 742 | GLOBALIZATION AND ACCESS TO DRUGS. PERSPECTIVES ON THE WTO/TRIPS AGREEMENT – HEALTH ECONOMICS AND DRUGS SERIES, NO. 007 (REVISED) | WHO HEADQUARTERS IN GENEVA |
| 743 | GLOBALIZATION, PATENTS AND DRUGS (FIRST EDITION). AN ANNOTATED BIBLIOGRAPHY – HEALTH ECONOMICS AND DRUGS SERIES NO. 009 | WHO HEADQUARTERS IN GENEVA |
| 744 | GLOBALIZATION, PATENTS AND DRUGS (SECOND EDITION). AN ANNOTATED BIBLIOGRAPHY – HEALTH ECONOMICS AND DRUGS SERIES NO. 010 | WHO HEADQUARTERS IN GENEVA |
| 745 | GLOSSARY OF TERMS USED FOR PHARMACEUTICALS AND PHARMACEUTICAL POLICIES IN LOW- AND MIDDLE-INCOME COUNTRIES. | WHO HEADQUARTERS IN GENEVA |
| 746 | GLYCOSAMINOGLYCANS AND PROTEOGLYCANS | MDPI AG |
| 747 | GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR | WHO HEADQUARTERS IN GENEVA |
| 748 | GOOD MANUFACTURING PRACTICE GUIDELINE FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES. FIRST EDITION, 2014 – ETHIOPIA | ETHIOPIAN FOOD, MEDICINE & HEALTHCARE ADMINISTRATION & CONTROL AUTHORITY |
| 749 | GOOD PHARMACOVIGILANCE PRACTICE REGULATIONS 2009. NIGERIA NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL (NAFDAC) ACT 1993 | NIGERIA MINISTRY OF HEALTH – NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL |
| 750 | GOOD PHARMACOVIGILANCE PRACTICES FOR THE AMERICAS – PANDRH TECHNICAL DOCUMENT Nº 5 (PAN AMERICAN NETWORK ON DRUG REGULATORY HARMONIZATION) | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE AMERICAS |
| 751 | GOOD PHARMACY PRACTICE (GPP) IN COMMUNITY AND HOSPITAL PHARMACY SETTINGS | WHO HEADQUARTERS IN GENEVA |
| 752 | GOOD PHARMACY PRACTICE IN SOUTH AFRICA. FOURTH EDITION, 2010 | SOUTH AFRICA – SOUTH AFRICAN PHARMACY COUNCIL |
| 753 | GOOD RESEARCH PRACTICE IN NON-CLINICAL PHARMACOLOGY AND BIOMEDICINE | SPRINGER |
| 754 | GOVERNANCE AND PHARMACOVIGILANCE IN BRAZIL: A SCOPING REVIEW | GOVERNANCE AND PHARMACOVIGILANCE IN BRAZIL: A SCOPING REVIEW |
| 755 | GPCR CONFORMATIONS: IMPLICATIONS FOR RATIONAL DRUG DESIGN | MDPI AG |
| 756 | GUIDANCE DOCUMENT: BEST MANAGEMENT PRACTICES FOR UNUSED PHARMACEUTICALS AT HEALTH CARE FACILITIES | NA |
| 757 | GUIDE FOR THE FORMULATION AND IMPLEMENTATION OF A NATIONAL DRUG POLICY AND A NATIONAL PHARMACEUTICAL MASTERPLAN | WHO HEADQUARTERS IN GENEVA |
| 758 | GUIDE TO APPLICATION FOR REGISTRATION OF MEDICINAL PRODUCTS, 2ND EDITION, OCTOBER 2008 – BRUNEI DARUSSALAM | BRUNEI DARUSSALAM – MINISTRY OF HEALTH, DEPARTMENT OF PHARMACEUTICAL SERVICES |
| 759 | GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II – PIC/S, PE 009-8 (PART II), 15 JANUARY 2009. DEVELOPED BY THE INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE | PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME |
| 760 | GUIDE TO GOOD PRESCRIBING – A PRACTICAL MANUAL | WHO HEADQUARTERS IN GENEVA |
| 761 | GUIDELINE FOR THE RATIONAL USE OF CONTROLLED DRUGS, APRIL 2000 – REPUBLIC OF MALDIVES | REPUBLIC OF MALDIVES, MINISTRY OF HEALTH & FAMILY |
| 762 | GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV. SEPTEMBER 2015 | WHO HEADQUARTERS IN GENEVA |
| 763 | GUIDELINES FOR ANTIRETROVIRAL DRUG THERAPY IN KENYA, 3RD EDITION, DECEMBER 2005 | KENYA MINISTRY OF HEALTH – PHARMACY AND POISONS BOARD |
| 764 | GUIDELINES FOR APPLICATION FOR REGISTRATION OF MEDICINAL PRODUCTS – KINGDOM OF BHUTAN | BHUTAN – DRUG REGUATORY AUTHORITY, MINISTRY OF HEALTH |
| 765 | GUIDELINES FOR APPLICATION TO CONDUCT CLINICAL TRIALS IN TANZANIA. (MADE UNDER SECTION 63(1) OF THE TANZANIA FOOD, DRUGS AND COSMETICS ACT, 2003) | TANZANIA FOOD AND DRUGS AUTHORITY |
| 766 | GUIDELINES FOR DEVELOPING NATIONAL DRUG POLICIES, 1988 | WHO HEADQUARTERS IN GENEVA |
| 767 | GUIDELINES FOR DISPENSING OF MEDICINES – PHARMACY BOARD OF AUSTRALIA | AUSTRALIA – PHARMACY BOARD OF AUSTRALIA |
| 768 | GUIDELINES FOR DISPOSAL OF PHARMACEUTICAL WASTES SUPERVISED BY NATIONAL DRUG AUTHORITY – UGANDA | UGANDA – NATIONAL DRUG AUTHORITY |
| 769 | GUIDELINES FOR DRUG DONATIONS – REVISED 1999 | CARITAS INTERNATIONALIS |
| 770 | GUIDELINES FOR EVALUATION OF DRUGS FOR USE IN MAN : REPORT OF A WHO SCIENTIFIC GROUP – WHO TECHNICAL REPORT SERIES, NO. 563 | WHO HEADQUARTERS IN GENEVA |
| 771 | GUIDELINES FOR IMPLEMENTATION OF PHARMACEUTICAL AND THERAPEUTICS COMMITTEES IN GAUTENG PROVINCE. FIRST EDITION | MANAGEMENT SCIENCES FOR HEALTH |
| 772 | GUIDELINES FOR IMPLEMENTING DRUG UTILIZATION REVIEW PROGRAMS IN HOSPITALS | MANAGEMENT SCIENCES FOR HEALTH |
| 773 | GUIDELINES FOR IMPORTATION AND EXPORT OF PHARMACEUTICALS – NATIONAL DRUG AUTHORITY, UGANDA | UGANDA – NATIONAL DRUG AUTHORITY |
| 774 | GUIDELINES FOR PRICE DISCOUNTS OF SINGLE-SOURCE PHARMACEUTICALS | WORLD HEALTH ORGANIZATION |
| 775 | GUIDELINES FOR PRODUCT RECALL AND PRODUCT WITHDRAWAL – KENYA. FIRST EDITION, JUNE 2006 | KENYA MINISTRY OF HEALTH – PHARMACY AND POISONS BOARD |
| 776 | GUIDELINES FOR REGISTRATION OF DRUGS AND RELATED PRODUCTS MANUFACTURED IN NIGERIA NAFDAC/RR/003/00. DIRECTORATE OF REGISTRATION AND REGULATORY AFFAIRS | NIGERIA MINISTRY OF HEALTH – NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL |
| 777 | GUIDELINES FOR SURVEILLANCE OF DRUG RESISTANCE IN TUBERCULOSIS – 4TH EDITION | WHO HEADQUARTERS IN GENEVA |
| 778 | GUIDELINES FOR SURVEILLANCE OF DRUG RESISTANCE IN TUBERCULOSIS – 5TH EDITION | WHO HEADQUARTERS IN GENEVA |
| 779 | GUIDELINES FOR THE COMPILATION OF A PRODUCT DOSSIER FOR SUBMISSION IN THE ASSESSMENT PROCEDURE FOR NEW AND MULTI-SOURCE (GENERIC) PRODUCTS USED IN THE TREATMENT OF MALARIA | UGANDA – NATIONAL DRUG AUTHORITY |
| 780 | GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS: CAN THE UK LEARN FROM AUSTRALIA AND CANADA? | OHE |
| 781 | GUIDELINES FOR THE FORMULATION, IMPLEMENTATION, MONITORING AND EVALUATION OF NATIONAL DRUG POLICIES | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 782 | GUIDELINES FOR THE NATIONAL PHARMACOVIGILANCE SYSTEM IN KENYA. FEBRUARY 2009, SECOND EDITION | KENYA – MINISTRY FOR MEDICAL SERVICES |
| 783 | GUIDELINES FOR THE PHARMACOVIGILANCE ON SAFETY OF VACCINES IN MALAYSIA | MALAYSIAN ADVERSE DRUG REACTIONS ADVISORY COMMITTEE |
| 784 | GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS – 2011 UPDATE | WHO HEADQUARTERS IN GENEVA |
| 785 | GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS. EMERGENCY UPDATE, 2008 | WHO HEADQUARTERS IN GENEVA |
| 786 | GUIDELINES ON ADVERTISING AND PROMOTION OF MEDICINES. FIRST EDITION, 2008 – ZAMBIA | ZAMBIA, PHARMACEUTICAL REGULATORY AUTHORITY |
| 787 | GUIDELINES ON APPLICATION FOR REGISTRATION OF VACCINES AND OTHER BIOLOGICAL PRODUCTS FOR HUMAN AND VETERINARY USE (2008). FIRST EDITION, 2008 – ZAMBIA | ZAMBIA, PHARMACEUTICAL REGULATORY AUTHORITY |
| 788 | GUIDELINES ON DRUG REGISTRATION APPLICATIONS IN BOTSWANA. FIRST REVISED EDITION, MARCH 2000 | BOTSWANA – DRUGS ADVISORY BOARD |
| 789 | GUIDELINES ON GMP INSPECTION OF FOREIGN PHARMACEUTICAL MANUFACTURING PLANTS USE IN UGANDA, FEBRUARY 2007 – NATIONAL DRUG AUTHORITY, UGANDA | BOTSWANA – DRUGS ADVISORY BOARD |
| 790 | GUIDELINES ON PRACTICE-SPECIFIC ISSUES – PHARMACY BOARD OF AUSTRALIA | AUSTRALIA – PHARMACY BOARD OF AUSTRALIA |
| 791 | GUIDELINES ON REGULATING THE CONDUCT OF CLINICAL TRIAL IN HUMAN PARTICIPANTS. FIRST EDITION, 2008 – ZAMBIA | ZAMBIA MINISTRY OF HEALTH |
| 792 | GUIDELINES ON SPECIALISED SUPPLY ARRANGEMENTS – PHARMACY BOARD OF AUSTRALIA | AUSTRALIA – PHARMACY BOARD OF AUSTRALIA |
| 793 | GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF MEDICAL DEVICES. KENYA, 2011 | KENYA MINISTRY OF HEALTH – PHARMACY AND POISONS BOARD |
| 794 | HALOFANTRINE SAFETY, TOLERANCE AND METABOLISM STUDIES | DEFENSE TECHNICAL INFORMATION CENTER |
| 795 | HANDBOOK OF PHARMACEUTICAL MANUFACTURING FORMULATIONS SEMISOLID PRODUCTS , VOL. 4 | MARCEL DEKKER INC. |
| 796 | HANDBOOK OF ANTIMICROBIAL THERAPY | THE MEDICAL LETTER, INC |
| 797 | HANDBOOK OF DRUG INTERACTIONS | HUMANA PRESS |
| 798 | HANDBOOK OF MODERN PHARMACEUTICAL ANALYSIS | ACADEMIC PRESS |
| 799 | HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, | MARCEL DEKKER INC. |
| 800 | HANDBOOK OF THE HOSPITAL CORPS | WASHINGTON, D.C |
| 801 | HARMONIZATION OF UNDERGRADUATE PHARMACY CURRICULA IN SOUTHERN AND EASTERN AFRICA: FUTURE TRENDS. REPORT OF A WORKSHOP IN KARIBA, ZIMBABWE 8 – 11 APRIL 2001 | WHO HEADQUARTERS IN GENEVA |
| 802 | HEALTH CARE AND ADA LANGUAGE EDUCATION PROGRAMS. COOPERATIVE DEMONSTRATION PROGRAM: HIGH TECHNOLOGY | ERIC |
| 803 | HEALTH CARE AND PHARMACEUTICAL POLICIES IN TURKEY AFTER 2003 | HEALTH CARE AND PHARMACEUTICAL POLICIES IN TURKEY AFTER 2003 |
| 804 | HEALTH CAREERS FILM GUIDE | ERIC |
| 805 | HEALTH FACILITIES SURVEY IN GHANA. REPORT OF A SURVEY CONDUCTED MAY-JUNE 2008. WHO PHARMACEUTICAL SITUATION ASSESSMENT – LEVEL II | GHANA, MINISTRY OF HEALTH |
| 806 | HEALTH TECHNOLOGIES AND PHARMACEUTICALS (HTP) PROGRAMME ANNUAL REPORT 2013. WHO REGIONAL OFFICE FOR EUROPE | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 807 | HEALTH TECHNOLOGIES AND PHARMACEUTICALS (HTP) PROGRAMME ANNUAL REPORT 2014. WHO REGIONAL OFFICE FOR EUROPE | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 808 | HEALTH TECHNOLOGIES AND PHARMACEUTICALS DIVISION OF HEALTH SYSTEMS AND PUBLIC HEALTH. ANNUAL REPORT 2012, WHO/EUROPE. ACCESS TO ESSENTIAL, QUALITY MEDICINES AND HEALTH TECHNOLOGIES IS A FUNDAMENTAL PART OF EVERY PERSON’S RIGHT TO HEALTH | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR EUROPE |
| 809 | HEALTH/COSMETOLOGY. CAREER EDUCATION GUIDE | ERIC |
| 810 | HEAT TOLERANCE AND THE PERIPHERAL EFFECTS OF ANTICHOLINERGICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 811 | HERBAL MEDICINE: BIOMOLECULAR AND CLINICAL ASPECTS | CRC PRESS |
| 812 | HETEROCYCLIC CHEMISTRY | SPRINGER |
| 813 | HIGH ENERGY SLIT APERTURE SPECT AND SIMPLIFIED INVITRO METHODS FOR THE DOSIMETRY OF POSITRON EMITTING RADIOTRACERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 814 | HISTAMINERGIC NEUROTRANSMISSION AS A GATEWAY FOR THE EFFECTS OF THE FAT SENSING MOLECULE OLEOYLETHANOLAMIDE : FOCUS ON COGNITION AND STRESS-REACTIVITY | TORROSSA OPEN |
| 815 | HOSPITAL CORPS QUARTERLY | GOVERNMENT PRINTING OFFICE |
| 816 | HOSPITAL PHARMACY MANAGEMENT. (MDS-3: MANAGING ACCESS TO MEDICINES AND HEALTH TECHNOLOGIES, CHAPTER 45) | MANAGEMENT SCIENCES FOR HEALTH |
| 817 | HOSPITAL PHARMACY TECHNICIAN PROJECT; DEVELOPMENT AND VALIDATION OF THE TASK INVENTORY. INTERIM REPORT | ERIC |
| 818 | HOW FINANCIAL SLACK AFFECTS CORPORATE PERFORMANCE [ELECTRONIC RESOURCE] : AN EXAMINATION IN AN UNCERTAIN AND RESOURCE SCARCE ENVIRONMENT | SPRINGER |
| 819 | HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY | DEFENSE TECHNICAL INFORMATION CENTER |
| 820 | HOW TO DEVELOP AND IMPLEMENT A NATIONAL DRUG POLICY, SECOND EDITION) | WORLD HEALTH ORGANIZATION |
| 821 | HOW TO ESTIMATE WAREHOUSE SPACE FOR DRUGS | WHO HEADQUARTERS IN GENEVA |
| 822 | HOW TO IMPLEMENT COMPUTER-ASSISTED DRUG REGISTRATION – A PRACTICAL GUIDE FOR DRUG REGULATORY AUTHORITIES – REGULATORY SUPPORT SERIES NO. 002 | WORLD HEALTH ORGANIZATION |
| 823 | HOW TO IMPROVE MANAGEMENT OF AN ESSENTIAL DRUGS PROGRAMME BY REGULAR SURVEYS | WORLD HEALTH ORGANIZATION |
| 824 | HOW TO INVESTIGATE DRUG USE IN COMMUNITIES. GUIDELINES FOR SOCIAL SCIENCE RESEARCH – EDM RESEARCH SERIES NO. 002 | WORLD HEALTH ORGANIZATION |
| 825 | HOW TO INVESTIGATE DRUG USE IN HEALTH FACILITES. | WHO HEADQUARTERS IN GENEVA |
| 826 | HOW TO INVESTIGATE DRUG USE IN HEALTH FACILITIES: SELECTED DRUG USE INDICATORS – EDM RESEARCH SERIES NO. 007 | WHO HEADQUARTERS IN GENEVA |
| 827 | HYDRASTINE | U.S. NATIONAL LIBRARY OF MEDICINE |
| 828 | IDA AND THE CONCEPT OF ESSENTIAL DRUGS | IDA AND THE CONCEPT OF ESSENTIAL DRUGS |
| 829 | IDENTIFICATION OF CRITICAL BIOLOGICAL PARAMETERS AFFECTING GASTROINTESTINAL ABSORPTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 830 | IDENTIFYING PREDICTORS OF ADVERSE DRUG REACTIONS AND ASSOCIATED COSTS USING A CLAIMS DATABASE | DEFENSE TECHNICAL INFORMATION CENTER |
| 831 | IDPC DRUG POLICY GUIDE, 1ST EDITION, MARCH 2010 – INTERNATIONAL DRUG POLICY CONSORTIUM | INTERNATIONAL DRUG POLICY CONSORTIUM |
| 832 | IMAGING PRIMARY PROSTATE CANCER AND BONE METASTASIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 833 | IMPACT OF A SHORT COURSE IN PHARMACOTHERAPY FOR UNDERGRADUATE MEDICAL STUDENTS: AN INTERNATIONAL MULTICENTRE STUDY | WHO HEADQUARTERS IN GENEVA |
| 834 | IMPACT OF A UNIFORM FORMULARY ON MILITARY HEALTH SYSTEM PRESCRIBERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 835 | IMPACT OF AN ESSENTIAL DRUGS PROGRAMME ON AVAILABILITY AND RATIONAL USE OF DRUGS | IMPACT OF AN ESSENTIAL DRUGS PROGRAMME ON AVAILABILITY AND RATIONAL USE OF DRUGS |
| 836 | IMPACT OF PHARMACIST RECRUITMENT ON ADR REPORTING: MALAYSIAN EXPERIENCE – SOUTHERN MED REVIEW VOL 4 ISSUE 2 DEC 2011 | SOUTHERN MED REVIEW |
| 837 | IMPACT OF REGULATORY REQUIREMENTS ON MEDICINE REGISTRATION IN AFRICAN COUNTRIES – PERCEPTIONS AND EXPERIENCES OF PHARMACEUTICAL COMPANIES IN SOUTH AFRICA – SOUTHERN MED REVIEW VOL 5 ISSUE 1 JULY 2012 | WORLD HEALTH ORGANIZATION |
| 838 | IMPACT OF REGULATORY REQUIREMENTS ON MEDICINES ACCESS IN AFRICAN COUNTRIES. PIASA MEMBER SURVEY RESULTS | PHARMACEUTICAL INDUSTRY ASSOCIATION OF SOUTH AFRICA |
| 839 | IMPACT OF THE ECONOMIC RECESSION ON THE PHARMACEUTICAL SECTOR | WHO COLLABORATING CENTRE FOR PHAMACOEPIDEMIOLOGY AND PHARMACEUTICAL POLICY ANALYSIS |
| 840 | IMPACTS OF INTERNATIONAL SANCTIONS ON IRANIAN PHARMACEUTICAL MARKET | IMPACTS OF INTERNATIONAL SANCTIONS ON IRANIAN PHARMACEUTICAL MARKET |
| 841 | IMPLEMENTATION OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN ELDORET, KENYA – VOLUME 3 ISSUE 2 OCTOBER 2010 | IMPLEMENTATION OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN ELDORET, KENYA – VOLUME 3 ISSUE 2 OCTOBER 2010 |
| 842 | IMPLEMENTATION OF THE WTO GENERAL COUNCIL DECISION ON PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH – HEALTH ECONOMICS AND DRUGS SERIES NO. 016 | WHO HEADQUARTERS IN GENEVA |
| 843 | IMPLEMENTING ACTIVE PHARMACOVIGILANCE AND COHORT EVENT MONITORING FOR MULTIDRUG-RESISTANT TUBERCULOSIS REGIMENS IN THE PHILIPPINES, APRIL 2015 | MANAGEMENT SCIENCES FOR HEALTH |
| 844 | IMPLEMENTING PHARMACOVIGILANCE IN SURINAME, 2006-2009 | SURINAME, MINISTRY OF HEALTH |
| 845 | IMPLICATIONS OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH – HEALTH ECONOMICS AND DRUGS SERIES NO. 012 | WHO HEADQUARTERS IN GENEVA |
| 846 | IMPORTED DRUGS LIST – IRAN, 1989 | IRAN – MINISTRY OF HEALTH AND MEDICAL EDUCATION |
| 847 | IMPROVING AND ACCELERATING THERAPEUTIC DEVELOPMENT FOR NERVOUS SYSTEM DISORDERS | NATIONAL ACADEMIES PRESS |
| 848 | IMPROVING PRIVATE DRUG SELLERS’ PRACTICES FOR MANAGING COMMON HEALTH PROBLEMS IN NEPAL | IMPROVING PRIVATE DRUG SELLERS’ PRACTICES FOR MANAGING COMMON HEALTH PROBLEMS IN NEPAL |
| 849 | IMPROVING RATIONAL DRUG USE IN AFRICA: THE EXAMPLE OF SUDAN | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 850 | IMPROVING TB DRUG MANAGEMENT: ACCELERATING DOTS EXPANSION | MANAGEMENT SCIENCES FOR HEALTH |
| 851 | INCORPORATING LIFE-CYCLE PRICE MODELLING INTO PHARMACEUTICAL COST-EFFECTIVENESS EVALUATIONS | OHE |
| 852 | INDEX OF PHARMACOPOEIAS | WHO HEADQUARTERS IN GENEVA |
| 853 | INDIAN HEALTH TRENDS AND SERVICES | ERIC |
| 854 | INDIAN MEDICINAL PLANTS | SPRINGER-VERLAG |
| 855 | INDICATOR-BASED PHARMACOVIGILANCE ASSESSMENT TOOL: MANUAL FOR CONDUCTING ASSESSMENTS IN DEVELOPING COUNTRIES | MANAGEMENT SCIENCES FOR HEALTH |
| 856 | INDICATORS FOR MONITORING NATIONAL DRUG POLICIES | WHO HEADQUARTERS IN GENEVA |
| 857 | INDICATORS OF RATIONAL DRUG USE AND HEALTH SERVICES IN HADRAMOUT, YEMEN | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 858 | INDIGENOUS DRUGS OF INDIA – 2ND ED. | THACKER, SPINK AND CO. |
| 859 | INDIGENOUS DRUGS OF INDIA ED. 2 | DEFENSE TECHNICAL INFORMATION CENTER |
| 860 | INDIVIDUAL DIFFERENCES IN NEUROBEHAVIORAL EFFECTS OF PYRIDOSTIGMINE | DEFENSE TECHNICAL INFORMATION CENTER |
| 861 | INDONESIA – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | INDONESIA – MINISTRY OF HEALTH |
| 862 | INDUSTRIAL POLICY AND THE PHARMACEUTICAL INDUSTRY | OHE |
| 863 | INITIATION AND IMPLEMENTATION OF A PHARMACOVIGILANCE SYSTEM IN RWANDA | MANAGEMENT SCIENCES FOR HEALTH |
| 864 | INNOVATION AND ACCESS TO MEDICINES FOR NEGLECTED POPULATIONS: COULD A TREATY ADDRESS A BROKEN PHARMACEUTICAL R&D SYSTEM? | WHO HEADQUARTERS IN GENEVA |
| 865 | INNOVATION AND REGULATION IN THE BIOPHARMACEUTICALS SECTOR | INNOVATION AND REGULATION IN THE BIOPHARMACEUTICALS SECTOR |
| 866 | INNOVATION BALANCE OF PAYMENTS: THE EXPERIENCE OF THE PHARMACEUTICAL INDUSTRY | OHE |
| 867 | INORGANIC GENERAL, MEDICAL AND PHARMACEUTICAL CHEMISTRY, THEORETICAL AND PRACTICAL | UNIVERSITY OF MICHIGAN |
| 868 | INORGANIC GENERAL, MEDICAL AND PHARMACEUTICAL CHEMISTRY, THEORETICAL AND PRACTICAL; A TEXT-BOOK AND LABORATORY MANUAL, CONTAINING THEORETICAL, DESCRIPTIVE, AND TECHNOLOGICAL CHEMISTRY | UNIVERSITY OF CALIFORNIA |
| 869 | INSTITUTIONS FOR INDUSTRIAL COMPETITIVENESS IN THE INTERNATIONAL PHARMACEUTICAL INDUSTRY | OHE |
| 870 | INSTRUCTION ON DRUG REGISTRATION, MANUFACTURE AND IMPORTS – IRAN, 2009 | IRAN – MINISTRY OF HEALTH AND MEDICAL EDUCATION |
| 871 | INTEGRATED PHARMACEUTICAL SUPPLY MANAGEMENT AS A STRATEGY FOR STRENGTHENING THE NATIONAL HEALTH SYSTEM IN THE DOMINICAN REPUBLIC | MANAGEMENT SCIENCES FOR HEALTH |
| 872 | INTELLECTUAL PROPERTY AND PUBLIC HEALTH IN THE DEVELOPING WORLD | OPEN BOOK PUBLISHERS |
| 873 | INTERNATIONAL DRUG PRICE INDICATOR GUIDE – GUÍA INTERNACIONAL DE INDICADORES DE PRECIOS DE MEDICAMENTOS – INDICATEUR DE PRIX INTERNATIONAUX DES MÉDICAMENTS. 2010 EDITION | INTERNATIONAL ATOMIC ENERGY AGENCY |
| 874 | INTERNATIONAL DRUG PRICE INDICATOR GUIDE – GUÍA INTERNACIONAL DE INDICADORES DE PRECIOS DE MEDICAMENTOS – INDICATEUR DE PRIX INTERNATIONAUX DES MÉDICAMENTS. 2011 EDITION | MANAGEMENT SCIENCES FOR HEALTH |
| 875 | INTERNATIONAL DRUG PRICE INDICATOR GUIDE – GUÍA INTERNACIONAL DE INDICADORES DE PRECIOS DE MEDICAMENTOS – INDICATEUR DE PRIX INTERNATIONAUX DES MÉDICAMENTS. 2012 EDITION | MANAGEMENT SCIENCES FOR HEALTH |
| 876 | INTERNATIONAL DRUG PRICE INDICATOR GUIDE – GUÍA INTERNACIONAL DE INDICADORES DE PRECIOS DE MEDICAMENTOS – INDICATEUR DE PRIX INTERNATIONAUX DES MÉDICAMENTS. 2013 EDITION | MANAGEMENT SCIENCES FOR HEALTH |
| 877 | INTERNATIONAL DRUG PRICE INDICATOR GUIDE – GUÍA INTERNACIONAL DE INDICADORES DE PRECIOS DE MEDICAMENTOS – INDICATEUR DE PRIX INTERNATIONAUX DES MÉDICAMENTS. 2014 EDITION | MANAGEMENT SCIENCES FOR HEALTH |
| 878 | INTERSPECIES EXTRAPOLATIONS OF HALOCARBON RESPIRATORY AND TISSUE KINETICS: APPLICATIONS TO PREDICTING TOXICITY IN DIFFERENT SPECIES | DEFENSE TECHNICAL INFORMATION CENTER |
| 879 | INTERVENTION RESEARCH IN RATIONAL USE OF DRUGS: A REVIEW | INTERVENTION RESEARCH IN RATIONAL USE OF DRUGS: A REVIEW |
| 880 | INTERVIEW EVALUATION OF THE DATASTAT OUTPATIENT PHARMACY SYSTEM AT NAVAL REGIONAL MEDICAL CENTER CHARLESTON | DEFENSE TECHNICAL INFORMATION CENTER |
| 881 | INTRODUCTION TO MATERIA MEDICA AND PHARMACOLOGY, INCLUDING THE ELEMENTS OF MEDICAL PHARMACY, PRESCRIPTION WRITING, MEDICAL LATIN, TOXICOLOGY, AND METHODS OF LOCAL TREATMENT | UNIVERSITY OF TORONTO |
| 882 | INTRODUCTION TO THE ANALYSIS OF DRUGS AND MEDICINES; AN ELEMENTARY HANDBOOK FOR THE BEGINNER | WILEY |
| 883 | INVESTIGATION OF THE KINETIC MECHANISM OF GLUTAMINE- AND AMMONIA-DEPENDENT REACTIONS OF E. COLI ASPARAGINE SYNTHETASE B USING ISOTOPE PARTITIONING AND STEADY-STATE KINETICS | UNIVERSITY OF FLORIDA |
| 884 | INVESTIGATIONS CONCERNING HYDROLYSIS AND STABILIZATION OF ANTIRADIATION COMPOUNDS | DEFENSE TECHNICAL INFORMATION CENTER |
| 885 | INVESTMENT IN PHARMACEUTICAL PRODUCTION IN THE LEAST DEVELOPED COUNTRIES. A GUIDE FOR POLICY MAKERS AND INVESTMENT PROMOTION AGENCIES | UNITED NATIONS CONFERENCE ON TRADE AND DEVELOPMENT |
| 886 | ION-SELECTIVE ELECTRODES FOR SOME BETA-ADRENERGIC AND CALCIUM BLOCKERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 887 | IPAP 18: INNOVATIONS IN PHARMACY: ADVANCES AND PERSPECTIVES | TORROSSA OPEN |
| 888 | IPR IN CHINA: THE DOHA DECLARATION AND THE PROTECTION OF PUBLIC HEALTH. A REVIEW OF CHINESE LEGISLATION, JUNE 2003 – HEALTH ECONOMICS AND DRUGS SERIES NO. 015 | WHO HEADQUARTERS IN GENEVA |
| 889 | IRAQ PHARMACEUTICAL COUNTRY PROFILE, 2011 | IRAQ – MINISTRY OF HEALTH OF THE REPUBLIC OF IRAQ |
| 890 | IS THE PHARMACEUTICAL INDUSTRY IMPROVING WITH REGARD TO ACCESS TO ESSENTIAL MEDICINES? | IS THE PHARMACEUTICAL INDUSTRY IMPROVING WITH REGARD TO ACCESS TO ESSENTIAL MEDICINES? |
| 891 | IS THERE A ROLE FOR PHARMACOECONOMICS IN DEVELOPING COUNTRIES? | SCHOOL OF PHARMACY – THE UNIVERSITY OF AUCKLAND |
| 892 | ISRAEL – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | ISRAEL – MINISTRY OF HEALTH |
| 893 | JAUNDICE AND ABDOMINAL DROPSY | LONGMANS, GREEN AND CO. |
| 894 | JOINT FIP/WHO GUIDELINES ON GOOD PHARMACY PRACTICE: STANDARDS FOR QUALITY OF PHARMACY SERVICES. WHO TECHNICAL REPORT SERIES, NO. 961, 2011, ANNEX 8 | WORLD HEALTH ORGANIZATION |
| 895 | JORDAN NATIONAL DRUG FORMULARY (JNDF), VERSION 2, 2011 | JORDAN – MINISTRY OF HEALTH |
| 896 | JORDAN PHARMACEUTICAL COUNTRY PROFILE, 2011 | JORDAN – MINISTRY OF HEALTH |
| 897 | JORDAN RATIONAL DRUG LIST, VERSION 1, 2006 | JORDAN – MINISTRY OF HEALTH |
| 898 | KATZUNG BASIC & CLINICAL PHARMACOLOGY 11TH ED | MCGRAW-HILL |
| 899 | KENYA ESSENTIAL DRUGS LIST (THIRD EDITION, 2003) | KENYA MINISTRY OF HEALTH |
| 900 | KENYA NATIONAL DRUG POLICY, JULY 1994 | KENYA MINISTRY OF HEALTH |
| 901 | KENYA NATIONAL FORMULARY FOR PRIMARY CARE LEVEL – KNF-PCL 2008. A PILOT EDITION FOR LIMITED DISTRIBUTION | KENYA – MINISTRY FOR MEDICAL SERVICES |
| 902 | KENYA NATIONAL PHARMACEUTICAL POLICY, 2008 | KENYA – MINISTRY FOR MEDICAL SERVICES |
| 903 | KENYA PHARMACEUTICAL COUNTRY PROFILE, NOVEMBER 2010 | KENYA MINISTRY OF HEALTH |
| 904 | KENYA’S PHARMACEUTICAL INDUSTRY 2005 | EXPORT PROCESSING ZONES AUTHORITY – KENYA |
| 905 | KIRIBATI ESSENTIAL DRUGS LIST (REVISED MARCH 2009) | KIRIBATI – MINISTRY OF HEALTH |
| 906 | KIRIBATI PHARMACEUTICAL COUNTRY PROFILE, 2012 | KIRIBATI – MINISTRY OF HEALTH |
| 907 | KRAM (LAW) DATED JUNE 17, 1996 ON THE MANAGEMENT OF PHARMACEUTICALS – CAMBODIA | CAMBODIA – ROYAL KINGDOM OF CAMBODIA |
| 908 | KYRGYZSTAN – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | KYRGYZSTAN – MINISTRY OF HEALTH |
| 909 | LABORATORY MANUAL OF ELEMENTARY CHEMICAL PHYSIOLOGY AND URINE ANALYSIS | CORNELL UNIVERSITY |
| 910 | LABORATORY MANUAL OF FUNDAMENTAL PRINCIPLES OF BACTERIOLOGY | MCGRAW-HILL |
| 911 | LABORATORY MANUAL OF INORGANIC AND ORGANIC PHARMACEUTICAL PREPARATIONS | UNIVERSITY OF TORONTO |
| 912 | LABORATORY TECHNIQUES FOR DETERMINING THE EFFECTS OF PYRIDOSTIGMINE BROMIDE | DEFENSE TECHNICAL INFORMATION CENTER |
| 913 | LAO NATIONAL DRUG POLICY PROGRAMME | WHO HEADQUARTERS IN GENEVA |
| 914 | LAW ON THE AMENDMENT OF LAW ON MANAGEMENT OF PHARMACEUTICAL, DECEMBER 2007 (UNOFFICIAL TRANSLATION) – CAMBODIA | CAMBODIA – ROYAL KINGDOM OF CAMBODIA |
| 915 | LAWS OF KENYA. THE PHARMACY AND POISONS ACT, CHAPTER 244, REVISED EDITION 2009 | KENYA PARLIAMENT |
| 916 | LEBANON – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | WORLD HEALTH ORGANIZATION |
| 917 | LECTURES ON THE ACTIONS OF MEDICINES : COURSE OF LECTURES ON PHARMACOLOGY AND THERAPEUTICS DELIVERED AT ST. BARTHOLOMEW’S HOSPITAL DURING THE SUMMER SESSION OF 1896 | MACMILLAN COMPANY |
| 918 | LEGAL BARRIERS TO THE BETTER USE OF HEALTH DATA TO DELIVER PHARMACEUTICAL INNOVATION | OHE |
| 919 | LEGISLATION, REGULATION, AND CONSOLIDATION IN THE RETAIL PHARMACY SECTOR IN LOW-INCOME COUNTRIES – SOUTHERN MED REVIEW | LEGISLATION, REGULATION, AND CONSOLIDATION IN THE RETAIL PHARMACY SECTOR IN LOW-INCOME COUNTRIES – SOUTHERN MED REVIEW |
| 920 | LESOTHO – COUNTRY DATA PROFILE ON THE PHARMACEUTICAL SITUATION IN THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) | LESOTHO MINISTRY OF HEALTH & SOCIAL WELFARE |
| 921 | LIBERIA – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | LIBERIA – MINISTRY OF HEALTH & SOCIAL WELFARE |
| 922 | LIPOSOME TECHNOLOGY THIRD EDITION , VOL. I | AJPRD |
| 923 | LIPOSOME TECHNOLOGY THIRD EDITION , VOL. II | AJPRD |
| 924 | LIST OF ESSENTIAL DRUGS, 2008 – BANGLADESH | BANGLADESH, MINISTRY OF HEALTH AND FAMILY WELFARE, GOVERNMENT OF THE PEOPLE’S REPUBLIC OF BANGLADESH |
| 925 | LIST OF MEDICINES FOR ETHIOPIA. SIXTH EDITION, SEPTEMBER 2010 | ETHIOPIA – FOOD, MEDICINES AND HEALTHCARE ADMINISTRATION AND CONTROL AUTHORITY |
| 926 | LOCAL PRODUCTION OF PHARMACEUTICALS AND RELATED TECHNOLOGY TRANSFER IN DEVELOPING COUNTRIES: A SERIES OF CASE STUDIES BY THE UNCTAD SECRETARIAT | UNITED NATIONS |
| 927 | LOCAL PRODUCTION OF PHARMACEUTICALS: INDUSTRIAL POLICY AND ACCESS TO MEDICINES. AN OVERVIEW OF KEY CONCEPTS, ISSUES AND OPPORTUNITIES FOR FUTURE RESEARCH | THE WORLD BANK GROUP |
| 928 | LOCALIZATION OF 99M SUB T C DIPHOSPHONATE IN ACUTELY INJURED MUSCLE: RELATIONSHIP TO MUSCLE CALCIUM DEPOSITION | DEFENSE TECHNICAL INFORMATION CENTER |
| 929 | LOCALIZATION OF SITES OF ACTION OF HIGH-ABUSE-LIABILITY DRUGS IN THE CENTRAL NERVOUS SYSTEM | DEFENSE TECHNICAL INFORMATION CENTER |
| 930 | MAGNETIC RESONANCE ARTERIAL SPIN TAGGING FOR NON-INVASIVE PHARMACOKINETIC ANALYSIS OF BREAST CANCER | UNIVERSITY OF FLORIDA |
| 931 | MAGNETIC RESONANCE ARTERIAL SPIN TAGGING FOR NONINVASIVE PHARMACOKINETIC ANALYSIS OF BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 932 | MAKING NATIONAL DRUG POLICIES A DEVELOPMENT PRIORITY. A STRATEGY PAPER AND SIX COUNTRY STORIES | THE DAG HAMMARSKJÖLD FOUNDATION |
| 933 | MALAWI – COUNTRY DATA PROFILE ON THE PHARMACEUTICAL SITUATION IN THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) | MALAWI MINISTRY OF HEALTH |
| 934 | MALAWI – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | MALAWI MINISTRY OF HEALTH |
| 935 | MALAWI: BUSINESS CASE FOR AN ELECTRONIC LOGISTICS MANAGEMENT INFORMATION SYSTEM | JOHN SNOW INC. |
| 936 | MALAYSIA – NATIONAL ESSENTIAL DRUG LIST (NEDL), 2ND EDITION, 2008 | MALAYSIA – MINISTRY OF HEALTH |
| 937 | MALAYSIA DRUG CODE, 2010, 6TH EDITION | MALAYSIA – MINISTRY OF HEALTH |
| 938 | MALAYSIAN NATIONAL MEDICINES POLICY (MNMP). 2ND EDITION, 2012 / DASAR UBAT NASIONAL (DUNAS), EDISI KEDUA, 2012 | MALAYSIA – MINISTRY OF HEALTH, PHARMACEUTICAL SERVICES DIVISION |
| 939 | MALDIVES – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | MALDIVES – MINISTRY OF HEALTH |
| 940 | MALTA – PHARMACEUTICAL SECTOR COUNTRY PROFILE (QUESTIONNAIRE 2011) | WORLD HEALTH ORGANIZATION |
| 941 | MAMMALIAN TOXICOLOGICAL EVALUATION OF DIMP AND DCPD | DEFENSE TECHNICAL INFORMATION CENTER |
| 942 | MAMMALIAN TOXICOLOGICAL EVALUATION OF DIMP AND DCPD. PHASE 2 | DEFENSE TECHNICAL INFORMATION CENTER |
| 943 | MANAGEMENT OF ALCOHOL- AND DRUG-RELATED ISSUES IN THE WORKPLACE. CODE OF PRACTICE | INTERNATIONAL LABOUR ORGANIZATION |
| 944 | MANAGEMENT OF DRUGS AT HEALTH CENTRES. TECHNICAL GUIDELINES | WHO HEADQUARTERS IN GENEVA |
| 945 | MANAGEMENT OF MDR-TB: A FIELD GUIDE. A COMPANION DOCUMENT TO GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS | WHO HEADQUARTERS IN GENEVA |
| 946 | MANAGERIAL AND ORGANIZATIONAL DETERMINANTS OF EFFICIENCY IN RESEARCH TEAMS | DEFENSE TECHNICAL INFORMATION CENTER |
| 947 | MANAGING PHARMACEUTICAL PROGRAMS. (MDS-3: MANAGING ACCESS TO MEDICINES AND HEALTH TECHNOLOGIES, CHAPTER 37) | MANAGEMENT SCIENCES FOR HEALTH |
| 948 | MANAGING PHARMACEUTICALS AND COMMODITIES FOR TUBERCULOSIS. A GUIDE FOR NATIONAL TUBERCULOSIS PROGRAMS. (REVISED AUGUST 2008) | MANAGEMENT SCIENCES FOR HEALTH |
| 949 | MANAGING PHARMACEUTICALS FOR TB/HIV PROGRAM COLLABORATIONS: A PLANNING GUIDE | MANAGEMENT SCIENCES FOR HEALTH |
| 950 | MANUAL OF BASIC TECHNIQUES FOR A HEALTH LABORATORY | WHO HEADQUARTERS IN GENEVA |
| 951 | MANUAL OF CHEMICAL ANALYSIS AS APPLIED TO THE EXAMINATION OF MEDICINAL CHEMICALS. A GUIDE FOR THE DETERMINATION OF THEIR IDENTITY AND QUALITY | D. APPLETON AND COMPANY |
| 952 | MANUAL OF CHEMISTRY. A GUIDE TO LECTURES AND LABORATORY WORK FOR BEGINNERS IN CHEMISTRY. A TEXT-BOOK SPECIALLY ADAPTED FOR STUDENTS OF PHARMACY AND MEDICINE | LEA BROTHERS & CO. |
| 953 | MANUAL OF CLINICAL CHEMISTRY | CORNELL UNIVERSITY |
| 954 | MANUAL OF MATERIA MEDICA AND THERAPEUTICS | JOHN CHURCHILL |
| 955 | MANUAL OF PHARMACY AND PHARMACEUTICAL CHEMISTRY : DESIGNED ESPECIALLY FOR THE USE OF THE PHARMACEUTICAL STUDENT AND FOR PHARMACISTS IN GENERAL | U.S. NATIONAL LIBRARY OF MEDICINE |
| 956 | MANUAL OF PRACTICAL PHARMACEUTICAL ASSAYING, INCLUDING DETAILS OF THE SIMPLEST AND BEST METHODS OF DETERMINING THE STRENGTH OF CRUDE DRUGS AND GALENICAL PREPARATIONS | UNIVERSITY OF MICHIGAN |
| 957 | MANUAL OF PRACTICAL PHARMACEUTICAL CHEMISTRY | WELLCOME LIBRARY |
| 958 | MANUAL ON MANAGEMENT OF DRUGS, 3RD EDITION, SECOND REVISION, 2008 – SRI LANKA | SRI LANKA – MINISTRY OF HEALTHCARE AND NUTRITION |
| 959 | MAPPING PRIVATE PHARMACIES AND THEIR CHARACTERISTICS IN UJJAIN DISTRICT, CENTRAL INDIA (BMC HEALTH SERVICES RESEARCH 2011, 11:351) | BMC PUBLIC HEALTH |
| 960 | MAPPING THE AVAILABILITY, PRICE, AND AFFORDABILITY OF ANTIEPILEPTIC DRUGS IN 46 COUNTRIES (EPILEPSIA, **(*):1–8, 2012) | MAPPING THE AVAILABILITY, PRICE, AND AFFORDABILITY OF ANTIEPILEPTIC DRUGS IN 46 COUNTRIES |
| 961 | MARINE COMPOUNDS AND CANCER | MDPI AG |
| 962 | MARINE CORPS OPERATIONAL MEDICINE: DETERMINING MEDICAL SUPPLY NEEDS OF THE SURGICAL COMPANY WARD, LAB, AND PHARMACY | DEFENSE TECHNICAL INFORMATION CENTER |
| 963 | MARKETING AUTHORIZATION OF PHARMACEUTICAL PRODUCTS WITH SPECIAL REFERENCE TO MULTISOURCE, GENERIC PRODUCTS: A MANUAL FOR NATIONAL MEDICINES REGULATORY AUTHORITIES, NMRAS – 2ND EDITION | WHO HEADQUARTERS IN GENEVA |
| 964 | MATERIA MEDICA AND THERAPEUTICS, INORGANIC SUBSTANCES | OXFORD UNIVERSITY PRESS |
| 965 | MATERIA MEDICA FOR PHARMACY TECHNICIANS | U.S. NATIONAL LIBRARY OF MEDICINE |
| 966 | MATERNAL-FETAL COCAINE METABOLISM, DISTRIBUTION, AND IMMUNOTOXICOLOGY | UNIVERSITY OF FLORIDA |
| 967 | MATRIX METALLOPROTEINASES AS A THERAPEUTIC TARGET TO IMPROVE NEUROLOGIC RECOVERY AFTER SPINAL CORD INJURY | DEFENSE TECHNICAL INFORMATION CENTER |
| 968 | MAURITIUS – COUNTRY DATA PROFILE ON THE PHARMACEUTICAL SITUATION IN THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) | MAURITIUS MINISTRY OF HEALTH |
| 969 | MAURITIUS THE DANGEROUS DRUGS ACT (ACT NO. 41 OF 2000) | MAURITIUS – PARLIAMENT |
| 970 | MEASURING TRANSPARENCY IN THE PUBLIC PHARMACEUTICAL SECTOR. ASSESSMENT INSTRUMENT | WHO HEADQUARTERS IN GENEVA |
| 971 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR – KENYA | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 972 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR – ZAMBIA | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR AFRICA |
| 973 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR IN JORDAN | JORDAN – MINISTRY OF HEALTH |
| 974 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR IN MALAWI | WHO HEADQUARTERS IN GENEVA |
| 975 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR, LEBANON | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 976 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR, SYRIAN ARAB REPUBLIC | WORLD HEALTH ORGANIZATION – REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN |
| 977 | MEASURING TRANSPARENCY TO IMPROVE GOOD GOVERNANCE IN THE PUBLIC PHARMACEUTICAL SECTOR. A COMPARATIVE ANALYSIS OF FIVE COUNTRY ASSESSMENT STUDIES: BOLIVIA, CAMBODIA, INDONESIA, MONGOLIA, PAPUA NEW GUINEA | WHO HEADQUARTERS IN GENEVA |
| 978 | MECHANISTIC MODELS FOR IGNITION AND COMBUSTION OF METALLIC POWDERS IN DIFFERENT ENVIRONMENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 979 | MEDEDPORTAL AUTHOR HANDBOOK | AMERICAN MEDICAL COLLEGES |
| 980 | MEDICAL ASSISTING PROGRAM GUIDE | ERIC |
| 981 | MEDICAL ASSISTING PROGRAM STANDARDS | ERIC |
| 982 | MEDICAL LEXICON : A DICTIONARY OF MEDICAL SCIENCE : CONTAINING A CONCISE EXPLANATION OF THE VARIOUS SUBJECTS AND TERMS OF ANATOMY, PHYSIOLOGY, PATHOLOGY, HYGIENE, THERAPEUTICS, PHARMACOLOGY, PHARMACY, SURGERY, OBSTETRICS, MEDICAL JURISPRUDENCE, DENTISTRY, ETC. : NOTICES OF CLIMATE, AND OF MINERAL WATERS : FORMULAE FOR VARIOUS OFFICINAL, EMPIRICAL, AND DIETETIC PREPARATIONS, ETC. : WITH FRENCH AND OTHER SYNONYMES | BLANCHARD AND LEA |
| 983 | MEDICATION DEVELOPMENT FOR THE TREATMENT OF COCAINE DEPENDENCE : ISSUES IN CLINICAL EFFICACY TRIALS | NATIONAL INSTITUTES OF HEALTH |
| 984 | MEDICATION FOR THE TREATMENT OF ALCOHOL USE DISORDER: A BRIEF GUIDE | NATIONAL INSTITUTE ON ALCOHLO ABUSE AND ALCOHOLISM |
| 985 | MEDICINAL CHEMISTRY AND DRUG DESIGN | INTECH |
| 986 | MEDICINES BY DESIGN | NATIONAL INSTITUTES OF HEALTH |
| 987 | MEETING REPORT OF NATIONAL TECHNICAL ADVISORY COMMITTEE FOR PHARMACY; LOS ANGELES, CALIFORNIA (MARCH 23-25, 1969) | ERIC |
| 988 | METABOLISM AND PHARMACOKINETICS OF 14C-WR 178,460.HC1 IN THE DOG | DEFENSE TECHNICAL INFORMATION CENTER |
| 989 | METHEMOGLOBIN AS A POSSIBLE ANTIDOTE IN CYANIDE POISONING | DEFENSE TECHNICAL INFORMATION CENTER |
| 990 | MICROCOMPUTER-ASSISTED FLOW-THROUGH ASV SYSTEM | DEFENSE TECHNICAL INFORMATION CENTER |
| 991 | MICROSCALE TESTING IN AQUATIC TOXICOLOGY: ADVANCES, TECHNIQUES, AND PRACTICE | TAYLOR & FRANCIS ONLINE |
| 992 | MILITARY INTEROPERABLE DIGITAL HOSPITAL TESTBED | DEFENSE TECHNICAL INFORMATION CENTER |
| 993 | MODERN PHARMACEUTICS | MARCEL DEKKER INC. |
| 994 | MODIFICATION AND IMPROVEMENT OF SOFTWARE FOR MODELING MULTIDIMENSIONAL REACTING FUEL FLOWS | DEFENSE TECHNICAL INFORMATION CENTER |
| 995 | MODULATION OF PACLITAXEL ANTITUMOR EFFECTS BY CALCITRIOL: PRECLINICAL STUDIES OF MECHANISM, TOXICITY AND EFFICACY IN PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 996 | MOLECULAR SIZE-BASED MODEL TO ESTIMATE PHARMACEUTICALLY RELEVANT PHYSICOCHEMICAL PROPERTIES | UNIVERSITY OF FLORIDA |
| 997 | MULTIDRUG RESISTANCE IN BREAST CANCER: OCCURRENCE AND THERAPEUTIC IMPLICATIONS | DEFENSE TECHNICAL INFORMATION CENTER |
| 998 | MULTIFACTORIAL ASSESSMENT OF DEPLETED URANIUM NEUROTOXICITY | DEFENSE TECHNICAL INFORMATION CENTER |
| 999 | NANOCOSMETICS AND NANOMEDICINES | SPRINGER |
| 1000 | NANOFIBRES IN DRUG DELIVERY | UCL PRESS |
| 1001 | NANOPARTICLE TECHNOLOGY FOR DRUG DELIVERY | AJPRD |
| 1002 | NANOPARTICULATE DRUG DELIVERY SYSTEM | AJPRD |
| 1003 | NATIONAL REHABILITATION HOSPITAL ASSISTIVE TECHNOLOGY RESEARCH CENTER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1004 | NATURAL HISTORY OF PLEXIFORM NEUROFIBROMAS IN NF1 | DEFENSE TECHNICAL INFORMATION CENTER |
| 1005 | NAVAL HOSPITAL GUAM PATIENT HANDBOOK 2014 | NA |
| 1006 | NEEDS OF THE PHARMACEUTICAL MANUFACTURERS FROM THEIR MEDICAL DEPARTMENTS IN THE 1980S | OHE |
| 1007 | NEURAL RESPONSES TO INJURY: PREVENTION, PROTECTION, AND REPAIR. NEUROPHARMACOLOGY OF DELTA RECEPTOR AGONISTS AND ANTAGONISTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1008 | NEUROPSYCHOPHARMACOLOGY: 5TH GENERATION OF PROGRESS | LIPPINCOTT WILLIAMS & WILKINS |
| 1009 | NEW AND NONOFFICIAL DRUGS | LIPPINCOTT COMPANY |
| 1010 | NEW APPROACHES FOR THE DISCOVERY OF PHARMACOLOGICALLY-ACTIVE NATURAL COMPOUNDS | MDPI AG |
| 1011 | NEW INSIGHTS INTO TOXICITY AND DRUG TESTING | INTECH |
| 1012 | NEW RHENIUM RADIOPHARMACEUTICALS FOR THE SELECTIVE IMAGING AND THERAPY OF BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1013 | NIDA RESEARCH MONOGRAPH SERIES #173: PHARMACOKINETICS, METABOLISM, AND PHARMACEUTICS OF DRUGS OF ABUSE | NATIONAL INSTITUTE ON DRUG ABUSE |
| 1014 | NMR SPECTROSCOPY | CAMBRIDGE UNIVERSITY PRESS |
| 1015 | NMR-ACTIVE NUCLEI FOR BIOLOGICAL AND BIOMEDICAL APPLICATIONS | OPEN MEDSCIENCE LIMITED |
| 1016 | NOMINATIONS TO INDEPENDENT AGENCIES, BOARDS AND COMMISSIONS | GOVERNMENT PUBLISHING OFFICE |
| 1017 | NONCANCER EFFECTS OF TRICHIOROETHYLENE: PHARMACOKINETICS AND RISK ASSESSMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 1018 | NONINVASIVE SPATIALLY OFFSET AND TRANSMISSION RAMAN MAPPING OF BREAST TISSUE: A MULTIMODAL APPROACH TOWARD THE IN VIVO ASSESSMENT OF TISSUE PATHOLOGY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1019 | NONINVASIVE SPATIALLY OFFSET AND TRANSMISSION RAMAN MAPPING OF BREAST TISSUE: A MULTIMODAL APPROACH TOWARDS THE IN VIVO ASSESSMENT OF TISSUE PATHOLOGY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1020 | NOVEL RADIOPHARMACEUTICALS FOR RADIOGUIDED SURGERY OF DUCTAL CARCINOMA IN SITU OF THE BREAST | DEFENSE TECHNICAL INFORMATION CENTER |
| 1021 | NUCLEAR MEDICINE AND PET CT TECHNOLOGY AND TECHNIQUES CHRISTIAN | ELSEVIER |
| 1022 | NUMERICAL SOLUTIONS FOR BAYES SEQUENTIAL DECISION APPROACH TO BIOEQUIVALENCE PROBLEM | DEFENSE TECHNICAL INFORMATION CENTER |
| 1023 | NURSING PHARMACOLOGY | WI TECHNICAL COLLEGES OPEN PRESS |
| 1024 | OBSERVATIONS ON THE USE OF CAUSTIC ALKALI IN SCROFULA AND OTHER CHRONIC DISEASES | KING’S COLLEGE |
| 1025 | OCCUPATIONAL RISK FROM CHROMIUM | DEFENSE TECHNICAL INFORMATION CENTER |
| 1026 | OFF-LABEL DRUGS. INITIAL RESULTS OF A NATIONAL SURVEY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1027 | OHIO BIOTECHNOLOGY COMPETENCY PROFILE | ERIC |
| 1028 | OLD RECEPTORS, NEW TREATMENT STRATEGIES FOR BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1029 | ONCOLYTIC GENE THERAPY FOR PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1030 | OPEN THIS DOCUMENT AND VIEW ITS CONTENT APPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT – MALDIVES FOOD AND DRUG AUTHORITY | REPUBLIC OF MALDIVES, MINISTRY OF HEALTH & FAMILY |
| 1031 | OPERATE A CHEMICAL SURETY PROGRAM AND STUDIES SUPPORTING THE MEDICAL CHEMICAL DEFENSE RESEARCH PROGRAM | DEFENSE TECHNICAL INFORMATION CENTER |
| 1032 | OPTICAL IMAGING OF MAMMAGLOBIN EXPRESSION IN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1033 | OPTIMAL DESIGNS FOR RANDOM EFFECT MODELS WITH CORRELATED ERRORS WITH APPLICATIONS IN POPULATION PHARMACOKINETICS | ARXIV |
| 1034 | ORAL DIABETES MEDICATIONS FOR ADULTS WITH TYPE 2 DIABETES: AN UPDATE | AHRQ |
| 1035 | ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE | DEPARTMENT OF HEALTH AND HUMAN SERVICES |
| 1036 | ORGANIC CHEMISTRY, INCLUDING CERTAIN PORTIONS OF PHYSICAL CHEMISTRY FOR MEDICAL, PHARMACEUTICAL, AND BIOLOGICAL STUDENTS | WILEY |
| 1037 | ORGANIC CHEMISTRY, INCLUDING CERTAIN PORTIONS OF PHYSICAL CHEMISTRY FOR MEDICAL, PHARMACEUTICAL, AND BIOLOGICAL STUDENTS, WITH PRACTICAL EXERCISES | WILEY |
| 1038 | ORGANIC ISOTHIOCYANATES: DIETARY MODULATORS OF DOXORUBICIN RESISTANCE IN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1039 | ORGANOFLUORINE CHEMISTRY [ELECTRONIC RESOURCE] : TECHNIQUES AND SYNTHONS | SPRINGER |
| 1040 | OSTEOPOROSIS [ELECTRONIC RESOURCE] : PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT | HUMANA PRESS INC. |
| 1041 | OUTLINES OF BIOCHEMISTRY | WILEY |
| 1042 | OUTLINES OF BIOCHEMISTRY : THE ORGANIC CHEMISTRY AND THE PHYSICO-CHEMICAL REACTIONS OF BIOLOGICALLY IMPORTANT COMPOUNDS AND SYSTEMS | WILEY |
| 1043 | OUTLINES OF PHYSIOLOGICAL CHEMISTRY | H.K. LEWIS |
| 1044 | OUTLINES OF PHYSIOLOGICAL CHEMISTRY: INCLUDING THE QUALITATIVE AND QUANTITATIVE ANALYSIS OF THE TISSUES FLUIDS AND EXCRETORY PRODUCTS | H.K. LEWIS |
| 1045 | OVERSIGHT OF THE SAFE DRINKING WATER ACT | GOVERNMENT PUBLISHING OFFICE |
| 1046 | PAIN MANAGEMENT – CURRENT ISSUES AND OPINIONS | INTECH |
| 1047 | PARENTRAL QUALITY CONTROL | AJPRD |
| 1048 | PATHWAYS TO HEALTH CAREERS, EXPLORING HEALTH OCCUPATIONS AND PROFESSIONS | ERIC |
| 1049 | PBPK MODELING IN MEDAKA WITH BROMODICHLOROMETHANE (BDCM) AND THE SIX MONTH FLOW-THROUGH EXPOSURE OF BDCM TO MEDAKA | DEFENSE TECHNICAL INFORMATION CENTER |
| 1050 | PENTAFLUOROSULFUR COMPOUNDS FOR NAVAL MATERIALS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1051 | PERCEIVED VALUE FRAMEWORK FOR EXPLAINING PATIENTS’ INTENTIONS TO USE PHARMACEUTICAL CARE SERVICES | UNIVERSITY OF FLORIDA |
| 1052 | PERFORMANCE MODIFICATION FOLLOWING ALTERATION OF MOLECULAR MECHANISMS OF THERMOREGULATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1053 | PERSONAL HEALTH SERVICES: A PERSPECTIVE OF THE GENERAL MEDICAL & THE PHARMACEUTICAL SERVICES | OHE |
| 1054 | PET IMAGING OF A MARKER FOR BREAST CANCER METASTASIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1055 | PHARMACEUTICAL AND CLINICAL CALCULATIONS | MARCEL DEKKER INC. |
| 1056 | PHARMACEUTICAL AND FOOD ANALYSIS; A MANUAL OF STANDARD METHODS FOR THE ANALYSIS OF OILS, FATS AND WAXES, AND SUBSTANCES IN WHICH THEY EXIST; TOGETHER WITH ALLIED PRODUCTS | D. VAN NOSTRAND COMPANY, INC. |
| 1057 | PHARMACEUTICAL BIOTECHNOLOGY | NEW AGE INTERNATIONAL PVT. LTD |
| 1058 | PHARMACEUTICAL HUMAN RESOURCES ASSESSMENT TOOLS | WORLD HEALTH ORGANIZATION |
| 1059 | PHARMACEUTICAL INDUSTRY AND SOCIETY: A STUDY OF THE CHANGING ENVIRONMENT AND ECONOMICS OF THE INTERNATIONAL INDUSTRY | OHE |
| 1060 | PHARMACEUTICAL INNOVATION: RECENT TRENDS, FUTURE PROSPECTS | OHE |
| 1061 | PHARMACEUTICAL MICROBIOLOGY | NEW AGE INTERNATIONAL LIMITED PUBLISHERS |
| 1062 | PHARMACEUTICAL PREFORMULATION AND FORMULATION | INFORMA HEALTH CARE |
| 1063 | PHARMACEUTICAL PRICES: A CONTINENTAL VIEW | OHE |
| 1064 | PHARMACEUTICAL RESEARCH: THE CASE FOR GROWTH IN BRITAIN | OHE |
| 1065 | PHARMACEUTICAL SECTOR COUNTRY PROFILE QUESTIONNAIRE | WORLD HEALTH ORGANIZATION |
| 1066 | PHARMACEUTICAL SECTOR SCAN. PART OF COMPONENT 1 OF META BASELINE ASSESSMENTS – GHANA; PERIOD OF DATA COLLECTION: NOVEMBER 2009 – FEBRUARY 2010 | WORLD HEALTH ORGANIZATION |
| 1067 | PHARMACEUTICAL SITUATION IN AFGHANISTAN. PRELIMINARY ASSESSMENT, 14-23 JANUARY 2002 | WORLD HEALTH ORGANIZATION |
| 1068 | PHARMACEUTICAL SITUATION IN BARBADOS: WORLD HEALTH ORGANIZATION, WHO; LEVEL II HEALTH FACILITY AND HOUSEHOLD SURVEYS, FEBRUARY, 2011 | WORLD HEALTH ORGANIZATION |
| 1069 | PHARMACEUTICAL SITUATION IN JAMAICA. WHO ASSESSMENT OF LEVEL II – HEALTH FACILITIES AND HOUSEHOLD SURVEY. TECHNICAL SERIES: ESSENTIAL MEDICINES, PHARMACEUTICAL POLICIES, Nº 5 | WORLD HEALTH ORGANIZATION |
| 1070 | PHARMACEUTICAL SITUATION IN SAINT LUCIA. WHO ASSESSMENT OF LEVEL II – HEALTH FACILITIES SURVEY. PAHO TECHNICAL SERIES: ESSENTIAL MEDICINES, PHARMACEUTICAL POLICIES, NO. 4, AUGUST 2012 | WORLD HEALTH ORGANIZATION |
| 1071 | PHARMACEUTICAL SITUATION IN THE CARIBBEAN. FACTBOOK ON LEVEL I MONITORING INDICATORS – 2007 | WORLD HEALTH ORGANIZATION |
| 1072 | PHARMACEUTICAL STABILITY AND FORMULATION OF PLASMID DNA | UNIVERSITY OF FLORIDA |
| 1073 | PHARMACEUTICAL SURGE REQUIREMENTS FOR THE PRIME VENDOR PROGRAM-EUROPE IN SUPPORT OF MILITARY OPERATIONS OTHER THAN WAR | DEFENSE TECHNICAL INFORMATION CENTER |
| 1074 | PHARMACEUTICALS AMONG THE SUNRISE INDUSTRIES | OHE |
| 1075 | PHARMACEUTICALS AND HEALTH SECTOR REFORM IN THE AMERICAS: AN ECONOMIC PERSPECTIVE | WORLD HEALTH ORGANIZATION |
| 1076 | PHARMACEUTICALS AND THE INTERNET DRUG REGULATORY AUTHORITIES’ PERSPECTIVE – JOINT NLN-WHI WORKSHOP, 24-25 SEPTEMBER 2001 | WORLD HEALTH ORGANIZATION |
| 1077 | PHARMACEUTICALS AND THE WTO TRIPS AGREEMENT: QUESTIONS AND ANSWERS | WORLD HEALTH ORGANIZATION |
| 1078 | PHARMACEUTICALS IN DEVELOPING COUNTRIES | OHE |
| 1079 | PHARMACEUTICALS IN DEVELOPING COUNTRIES 1981-82 | OHE |
| 1080 | PHARMACEUTICALS IN SEVEN NATIONS | OHE |
| 1081 | PHARMACEUTICALS IN THE TRADE RELATED ASPECTS OF THE INTELLECTUAL PROPERTY RIGHTS, TRIPS; AGREEMENT OF THE WORLD TRADE ORGANIZATION – A BRIEFING ON TRIPS | WORLD HEALTH ORGANIZATION |
| 1082 | PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY | WORLD HEALTH ORGANIZATION |
| 1083 | PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY. UPDATE OF THE FOURTEENTH ISSUE. PREPARED WITHIN THE CONTEXT OF THE UNITED NATIONS PUBLICATION, “CONSOLIDATED LIST OF PRODUCTS WHOSE CONSUMPTION AND/OR SALE HAVE BEEN BANNED, WITHDRAWN, SEVERELY RESTRICTED OR NOT APPROVED BY GOVERNMENTS” | WORLD HEALTH ORGANIZATION |
| 1084 | PHARMACIST IN SOCIETY | OHE |
| 1085 | PHARMACOKINETIC MANIPULATION AND MODELING OF THE TRIGGER FOR JP-8-INDUCED SKIN IRRITATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1086 | PHARMACOKINETIC MODELING OF TRIVALENT AND HEXAVALENT CHROMIUM BASED ON INGESTION AND INHALATION OF SOLUBLE CHROMIUM COMPOUNDS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1087 | PHARMACOKINETIC MODELS FOR THE ELIMINATION OF DRINKING WATER CONTAMINANTS FROM THE BODY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1088 | PHARMACOKINETIC STUDIES OF ACEPROMAZINE IN THE CAT AND THE HORSE, STUDIES IN LIPOPHILICITY, RED BLOOD CELL PARTITIONING AND PROTEIN BINDING | UNIVERSITY OF FLORIDA |
| 1089 | PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF PIPERACILLIN-TAZOBACTAM COMBINATIONS | UNIVERSITY OF FLORIDA |
| 1090 | PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE ANALGESIC EFFECT OF IBUPROFEN AND CODEINE | UNIVERSITY OF FLORIDA |
| 1091 | PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF CORTICOSTEROIDS AND SYSTEMIC EFFECTS | UNIVERSITY OF FLORIDA |
| 1092 | PHARMACOKINETICS | BOOKBOON |
| 1093 | PHARMACOKINETICS AND DRUG METABOLISM IN CANADA: THE CURRENT LANDSCAPE | MDPI AG |
| 1094 | PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN | WILEY |
| 1095 | PHARMACOKINETICS AND METABOLISM OF DICHLOROACETIC ACID AND TRICHLOROACETIC ACID ADMINISTERED IN DRINKING WATER IN RATS AND MICE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1096 | PHARMACOKINETICS AND PHARMACODYNAMICS OF CEFACLOR | UNIVERSITY OF FLORIDA |
| 1097 | PHARMACOKINETICS AND PHARMACODYNAMICS OF SUSTAINED LOW-DOSE INTRAVENOUS INFUSIONS OF PYRIDOSTIGMINE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1098 | PHARMACOKINETICS OF BUPRENORPHINE IN DOGS | UNIVERSITY OF FLORIDA |
| 1099 | PHARMACOKINETICS OF HCFC-123 IN DOGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1100 | PHARMACOKINETICS OF PLASMID DNA | UNIVERSITY OF FLORIDA |
| 1101 | PHARMACOKINETICS OF SODIUM DICHLOROACETATE | UNIVERSITY OF FLORIDA |
| 1102 | PHARMACOLOGIC AND NONPHARMACOLOGIC APPROACHES TO THE TREATMENT OF HYPERTENSION WITH IMPLICATIONS FOR THE CLINICAL NURSE SPECIALIST | DEFENSE TECHNICAL INFORMATION CENTER |
| 1103 | PHARMACOLOGICAL REGULATION OF PEROXISOME NUMBER IN GLIA | DEFENSE TECHNICAL INFORMATION CENTER |
| 1104 | PHARMACOLOGICAL SPARING OF PROTEIN AND GLUCOSE IN BURN INJURY AND/OR SEPSIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1105 | PHARMACOLOGY | INTECH |
| 1106 | PHARMACOLOGY AND NUTRITIONAL INTERVENTION IN THE TREATMENT OF DISEASE | INTECH |
| 1107 | PHARMACOLOGY AND THERAPEUTICS | INTECH |
| 1108 | PHARMACOLOGY AND THERAPEUTICS FOR DENTISTRY | ELSEVIER |
| 1109 | PHARMACOLOGY AND TOXIXOLOGY OF URANIUM COMPOUNDS | MCGRAW-HILL |
| 1110 | PHARMACOLOGY DEMYSTIFIED | MCGRAW-HILL |
| 1111 | PHARMACOLOGY FOR DENTISTRY | NEW AGE INTERNATIONAL PVT. LTD |
| 1112 | PHARMACOLOGY, CLINICAL AND EXPERIMENTAL : A GROUNDWORK OF MEDICAL TREATMENT : BEING A TEXTBOOK FOR STUDENTS AND PHYSICIANS | LIPPINCOTT COMPANY |
| 1113 | PHARMACOLOGY, CLINICAL AND EXPERIMENTAL : A GROUNDWORK OF MEDICAL TREATMENT BEING A TEXTBOOK FOR STUDENTS AND PHYSICIANS | LIPPINCOTT COMPANY |
| 1114 | PHARMACOLOGY, CLINICAL AND EXPERIMENTAL A GROUNDWORK OF MEDICAL TREATMENT | UNIVERSITY OF TORONTO |
| 1115 | PHARMACOLOGY, CLINICAL AND EXPERIMENTAL; A GROUNDWORK OF MEDICAL TREATMENT, BEING A TEXT-BOOK FOR STUDENTS AND PHYSICIANS | LIPPINCOTT COMPANY |
| 1116 | PHARMACOLOGY–AN ILLUSTRATED REVIEW | THIEME MEDICAL PUBLISHERS |
| 1117 | PHARMACOPOEIA COLLEGII REGALIS MEDICORUM LONDINENSIS | KING’S COLLEGE |
| 1118 | PHARMACOTHERAPEUTICS, MATERIA MEDICA AND DRUG ACTION | D. APPLETON AND COMPANY |
| 1119 | PHARMACOTHERAPY | INTECH |
| 1120 | PHARMACOTHERAPY HANDBOOK | MCGRAW-HILL |
| 1121 | PHARMACOTHERAPY IN CHILDREN: IDENTIFYING KNOWLEDGE GAPS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1122 | PHARMACOVIGILANCE IN THE EUROPEAN UNION | SPRINGER |
| 1123 | PHARMACY MANAGEMENT: ESSENTIALS FOR ALL PRACTICE SETTINGS | MCGRAW-HILL |
| 1124 | PHARMACY SECTION OF THE PACKAGED DISASTER HOSPITAL | GOVERNMENT PRINTING OFFICE |
| 1125 | PHARMACY STUDENT SURVIVAL GUIDE | MCGRAW-HILL |
| 1126 | PHARMACY USE AND COSTS IN EMPLOYER-PROVIDED HEALTH PLANS. INSIGHTS FOR TRICARE BENEFIT DESIGN FROM THE PRIVATE SECTOR | DEFENSE TECHNICAL INFORMATION CENTER |
| 1127 | PHASE I CLINICAL PHARMACOLOGY STUDIES | DEFENSE TECHNICAL INFORMATION CENTER |
| 1128 | PHASE I CLINICAL TESTING ANTIMALARIAL DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1129 | PHASE I EVALUATION OF DESBUTYIHALOFANTRINE IN HEALTHY VOLUNTEERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1130 | PHENETHYL ISOTHIOCYANATE IN BREAST CANCER PREVENTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1131 | PHOTONIC BREAST TOMOGRAPHY AND TUMOR AGGRESSIVENESS ASSESSMENT | DEFENSE TECHNICAL INFORMATION CENTER |
| 1132 | PHOTOSTABILITY OF DRUGS AND DRUG FORMULATION | AJPRD |
| 1133 | PHYSICAL CHEMISTRY AND ITS APPLICATIONS IN MEDICAL AND BIOLOGICAL SCIENCE | UNIVERSITY OF CALIFORNIA |
| 1134 | PHYSICAL PHARMACY | MARCEL DEKKER INC. |
| 1135 | PHYSICAL PHARMACY: PHYSICAL CHEMICAL PRINCIPLES IN THE PHARMACEUTICAL SCIENCES | LEA & FEBIGER |
| 1136 | PHYSICIAN SATISFACTION AT KELLER ARMY COMMUNITY HOSPITAL | DEFENSE TECHNICAL INFORMATION CENTER |
| 1137 | PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR EVALUATING A SIMULANT FOR TOXIC GASES IN PRIMATES | DEFENSE TECHNICAL INFORMATION CENTER |
| 1138 | PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING OF PERCUTANEOUSLY ABSORBED DIBROMOMETHANE UTILIZING MULTIPLE DERMAL SUB-COMPARTMENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1139 | PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS FOR THE TRANSPORT OF TRICHLOROETHYLENE IN ADIPOSE TISSUE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1140 | PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF SKIN ABSORPTION USING DERMAL SUBCOMPARTMENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1141 | POCKET ATLAS OF PHARMACOLOGY, 4TH ED | THIEME MEDICAL PUBLISHERS |
| 1142 | POISONING & DRUG OVERDOSE | MCGRAW-HILL |
| 1143 | POTENTIAL IMPACT ON THE GENERIC PHARMACEUTICAL INDUSTRY IN CANADA | POTENTIAL IMPACT ON THE GENERIC PHARMACEUTICAL INDUSTRY IN CANADA |
| 1144 | PRACTICAL ESTIMATION OF HIGH DIMENSIONAL STOCHASTIC DIFFERENTIAL MIXED-EFFECTS MODELS | ARXIV |
| 1145 | PRACTICAL MEDICAL CHEMISTRY, FOR PHYSICIANS AND STUDENTS | HARVARD UNIVERSITY |
| 1146 | PRACTICAL PHARMACEUTICAL CHEMISTRY. AN EXPLANATION OF CHEMICAL AND PHARMACEUTICAL PROCESSES | OXFORD UNIVERSITY PRESS |
| 1147 | PRACTICAL PHARMACY AND PRESCRIBING FOR STUDENTS OF MEDICINE, BEING THE COURSE IN USE AT ST.BARTHOLOMEW’S HOSPITAL | UNIVERSITY OF TORONTO |
| 1148 | PRECLINCAL STUDIES OF THE OXIME, HI-6, AN ELEMENT OF THE TREATMENT OF SOMAN POISONING. APPENDIX 13. THE PHARMACOKINETICS OF HI-6 IN THE RAT AND DOG | DEFENSE TECHNICAL INFORMATION CENTER |
| 1149 | PRECLINICAL AND CLINICAL EVALUATION OF NOVEL AGENTS FOR NONINVASIVE IMAGING OF PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1150 | PRECLINICAL PHARMACODYNAMIC AND PHARINACOKINETIC STUDIES OF INVESTIGATIONAL NEW DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1151 | PRECLINICAL PHARMACODYNAMIC AND PHARMACOKINETIC STUDIES OF INVESTIGATIONAL NEW DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1152 | PRECLINICAL PHARMACOLOGY OF ANTIVIRAL AGENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1153 | PREDICTING THE TOXICITY OF ADJUVANT BREAST CANCER DRUG COMBINATION THERAPY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1154 | PREDICTIVE BIOMARKERS OF RESPONSE TO BC1-2 BIOMODULATION BY G3139 AND DOCETAXEL IN HORMONE-REFRACTORY PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1155 | PRICE LIST OF CHEMICAL AND PHARMACEUTICAL PREPARATIONS | U.S. NATIONAL LIBRARY OF MEDICINE |
| 1156 | PRICES, COMPETITION AND REGULATION IN PHARMACEUTICALS: A CROSS-NATIONAL COMPARISON | OHE |
| 1157 | PRINCIPLES OF MEDICAL PHARMACOLOGY | OXFORD UNIVERSITY PRESS |
| 1158 | PRINCIPLES OF TOXICOLOGY | MCGILL UNIVERSITY |
| 1159 | PROBABILISTIC METHODS FOR ADDRESSING UNCERTAINTY AND VARIABILITY IN BIOLOGICAL MODELS: APPLICATION TO A TOXICOKINETIC MODEL | DEFENSE TECHNICAL INFORMATION CENTER |
| 1160 | PROCEEDINGS OF THE 17TH CONFERENCE ON TOXICOLOGY HELD IN DAYTON, OHIO ON 3-5 NOVEMBER 1987 | UNIVERSITY OF FLORIDA |
| 1161 | PROCEEDINGS OF THE 1993 CONFERENCE ON TOXICOLOGY – THE RISK ASSESSMENT PARADIGM AFTER TEN YEARS: POLICY AND PRACTICE THEN, NOW, AND IN THE FUTURE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1162 | PROCEEDINGS OF THE CONFERENCE ON TOXICOLOGY: APPLICATIONS OF ADVANCES IN TOXICOLOGY TO RISK ASSESSMENT. | DEFENSE TECHNICAL INFORMATION CENTER |
| 1163 | PRODUCTION METHODS FOR A MESENCHYMAL STEM CELL THERAPEUTIC AS A MEDICAL DEFENSE COUNTERMEASURE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1164 | PROGRAMS AFFECTING SAFETY AND INNOVATION IN PEDIATRIC THERAPIES | GOVERNMENT PUBLISHING OFFICE |
| 1165 | PROMISING PHARMACEUTICALS | INTECH |
| 1166 | PROPERTIES OF HIGH-AFFINITY L-GLUTAMATE TRANSPORT IN GLIAL- AND NEURONAL-ENRICHED FRACTIONS FROM RAT BRAIN | UNIVERSITY OF FLORIDA |
| 1167 | PROPHYLAXIS AND TREATMENT OF CYANIDE INTOXICATION CYANIDE – MECHANISM OF PROPHYLAXIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1168 | PROVIDING A THEORETICAL BASIS FOR NANOTOXICITY RISK ANALYSIS DEPARTING FROM TRADITIONAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING | DEFENSE TECHNICAL INFORMATION CENTER |
| 1169 | PSYCHOACTIVE DRUGS: IMPROVING PRESCRIBING PRACTICES | ERIC |
| 1170 | PSYCHOMOTOR FUNCTIONING: COMPARISON OF PATIENTS RECOVERING FROM GENERAL ANESTHESIA WITH REMIFENTANIL AND A VOLATILE ANESTHETIC VERSUS FENTANYL AND A VOLATILE ANESTHETIC | DEFENSE TECHNICAL INFORMATION CENTER |
| 1171 | PUBLIC HEALTH IN PHARMACY PRACTICE: A CASEBOOK | OPEN SUNY TEXTBOOKS |
| 1172 | PUBLIC HEALTH IN PHARMACY PRACTICE: A CASEBOOK – 2ND EDITION | SOFTWARE LIBERTY ASSOCIATION |
| 1173 | QUALITY ASSURANCE OF PHARMACEUTICALS – A COMPENDIUM OF GUIDELINES AND RELATED MATERIALS – VOLUME 1 | WORLD HEALTH ORGANIZATION |
| 1174 | QUANTIFY MEDICATION IN PATIENT | NA |
| 1175 | QUANTITATIVE EVALUATION OF DICHLOROACETIC ACID KINETICS IN HUMAN — A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING INVESTIGATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1176 | QUESTION OF BALANCE: THE BENEFITS AND RISKS OF PHARMACEUTICAL INNOVATION | OHE |
| 1177 | RADIATION DOSIMETRY FROM INTRATUMORAL INJECTION OF RADIONUCLIDES IN HUMAN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1178 | RADIATION DOSIMETRY OF INTRATUMORAL INJECTION OF RADIONUCLIDES INTO HUMAN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1179 | READINGS IN ADVANCED PHARMACOKINETICS – THEORY, METHODS AND APPLICATIONS | INTECH |
| 1180 | REAUTHORIZATION OF ANIMAL DRUG USER FEES: ADUFA AND AGDUFA | GOVERNMENT PUBLISHING OFFICE |
| 1181 | RECENT ADVANCES IN NOVEL DRUG CARRIER SYSTEMS | INTECH |
| 1182 | RECENT ADVANCES IN THE PATHOPHYSIOLOGY OF COPD | SPRINGER |
| 1183 | REGULATING PHARMACEUTICALS IN EUROPE: STRIVING FOR EFFICIENCY, EQUITY AND QUALITY | WORLD HEALTH ORGANIZATION |
| 1184 | REHABILITATION OF THE DRUG ABUSER: A REPORT FROM THE STUDY GROUP ON REHABILITATION OF THE DRUG ABUSER | NA |
| 1185 | RELATIONSHIPS OF BLOOD AND BRAIN HALOCARBON SOLVENT CONCENTRATIONS TO NEUROBEHAVIORAL TOXICITY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1186 | RESEARCH IN EXPERIMENTAL ANTIMALARIAL CHEMOTHERAPY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1187 | RESEARCH IN MAJOR STATE UNIVERSITIES: SOME QUANTITATIVE MEASURES | ERIC |
| 1188 | RESEARCH PUBLICATIONS IN AYURVEDIC SCIENCES | CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES |
| 1189 | RESIDUES OF SOME VETERINARY DRUGS IN ANIMALS AND FOODS | FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS |
| 1190 | RESOURCE MANUAL FOR ALCOHOL AND OTHER DRUG ABUSE EDUCATION IN INTERNAL MEDICINE | ERIC |
| 1191 | REVERSAL OF MULTIDRUG RESISTANCE IN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1192 | REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY | SPRINGER |
| 1193 | RICIN TOXIN | BENTHAM OPEN |
| 1194 | RISK AND RETURN IN THE PHARMACEUTICAL INDUSTRY | OHE |
| 1195 | ROLE OF HEALTH ECONOMIC DATA IN POLICY MAKING AND REIMBURSEMENT OF NEW MEDICAL TECHNOLOGIES | FRONTIERS MEDIA SA |
| 1196 | ROLE OF THE NEDDYLATION ENZYME UBA3, A NEW ESTROGEN RECEPTOR COREPRESSOR, IN BREAST CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1197 | RUNNING HEAD: IMPROVING PHARMACY CUSTOMER SATISFACTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1198 | SAFETY TOLERANCE PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PYRIDOSTIGMINE IN HEALTHY MEN AND THE INFLUENCE OF FOOD ON ORAL PYRIDOSTIGMINE PHARMACOKINETICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1199 | SCIENCE EDUCATION IN TWO-YEAR COLLEGES: CHEMISTRY | ERIC |
| 1200 | SCIENTIFIC AND CLINICAL M O N O G R A P H FOR BY HEATHER S. OLIFF, PHD AND MARK BLUMENTHAL PROPRIETARY BOTANICAL INGREDIENT PYCNOGENOL | AMERICAN BOTANICAL COUNCIL |
| 1201 | SCIENTIFIC AND CLINICAL MONOGRAPH PROPRIETARY BOTANICAL FOOD PRODUCT POM WONDERFUL® POMEGRANATE JUICE | AMERICAN BOTANICAL COUNCIL |
| 1202 | SECOND PHARMACOLOGICAL REVOLUTION | OHE |
| 1203 | SECONDARY ANALYSIS OF ELECTRONIC HEALTH RECORDS | SPRINGER |
| 1204 | SELECTION OF HUMAN ANTIBODY FRAGMENTS WHICH BIND NOVEL BREAST TUMOR ANTIGENS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1205 | SHORT-SUPPLY PRESCRIPTION DRUGS: SHINING A LIGHT ON THE GRAY MARKET | GOVERNMENT PUBLISHING OFFICE |
| 1206 | SIDEROPHORE-MEDIATED IRON TRANSPORT APPARATUS IN PARACOCCUS DENITRIFICANS | UNIVERSITY OF FLORIDA |
| 1207 | SILDENAFIL | SPRINGER |
| 1208 | SILDENAFIL [ELECTRONIC RESOURCE] | SPRINGER |
| 1209 | SINGLE-DOSE ABSORPTION AND PHARMACOKINETICS OF WR 6026. PHASE 1 | DEFENSE TECHNICAL INFORMATION CENTER |
| 1210 | SINUPRET® PRODUCT-SPECIFIC MONOGRAPH | AMERICAN BOTANICAL COUNCIL |
| 1211 | SLEEP AND WAKEFULNESS HANDBOOK FOR FLIGHT MEDICAL OFFICERS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1212 | SMART NANOVESICLES FOR DRUG TARGETING AND DELIVERY | MDPI AG |
| 1213 | SOLID STATE STABILITY OF DIGOXIN AS A FUNCTION OF TEMPERATURE AND HUMIDITY | UNIVERSITY OF FLORIDA |
| 1214 | SOLVING THE MEDICAL ISOTOPE CRISIS | GOVERNMENT PUBLISHING OFFICE |
| 1215 | SPECIAL SABBATICAL FOR TRAINING IN HEALTH DECISION SCIENCES WITH APPLICATION TO BREAST CANCER TREATMENT EVALUATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1216 | STARTING OR STRENGTHENING A DRUG BULLETIN – A PRACTICAL MANUAL | WORLD HEALTH ORGANIZATION |
| 1217 | STOCHASTIC MODELS FOR CELL SIGNALING AND TOXIC EFFECTS ON CELLS | NAVAL POSTGRADUATE SCHOOL |
| 1218 | STRATEGIES TO SUSTAIN AND ENHANCE PERFORMANCE IN STRESSFUL ENVIRONMENTS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1219 | STUDIES OF MECHANISMS OF PHARMACOLOGICAL ENHANCEMENT OF FUNCTIONAL RECOVERY AFTER CORTICAL CONTUSION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1220 | STUDIES OF THE PHARMACOKINETICS, CELLULAR ACTIONS AND MOTOR STIMULATANT EFFECTS OF CAFFEINE IN HORSES | UNIVERSITY OF FLORIDA |
| 1221 | SUICIDE INHIBITORS OF REVERSE TRANSCRIPTASE IN THE THERAPY OF AIDS AND OTHER RETROVIRUSES | DEFENSE TECHNICAL INFORMATION CENTER |
| 1222 | SUPPORT OF STUDY ENTITLED, ‘METABOLISM AND PHARMACOKINETICS OF DIHYDROARTEMISININ’ AND ‘IN VITRO AND IN VIVO METABOLISM OF SODIUM ARTELINATE AND DQHS IN RATS AND HUMANS’ | DEFENSE TECHNICAL INFORMATION CENTER |
| 1223 | SYNTHESES OF THIENYLAMPHETAMINE DERIVATIVES VIA BORANE CHEMISTRY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1224 | SYNTHESIS AND SCREENING OF NEW ANTIMALARIAL DRUGS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1225 | SYSTEM IDENTIFICATION OF A PHARMACOKINETIC MODEL FOR AIR FORCE APPLICATIONS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1226 | TABLET AND CAPSULE MACHINE INSTRUMENTATION | AJPRD |
| 1227 | TARGET PRODUCT PROFILE FOR DRUGS TO MANAGE PRETERM LABOUR | WORLD HEALTH ORGANIZATION |
| 1228 | TARGET PRODUCT PROFILE FOR DRUGS TO PREVENT PRE-ECLAMPSIA | WORLD HEALTH ORGANIZATION |
| 1229 | TARGET PRODUCT PROFILE FOR DRUGS TO PREVENT SPONTANEOUS PRETERM BIRTH | WORLD HEALTH ORGANIZATION |
| 1230 | TARGETED RADIOIMMUNOTHERAPY OF PROSTATE CANCER USING MONOCLONAL ANTIBODIES TO THE EXTRACELLUAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | DEFENSE TECHNICAL INFORMATION CENTER |
| 1231 | TARGETING PACLITAXEL-LOADED NANOPARTICLES TO OVARIAN CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1232 | TASK 89-06: DETERMINATION OF THE BIOEQUIVALENCE OF HI-6 AND ATROPINE WHEN DELIVERED BY WET/DRY AUTOINJECTOR OR SYRINGE IN SHEEP: A PHARMACOKINETIC AND EFFICACY EVALUATION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1233 | TECHNOLOGY AND BLOOM’S TAXONOMY: TOOLS TO FACILITATE HIGHER-LEVEL LEARNING IN CHEMISTRY | DEFENSE TECHNICAL INFORMATION CENTER |
| 1234 | TERRA MARIAE | UNIVERSITY OF MARYLAND |
| 1235 | TESTING REGRESSION MONOTONICITY IN ECONOMETRIC MODELS | ARXIV |
| 1236 | TESTOSTERONE [ELECTRONIC RESOURCE] : ACTION – DEFICIENCY – SUBSTITUTION | SPRINGER |
| 1237 | TEXT BOOK OF FORENSIC PHARMACY | PHARMAMED PRESS |
| 1238 | TEXT-BOOK OF MEDICAL AND PHARMACEUTICAL CHEMISTRY | HARVARD UNIVERSITY |
| 1239 | TEXT-BOOK OF MEDICAL CHEMISTRY FOR MEDICAL AND PHARMACEUTICAL STUDENTS AND PRACTITIONERS | HARVARD UNIVERSITY |
| 1240 | TEXT-BOOK OF MEDICAL CHEMISTRY: FOR MEDICAL AND PHARMACEUTICAL STUDENTS AND PRACTITIONERS | HARVARD UNIVERSITY |
| 1241 | THE ADOPTION OF THE PHARMACOECONOMIC CENTER AS A RESOURCE BY AIR FORCE MEDICAL TREATMENT FACILITIES | DEFENSE TECHNICAL INFORMATION CENTER |
| 1242 | THE AYURVEDIC PHARMACOPOEIA OF INDIA | DEPARTMENT OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY |
| 1243 | THE AYURVEDIC PHARMACOPOEIA OF INDIA PART I | DEPARTMENT OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY |
| 1244 | THE BIOCHEMIC SYSTEM OF MEDICINE | UNIVERSAL LIBRARY |
| 1245 | THE BIOPHARMACEUTICS AND PHARMACOKINETICS OF SOME SUBSTITUTED SUCCINIMIDES IN MALE WISTAR RATS | UNIVERSITY OF ALBERTA |
| 1246 | THE CHALLENGE OF CMC REGULATORY COMPLIANCE FOR BIOPHARMACEUTICALS | SPRINGER |
| 1247 | THE CHALLENGE OF NEW THERAPEUTIC APPROACHES FOR UNMET THERAPEUTIC NEEDS | FRONTIERS MEDIA SA |
| 1248 | THE CHEMISTRY AND ANALYSIS OF DRUGS AND MEDICINES | WILEY |
| 1249 | THE CHEMISTRY OF PHARMACY : AN EXPOSITION OF CHEMICAL SCIENCE IN ITS RELATIONS TO MEDICINAL SUBSTANCES ACCORDING TO A PRACTICAL AND ORIGINAL PLAN | WELLCOME LIBRARY |
| 1250 | THE CHEMISTRY OF PLANT CONSTITUENTS | BURGESS PUBLISHING CO. |
| 1251 | THE CHEMISTRY OF SYNTHETIC DRUGS | LONGMANS, GREEN AND CO. |
| 1252 | THE COLD-FX® PRODUCT-SPECIFIC MONOGRAPH | AMERICAN BOTANICAL COUNCIL |
| 1253 | THE CURIOUS CASE OF ZINC FOR DIARRHEA: UNAVAILABLE, UNPRESCRIBED, AND UNUSED | JOURNAL OF PHARMACOLOGY AND PHARMACOTHERAPEUTICS |
| 1254 | THE DETECTION OF PHARMACEUTICAL DRUG COMPOUNDS FROM INTACT BIOLOGICAL TISSUE BY MATRIX-ASSISTED LASER DESORPTION IONIZATION (MALDI) QUADRUPOLE ION TRAP MASS SPECTROMETRY | UNIVERSITY OF FLORIDA |
| 1255 | THE DEVELOPMENT OF THE ESSENTIAL DRUGS PROGRAM AND IMPLICATIONS FOR SELF-RELIANCE IN TANZANIA | INTERNATIONAL HEALTH POLICY PROGRAM |
| 1256 | THE DRUGS (FEDERAL INSPECTORS, FEDERAL DRUG LABORATORY AND FEDERAL GOVERNMENT ANALYSTS) RULES, 1976 | PAKISTAN GOVERNMENT |
| 1257 | THE DRUGS (RESEARCH) RULES, 1978 | PAKISTAN GOVERNMENT |
| 1258 | THE DRUGS AND COSMETICS ACT AND RULES. THE DRUGS AND COSMETICS ACT, 1940 (23 OF 1940) (AS AMENDED UP TO THE 30TH JUNE, 2005) AND THE DRUGS AND COSMETICS RULES, 1945 (AS AMENDED UP TO THE 30TH JUNE, 2005) | INDIA MINISTRY OF HEALTH & FAMILY WELFARE |
| 1259 | THE EC/ACP/WHO PARTNERSHIP ON PHARMACEUTICAL POLICIES. HIGHLIGHTS OF YEAR 4 | WHO HEADQUARTERS IN GENEVA |
| 1260 | THE EFFECT OF BLOOD LOSS DURING SURGERY ON THE PHARMACOKINETICS OF PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS | YALE UNIVERSITY |
| 1261 | THE EFFECT OF ECONOMIC FEEDBACK ON PROVIDERS’ PRESCRIPTION HABITS: ARE OUTCOMES IMPROVED? ARE INSTITUTIONAL SAVINGS REALIZED? | DEFENSE TECHNICAL INFORMATION CENTER |
| 1262 | THE EFFECTS OF DOPAMINE AND ESTROGEN UPON CORTICAL PARVALBUMIN EXPRESSION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1263 | THE EFFECTS OF WR242511 IN RHESUS MONKEYS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1264 | THE ELEMENTS OF THERAPEUTICS : A CLINICAL GUIDE TO THE ACTION OF MEDICINES | DEFENSE TECHNICAL INFORMATION CENTER |
| 1265 | THE ERICE DECLARATION: THE CRITICAL ROLE OF COMMUNICATION IN DRUG SAFETY | WHO COLLABORATING CENTRE FOR INTERNATIONAL DRUG MONITORING |
| 1266 | THE ESSENTIAL DRUGS CONCEPT AND ITS IMPLEMENTATION | WHO HEADQUARTERS IN GENEVA |
| 1267 | THE ESSENTIAL DRUGS PROGRAMME IN ZIMBABWE: NEW APPROACHES TO TRAINING | BHUTAN MINISTRY OF HEALTH |
| 1268 | THE EU PHARMACEUTICALS MARKET: PARAMETERS AND PATHWAYS | EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES |
| 1269 | THE EU/ACP/WHO RENEWED PARTNERSHIP 2012–2016 FOR STRENGTHENING PHARMACEUTICAL SYSTEMS AND IMPROVING ACCESS TO QUALITY ESSENTIAL MEDICINES | WHO HEADQUARTERS IN GENEVA |
| 1270 | THE EXPECTATIONS, THE REALITY AND THE BURDEN OF DRUG DONATIONS | SRI LANKA – MINISTRY OF HEALTHCARE AND NUTRITION |
| 1271 | THE FEDERAL EMPLOYEES HEALTH BENEFITS PROGRAM: IS IT A GOOD VALUE FOR FEDERAL EMPLOYEES? | GOVERNMENT PUBLISHING OFFICE |
| 1272 | THE FIGHT AGAINST FAKE DRUGS BY NAFDAC IN NIGERIA | KIT |
| 1273 | THE GAMBIA NATIONAL DRUG POLICY, 1994 | GAMBIA – MINISTRY OF HEALTH, WELFARE AND WOMEN’S AFFAIRS |
| 1274 | THE GAMBIA STANDARD DRUG TREATMENT GUIDELINES. SECOND EDITION, 2001 | GAMBIA – MINISTRY OF HEALTH & SOCIAL WELFARE, DEPARTMENT OF STATE FOR HEALTH & SOCIAL WELFARE |
| 1275 | THE GLOBAL DRUG FACILITY AS AN INTERVENTION IN THE MARKET FOR TUBERCULOSIS DRUGS | WHO HEADQUARTERS IN GENEVA |
| 1276 | THE GLOBAL PHARMACY WORKFORCE: A SYSTEMATIC REVIEW OF THE LITERATURE | THE GLOBAL PHARMACY WORKFORCE: A SYSTEMATIC REVIEW OF THE LITERATURE |
| 1277 | THE GLOBAL POLITICS OF PHARMACEUTICAL MONOPOLY POWER. DRUG PATENTS, ACCESS, INNOVATION AND THE APPLICATION OF THE WTO DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH | WHO HEADQUARTERS IN GENEVA |
| 1278 | THE GLOBAL VACCINE SAFETY INITIATIVE: ENHANCING VACCINE PHARMACOVIGILANCE CAPACITY AT COUNTRY LEVEL | WHO HEADQUARTERS IN GENEVA |
| 1279 | THE GOVERNMENT POLICY ON DRUGS. ADOPTION OF THE RESOLUTION NO: 68, 11 OCTOBER 2002, ULAANBAATAR, MONGOLIA | MONGOLIA – STATE GREAT HURAL |
| 1280 | THE HOSPITAL CORPS OF THE NAVY | WASHINGTON, D.C |
| 1281 | THE IMPACT OF FACE-TO-FACE EDUCATIONAL OUTREACH ON DIARRHOEA TREATMENT IN PHARMACIES | OXFORD UNIVERSITY PRESS |
| 1282 | THE IMPACT OF PHARMACEUTICAL EXPENSES AND THE USE OF FLEXIBLE BUDGETS AT THE JOHNS HOPKINS HOSPITAL | DEFENSE TECHNICAL INFORMATION CENTER |
| 1283 | THE IMPORTANCE OF IRON IN PATHOPHYSIOLOGIC CONDITIONS | FRONTIERS MEDIA SA |
| 1284 | THE IMPORTANCE OF PHARMACOVIGILANCE – SAFETY MONITORING OF MEDICINAL PRODUCTS | WORLD HEALTH ORGANIZATION |
| 1285 | THE INCIDENTAL EFFECTS OF DRUGS : A PHARMACOLOGICAL AND CLINICAL HAND-BOOK | DEFENSE TECHNICAL INFORMATION CENTER |
| 1286 | THE INDIAN PHARMACEUTICAL SECTOR: ISSUES AND OPTIONS FOR HEALTH SECTOR REFORM | THE WORLD BANK GROUP |
| 1287 | THE INTERNATIONAL PHARMACOPOEIA. FIFTH EDITION, 2015 | WHO HEADQUARTERS IN GENEVA |
| 1288 | THE LIFE CYCLE OF PHARMACEUTICALS: A CROSS-NATIONAL PERSPECTIVE | OHE |
| 1289 | THE LONDON DISPENSATORY | WELLCOME LIBRARY |
| 1290 | THE MECTIZAN (IVERMECTIN) DONATION PROGRAM FOR RIVERBLINDNESS AS A PARADIGM FOR PHARMACEUTICAL INDUSTRY DONATION PROGRAMS | THE WORLD BANK GROUP |
| 1291 | THE METRIC SYSTEM IN MEDICINE : CONTAINING AN ACCOUNT OF THE METRIC SYSTEM OF WEIGHTS AND MEASURES, AMERICANIZED AND SIMPLIFIED, A COMPREHENSIVE DOSE TABLE, AND THREE HUNDRED PRACTICAL ILLUSTRATIONS OF METRIC PRESCRIPTION WRITING, SELECTED FROM RECIPES IN ACTUAL USE IN HOSPITAL AND OUT-DOOR PRACTICE | P. BLAKISTON’S SON & CO. |
| 1292 | THE MICROSCOPICAL EXAMINATION OF FOODS AND DRUGS : A PRACTICAL INTRODUCTION TO THE METHODS ADOPTED IN THE MICROSCOPICAL EXAMINATION OF FOODS AND DRUGS, IN THE ENTIRE, CRUSHED AND POWDERED STATES | J. & A. CHURCHILL |
| 1293 | THE MODUS PROPAGANDI OF THE HUMAN SPECIES, PHYSIOLOGICALLY EXPLAINED | CLAYTON & COMPANY |
| 1294 | THE PHARMACOLOGY AND CLINICAL USE OF DIURETICS | CHARLES C THOMAS PUBLISHER |
| 1295 | THE PHARMACOLOGY OF ANESTHETIC DRUGS | CHARLES C THOMAS PUBLISHER |
| 1296 | THE PHARMACOLOGY OF USEFUL DRUGS | AMERICAN MEDICAL ASSOCIATION |
| 1297 | THE PHARMACOPOEIA OF KING’S COLLEGE HOSPITAL | KING’S COLLEGE |
| 1298 | THE PHARMACOPOEIA OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH. FAITHFULLY TRANSLATED FROM THE FOURTH EDITION. WITH USEFUL NOTES ON THE MATERIA MEDICA AND PRACTICAL OBSERVATIONS ON THE PREPARATIONS BOTH SIMPLE AND COMPOUND ; TO WHICH ARE ADDED, THE PRESCRIPTIONS AS WELL EXTEMPORANEOUS AND OFFICINAL, IN THE USE AT THE ROYAL HOSPITAL | WELLESLEY COLLEGE LIBRARY |
| 1299 | THE PHARMACOPOEIA OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON | KING’S COLLEGE |
| 1300 | THE PHARMACY TECHNICIAN | MORTON PUBLISHING COMPANY |
| 1301 | THE PHTHALEIN TEST [MICROFORM] : AN EXPERIMENTAL AND CLINICAL STUDY OF PHENOLSULPHONEPHTHALEIN IN RELATION TO RENAL FUNCTION IN HEALTH AND DISEASE | AMERICAN MEDICAL ASSOCIATION |
| 1302 | THE PHYSICIAN’S CHEMISTRY | U.S. NATIONAL LIBRARY OF MEDICINE |
| 1303 | THE PHYSIOLOGY AND PHARMACOLOGY OF LEUCINE-RICH REPEAT GPCRS | FRONTIERS MEDIA SA |
| 1304 | THE QUALITATIVE ANALYSIS OF MEDICINAL PREPARATIONS | WILEY |
| 1305 | THE QUANTITATION OF CELLULAR KINETICS FOR THE MODELLING OF CHEMICALLY-INDUCED CARCINOGENESIS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1306 | THE ROLE OF PITUITARY BETA-ENDORPHIN IN THE ATTENUATION OF NOCICEPTION | DEFENSE TECHNICAL INFORMATION CENTER |
| 1307 | THE ROLE OF THE COMPANY IN GENERATING SKILLS. THE LEARNING EFFECTS OF WORK ORGANIZATION. THE NETHERLANDS. | ERIC |
| 1308 | THE ROLE OF THE PHARMACIST IN NATIONAL DISASTER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1309 | THE SOCIAL CONSTRUCTION OF BREAST CANCER IN MASS MEDIA AND ITS INFLUENCE ON PUBLIC UNDERSTANDING AND CITIZEN DECISION-MAKING | DEFENSE TECHNICAL INFORMATION CENTER |
| 1310 | THE STAR QUIZZER ON PHARMACY, CHEMISTRY AND MATERIA MEDICA : DESIGNED FOR THE USE OF PHARMACEUTICAL STUDENTS PREPARING THEMSELVES FOR ADVANCED STANDING IN COLLEGES OF PHARMACY AND FOR PREPARING TO PASS THE STATE PHARMACEUTICAL EXAMINATIONS OF THE VARIOUS STATES | U.S. NATIONAL LIBRARY OF MEDICINE |
| 1311 | THE TOXICOLOGY, ENVIRONMENTAL FATE, AND HUMAN RISK OF HERBICIDE ORANGE AND ITS ASSOCIATED DIOXIN | DEFENSE TECHNICAL INFORMATION CENTER |
| 1312 | THE UNIVERSITY OF MICHIGAN, AN ENCYCLOPEDIC SURVEY | UNIVERSITY OF MICHIGAN PRESS |
| 1313 | THE UNTOWARD EFFECTS OF DRUGS; A PHARMACOLOGICAL AND CLINICAL MANUAL | LIBRARY OF CONGRESS |
| 1314 | THE URINE AND CLINICAL CHEMISTRY OF THE GASTRIC CONTENTS, THE COMMON POISONS, AND MILK | P. BLAKISTON’S SON & CO. |
| 1315 | THE USE OF SUGAR-OXIMES AND OTHER GLYCOSYLATED DRUGS IN TREATMENT AGAINST ORGANOPHOSPHATE POISONING | DEFENSE TECHNICAL INFORMATION CENTER |
| 1316 | THERAPEUTIC GUIDE FOR PHARMACEUTICALS IN THE PACKAGED DISASTER HOSPITAL | WASHINGTON, D.C |
| 1317 | THERMOREGULATION: RESEARCH AND CLINICAL APPLICATIONS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1318 | TIROCINIUM MEDICUM, OR, A DISSERTATION ON THE DUTIES OF YOUTH APPRENTICED TO THE MEDICAL PROFESSION | KING’S COLLEGE |
| 1319 | TO HEAL AND HARM: AN ECONOMIC VIEW OF DRUG SAFETY | OHE |
| 1320 | TOPICS ON DRUG METABOLISM | INTECH |
| 1321 | TOXIC HAZARDS RESEARCH UNIT | DEFENSE TECHNICAL INFORMATION CENTER |
| 1322 | TOXIC HAZARDS RESEARCH UNIT 1989 | DEFENSE TECHNICAL INFORMATION CENTER |
| 1323 | TOXIC HAZARDS RESEARCH UNIT ANNUAL REPORT | DEFENSE TECHNICAL INFORMATION CENTER |
| 1324 | TOXICOKINETICS METABOLISM AND GENOTOXICITY OF NITROPROPANE IN RATS AND MICE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1325 | TOXICOKINETICS OF MICROCYSTIN AND DIHYDRO-MICROCYSTIN IN SWINE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1326 | TOXICOKINETICS OF T-2 MYCOTOXIN AND ITS METABOLITES IN CYNOMOLGUS MONKEYS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1327 | TOXICOLOGY STUDIES – CELLS, DRUGS AND ENVIRONMENT | INTECH |
| 1328 | TOXINS IN DRUG DISCOVERY AND PHARMACOLOGY | MDPI AG |
| 1329 | TRADE AND PRICE DIFFERENTIALS FOR PHARMACEUTICALS: POLICY OPTIONS | OHE |
| 1330 | TRADE MARK LEGISLATION AND THE PHARMACEUTICAL INDUSTRY | OHE |
| 1331 | TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNELS IN DRUG DISCOVERY: OLD CONCEPTS & NEW THOUGHTS | MDPI AG |
| 1332 | TRANSLATING ADENOSINE A24 RECEPTOR BIOLOGY INTO NOVEL THERAPIES FOR PARKINSON’S DISEASE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1333 | TRANSLATIONAL ONCOGENOMICS | NA |
| 1334 | TRAVEL MEDICINE – SERIES ? | MDPI AG |
| 1335 | TREATMENT OF PANIC DISORDER: A CLINICAL UPDATE | ERIC |
| 1336 | TRICHLOROETHYLENE: METABOLISM AND OTHER BIOLOGICAL DETERMINANTS OF MOUSE LIVER TUMORS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1337 | UNIVERSITY OF CONNECTICUT SCHOOL OF ALLIED HEALTH PROFESSIONS: PROGRAM EVALUATION FOR THE 1979-1980 ACADEMIC YEAR | ERIC |
| 1338 | USING OLD SOLUTIONS TO NEW PROBLEMS – NATURAL DRUG DISCOVERY IN THE 21ST CENTURY | INTECH |
| 1339 | USING THE PATCH-CLAMP TECHNIQUE TO SHED LIGHT ON ION CHANNELS STRUCTURE, FUNCTION AND PHARMACOLOGY | TORROSSA OPEN |
| 1340 | VACCINATION | OHE |
| 1341 | VACCINE IMMUNOTHERAPY FOR PROSTATE CANCER | DEFENSE TECHNICAL INFORMATION CENTER |
| 1342 | VALIDATION AND APPLICATION OF PHARMACOKINETIC MODELS FOR INTERSPECIES EXTRAPOLATIONS IN TOXICITY RISK ASSESSMENTS OF VOLATILE ORGANICS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1343 | VALUE OF THE PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY | OHE |
| 1344 | VIRTUAL SCREENING | INTECH |
| 1345 | VOGEL’S QUALITATIVE INORGANIC ANALYSIS | CAMBRIDGE UNIVERSITY PRESS |
| 1346 | VOLUMETRIC ANALYSIS FOR STUDENTS OF PHARMACEUTICAL AND GENERAL CHEMISTRY | UNIVERSITY OF TORONTO |
| 1347 | WAR, CHOLERA, AND THE MINISTRY OF HEALTH. AN APPEAL TO SIR BENJAMIN HALL AND THE BRITISH PEOPLE | WELLCOME LIBRARY |
| 1348 | WATER POLLUTION RISKS OF METHYL TERTIARY BUTYL ETHER (MTBE) | GOVERNMENT PUBLISHING OFFICE |
| 1349 | WATER QUALITY CRITERIA FOR NITROCELLULOSE | DEFENSE TECHNICAL INFORMATION CENTER |
| 1350 | WATER QUALITY CRITERIA FOR NITROGLYCERIN | DEFENSE TECHNICAL INFORMATION CENTER |
| 1351 | WELL-POSEDNESS RESULTS FOR A CLASS OF TOXICOKINETIC MODELS | DEFENSE TECHNICAL INFORMATION CENTER |
| 1352 | WHITLAS PHARMACY MATERIA MEDICA AND THERAPEUTICS | BAILLIERE, TINDALL & COM |
| 1353 | WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS – WHO TECHNICAL REPORT SERIES, NO. 943 – FORTY-FIRST REPORT | WORLD HEALTH ORGANIZATION |
| 1354 | WILEY VCH INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGYY OF THE CELL | WILEY |
| 1355 | WORKPLACE CORRELATES AND SCHOLARLY PERFORMANCE OF CLINICAL PHARMACY FACULTY. ASHE ANNUAL MEETING PAPER | ERIC |
| 1356 | WORLD WITHOUT CANCER | WORLD WITHOUT CANCER |
| 1357 | YEAR-BOOK OF PHARMACY ABSTRACTS OF PAPERS PHARMACY MATERIA MEDICA AND CHEMISTRY AUGUST 1893 | J. & A. CHURCHILL |
REGISTRATION LINK - https://forms.gle/tLqTPQqxswsFgVRPA
This will close in 200 seconds